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3TC 2´, 3´-dideoxy-3´-thiacytidine  
3TCMP 2´, 3´-dideoxy-3´-thiacytidine  monophosphate 
3TCTP 2´, 3´-dideoxy-3´-thiacytidine  triphosphate 
AMP Adenosine monophosphate 
APOBEC Apolipoprotein B mRNA editing enzyme 
AZT 3´-azido-2´, 3´-dideoxythymidine 
AZTMP 3´-azido-2´, 3´-dideoxythymidine monophosphate 
AZTp4A 3´azido-3´-deoxythymidine-(5´)-tetraphospho-(5´)-adenosine 
AZTTP 3´-azido-2´, 3´-dideoxythymidine triphosphate 
CA Capsid protein (p24) 
CBV 2-amino-9-[(1R, 4S)-4-(hydroxymethyl)cyclopent-2-en-1-yl]-9H-purin-6-ol  
CBVMP 2-amino-9-[(1R,4S)-4-(hydroxymethyl)cyclopent-2-en-1-yl]-9H-purin-6-ol monophosphate 
CBVTP 2-amino-9-[(1R,4S)-4-(hydroxymethyl)cyclopent-2-en-1-yl]-9H-purin-6-ol triphosphate 
CCD Central catalytic domain 
CTD C-terminal domain 
CypA Cyclophilin A 
d4T 2´, 3´-didehydro-2´, 3´-dideoythymidine 
d4TMP 2´, 3´-didehydro-2´, 3´-dideoythymidine monophosphate 
d4TTP 2´, 3´-didehydro-2´, 3´-dideoythymidine triphosphate 
ddA 2´, 3´-dideoxyanosine 
ddAMP 2´, 3´-dideoxyanosine monophosphate 
ddATP 2´, 3´-dideoxyanosine triphosphate 
ddC 2´-3´-dideoxycytidine 
ddCTP 2´-3´-dideoxycytidine triphosphate 
DEC Dead-end-complex 
DLV Delavirdine 
dsDNA Double-stranded DNA 
EFV Efavirenz 
ETR Etravirine 
FTC (-)-β-L-3´-thia-2´, 3´-dideoxy-5-fluorocytidine  
FTCMP (-)-β-L-3´-thia-2´, 3´-dideoxy-5-fluorocytidine monophosphate 
FTCTP (-)-β-L-3´-thia-2´, 3´-dideoxy-5-fluorocytidine triphosphate 
HAART Highly active antiretroviral tratment 
HIV-1 Human immunodeficiency virus type 1 
HIV-2 Human immunodeficiency virus type 2 
IN Integrase 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
ITP Inosine triphosphate 
kcat Steady-state catalytic rate 
Kd Dissociation equilibrium constant 
Ki Inhibition constant 
kobs Pre-steady-state catalytic rate 
koff Dissociation rate constant 
kpol Nucleotide incorporation rate 
LEDGF/p75 Lens epithelium-derived growth factor 
LTR Long terminal repeats 
MA Matrix protein (p17) 
NC Nucleocapsid protein (p6) 
NNRTI Non-nucleoside RT inhibitor 
NRTI Nucleoside RT inhibitor 
NTD N-terminal domain 
NVP Nevirapine 
N-site Nucleotide binding site 
PBS Primer binding site 
PFV Prototype foamy virus 
PIC Pre-integration complex 
PPi Pyrophosphate 
PPT Polypurine tract 
PR Protease 
P-site Priming site 
RPV Rilpivirine 
RT Reverse transcriptase 
SAMHD1 Sterile α motif domain and histidine-aspartic domain-containing protein 1 
SIV Simian immunodeficiency virus 
ssDNA Single-stranded DNA 
SU Surface protein (gp120) 
TAM Thymidine analogue mutation 
TAM-1  Thymidine analogue mutation pathway 1 
TAM-2  Thymidine analogue mutation pathway 2 
Tenofovir-DF [(R)-9-(2-phosphonylmethoxypropyl)adenine] disoproxil fumarate 
Tenofovir-DP [(R)-9-(2-phosphonylmethoxypropyl)adenine]  diphosphate 
TM Trans-membrane protein (gp41) 
TRIM5α Tripartite motif-containing protein 5 
T/P Template/primer 
U3 Unique 3´-region 
U5 Unique 5´-region  
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One and three letters code for amino acids 
 
 
A (Ala) Alanine M (Met) Methionine 
C (Cys) Cysteine N (Asn) Asparagine 
D (Asp) Aspartic acid P (Pro) Proline 
E (Glu) Glutamic acid Q (Gln) Glutamine 
F (Phe) Phenylalanine R (Arg) Arginine 
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Summary 
 The human immunodeficiency virus (HIV) is the causative agent of the acquired 
immunodeficiency syndrome (AIDS). Highly active antiretroviral therapy (HAART) has resulted in 
substantial improvements of the health of HIV-infected patients. However, the emergence of drug-
resistant viral strains is still one of the major factors hampering effective response to antiretroviral 
therapy. HIV type 1 (HIV-1) reverse transcriptase (RT) is a multifunctional enzyme with RNA- and 
DNA-dependent DNA polymerase and RNase H activities. Due to its essential role in virus 
replication, RT is a key drug target. Thymidine analogue resistance mutations (TAMs) are frequently 
found in patients treated with nucleoside RT inhibitors (NRTIs). TAMs can be classified in two 
groups: TAM-1 (composed of mutations M41L, L210W and T215Y) and TAM-2 (including 
mutations D67N, K70R, K219E or Q and sometimes T215F). Combinations of those mutations 
confer different levels of resistance to almost all NRTIs currently used in the treatment of HIV-1 
infection, although the largest effects are observed with zidovudine (AZT), stavudine (d4T) and 
tenofovir.  Prolonged exposure to those drugs has led to emergence of resistant HIV-1 strains 
containing TAMs plus accessory mutations that facilitate their selection in vivo.  
In this Thesis project we have determined the molecular mechanisms that facilitate the selection 
of mutations associated with TAMs during treatment with antiretroviral drugs. Thus, in the presence 
of TAMs, H208Y improves rescue efficiency of primers terminated with NRTIs, particularly with 
AZT, by increasing the ATP-dependent excision activity of the RT. These results are consistent with 
molecular dynamics simulations that predict that Tyr-208 influences the conformation of Trp-212 
and this effect results in altered stacking interactions between Tyr-215 and the adenine ring of ATP.  
Mutations in the RT thumb subdomain influence NRTI resistance of TAM-containing enzymes 
through different mechanisms. While polymorphisms Pro-272/Arg-277/Thr-286 increase the affinity 
of the RT for RNA/DNA complexes, the amino acid substitution R284K improves the ability of the 
RT to incorporate nucleotides and therefore to extend growing DNA primers. The RT thumb 
subdomain plays an important role in the interaction with the nucleic acid substrate, and amino acid 
substitutions associated with TAMs and studied in this work could be affecting the proper 
positioning of the template/primer complex.  
Recent studies have shown that RT connection subdomain mutations could influence resistance 
to non-nucleoside RT inhibitors (NNRTIs). Studies carried out during this Thesis project demonstrate 
that the combination of the connection subdomain mutations N348I/T369I impairs the RNase H 
activity of the RT. Interestingly, these effects are particularly relevant for the release of the 
polypurine tract (PPT) that acts as a primer in reverse transcription during (+) strand DNA synthesis. 
In the presence of NNRTIs, the PPT becomes susceptible to cleavage by the RNase H activity of the 
wild-type RT, although the double-mutant N348I/T369I RT is unable to cleave the PPT primer, 
thereby protecting it from unwanted degradation. These results predict that in the presence of 
NNRTIs, fitness differences between virus carrying the wild-type enzyme and the double-mutant 
N348I/T369I should be reduced. Finally, we have also studied the interaction between the RT and 
HIV-1 integrase (IN) protein and its effects on the RT’s RNase H activity. Our results indicate that 
the viral IN facilitates the release of the PPT primer, without affecting the hydrolysis of 
heteropolymeric template/primer complexes. 
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Resumen 
 El virus de la inmunodeficiencia humana (VIH) es el agente causante del síndrome de 
inmunodeficiencia adquirida (SIDA). La terapia antirretroviral de gran actividad (HAART) ha 
producido una mejora sustancial en la salud de los pacientes infectados por el VIH. No obstante, la 
aparición de cepas resistentes del virus sigue siendo uno de los mayores inconvenientes que 
dificultan la adecuada respuesta a la terapia antirretroviral. La retrotranscriptasa (RT) del VIH de tipo 
1 (VIH-1) es una enzima  multifuncional con actividad ADN polimerasa dependiente de ARN y 
ADN y actividad RNasa H. Debido a que juega un papel fundamental durante la replicación del 
virus, la RT es una diana terapéutica de gran importancia. Las mutaciones de resistencia a análogos a 
timidina (TAMs) aparecen frecuentemente en pacientes tratados con inhibidores de la RT análogos a 
nucleósido (NRTIs). Las TAMs se clasifican en dos grupos: TAM-1 (formado por las mutaciones 
M41L, L210W y T215Y) y TAM-2 (que engloba las mutaciones D67N, K70R, K219E o Q y en 
ocasiones T215F). Combinaciones de estas mutaciones confieren distintos niveles de resistencia a 
casi todos los NRTIs usados actualmente en el tratamiento de la infección por VIH-1, aunque los 
niveles de resistencia más altos se han observado con zidovudina (AZT), estavudina (d4T) y 
tenofovir. La exposición prolongada a estos fármacos ha provocado la aparición de cepas resistentes 
del virus portadoras de TAMs junto con mutaciones accesorias que facilitan su selección in vivo. 
 En este proyecto de Tesis hemos determinado los mecanismos moleculares que facilitan la 
selección de mutaciones asociadas a TAMs durante el tratamiento con fármacos antirretrovirales. De 
esta manera, en presencia de TAMs, H208Y mejora la eficacia de rescate de iniciadores terminados 
con NRTIs, en especial con AZT, aumentando la actividad de escisión dependiente de ATP de la RT. 
Estos resultados son apoyados por simulaciones de dinámica molecular, las cuales predicen que la 
Tyr-208 afecta a la conformación del Trp-212 y como resultado de ello se produce una alteración en 
las interacciones de apilamiento entre la Tyr-215 y el anillo de adenina del ATP. Las mutaciones en 
el subdominio “thumb” de la RT afectan a la resistencia de RTs portadoras de TAMs mediante 
distintos mecanismos. Mientras que los polimorfismos Pro-272/Arg-277/Thr-286 aumentan la 
afinidad de la RT por complejos ARN/ADN, el cambio de aminoácido R284K mejora la capacidad 
de la RT para incorporar nucleótidos y por tanto para extender cadenas de ADN. El subdominio 
“thumb” de la RT juega un importante papel en la interacción con el ácido nucleico y las 
sustituciones de aminoácido asociadas con TAMs y que se estudian en este trabajo podrían estar 
afectando al posicionamiento correcto del complejo molde/iniciador. 
 Estudios recientes han puesto de manifiesto que mutaciones del subdominio “connection” de la 
RT podrían afectar a la resistencia de la RT a inhibidores no análogos a nucleósido (NNRTIs). Los 
estudios desarrollados durante este proyecto de Tesis demuestran que la combinación de mutaciones 
del subdominio “connection” N348I/T369I disminuye la actividad RNasa H de la RT. Estos efectos 
son especialmente relevantes durante la eliminación de la secuencia de purinas (PPT) que actúa como 
iniciadora durante la síntesis de la cadena de ADN de polaridad positiva en el proceso de 
retrotranscripción. En presencia de NNRTIs, el PPT es susceptible al corte por la RNasa H de la RT 
de genotipo silvestre, mientras que la RT N348I/T369I es incapaz de cortar el iniciador PPT, 
protegiéndolo así de una degradación no deseada. Estos resultados predicen que en presencia de 
NNRTIs las diferencias de capacidad replicativa entre los virus portadores de las enzimas de 
genotipo silvestre y del mutante N348I/T369I deberían ser menores que las observadas en ausencia 
de fármacos. Por último, también hemos estudiado la interacción entre la RT y la integrasa (IN) del 
VIH-1 y su efecto sobre la actividad RNasa H de la RT. Nuestros resultados indican que la IN facilita 
la liberación del iniciador PPT, sin afectar a la hidrólisis de complejos molde/iniciador 
heteropoliméricos. 
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1. Introduction  
 
1.1 Human Immunodeficiency Virus (HIV) 
 In 1983 a group from the Pasteur Institute led by Luc Montagnier isolated a new retrovirus 
(Barré-Sinoussi et al., 1983). This retrovirus, referred formerly as lymphadenopathy-associated virus 
(LAV) (Barré-Sinoussi et al., 1983) or human T-lymphotropic virus III (HTLV-III) (Gallo et al., 
1984; Popovic et al., 1984) was finally named human immunodeficiency virus (HIV), and is the 
etiological agent of the acquired immunodeficiency syndrome (AIDS). 
 HIV belongs to the Lentivirus genus, Lentivirinae subfamily, included in the Retroviridae 
family. HIV is classified into two different types, HIV-1 and HIV-2. HIV-2 infection courses with 
less morbidity and mortality (reviewed in de Silva et al., 2008). Both viruses originate from different 
zoonotic events from non-human primates. HIV-1 group M, N and O comes from a simian 
immunodeficiency virus (SIV) that infects chimpanzees (SIVcpz), while HIV-1 group P viruses 
come from a SIV that infects gorillas (SIVgor) (Sharp & Hahn, 2011). HIV-2 was transmitted from 
sooty mangabeys (SIVsm). The origin of HIV-1, calculated by molecular clock dating techniques, set 
the origin of the infection in early 1900s (Zhu et al., 1998, Korber et al., 2000, Keele et al., 2006, 
Wertheim et al., 2009; reviewed in Hemelaar, 2012). 
 The HIV-1 virion (the free form of the virus) contains a lipid bilayer derived from the infected 
cell (Fig 1A).  The gp41 (TM) protein is embedded in the viral envelope and is also anchored to the 
trimeric complex of surface protein gp120 (SU). The matrix (MA, p17) protein is associated with the 
inner leaflet of the viral membrane, forming a sort of protein layer. The viral core consists of a 
conical shell composed of roughly 250 capsid protein (CA, p24) hexamers and 12 CA pentamers. 
This core contains the virus genome (composed of two RNA copies) that is stabilized by interactions 
with the nucleocapsid (NC, p6) protein. Inside the viral capsid, there are three pivotal enzymes in the 
retroviral life cycle: (i) the reverse transcriptase (RT), responsible for converting the viral RNA into a 
double-stranded DNA (dsDNA); (ii) the integrase (IN), that carries out the insertion of the virus 
dsDNA (proviral DNA) in the host cell DNA; and (iii) the protease (PR) that catalyzes the proteolytic 
processing of precursor polyproteins yielding the mature proteins that form the virion. In addition, 
the HIV-1 genome codifies for 6 viral accessory and regulatory proteins Vpu, Vpr, Tat, Rev, Nef and 
Vif. These proteins are dispensable for a productive infection, but improve viral fitness. Only Vpr, 
Vif and Nef seem to be found in the virion, while the other three are produced upon infection of the 
host cell (reviewed in Turner & Summers, 1999; Adamson & Freed, 2007; Ganser-Pornillos, et al., 
2012). 
 The HIV-1 genome has approximately 9.8 kb and contains 9 different open reading frames 
(ORFs). Three of these ORFs codify the three structural genes: gag, pol and env, three codify 
regulatory genes nef, tat and rev, and the last three codify the accessory and regulatory genes vpu, 
vpr, and vif  (Fig 1B).  The HIV-1 genome is flanked in both extremes by long terminal repeats 
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(LTRs). Both LTRs are composed of three subregions designated U3 (unique 3´ region, located at the 
5´-end of each LTR), R (repeated sequence, in the central region of each LTR) and U5 (unique 5´ 
sequence, located at the 3´-end of the LTRs) (Gallo et al., 1988).  
 
Fig 1.  HIV-1 virion and genome organization. (A) Schematic representation of the viral particle. (B) Viral genome, showing 
the two long terminal repeats, as well as the genes codifying the principal and the accessory proteins. Major polyproteins 
derived from genes gag, pol and env are shown. Specific protease cleavage sites are represented as jagged lines. 
 HIV-1 transcription is a complex process where viral and cellular factors are implicated 
(reviewed in Colin & Van Lint, 2009; Ott et al., 2011). Transcription starts at the 5´ LTR generating 
a 9 kb transcript that is processed by the cellular splicing machinery into several spliced transcripts. 
After translation, these transcripts originate Tat, Rev and Nef. Tat binds the TAR (transactivation 
response) element, located at the U5 region of the LTR, increasing the level of viral RNA 
transcription. On the other hand, Rev accumulates in the cell and binds the Rev response element 
(RRE) located in the env gene. The bound Rev facilitates the transport of unspliced and singly 
spliced RNA molecules from the nucleus to the cytoplasm (Fig 2). The uncleaved forms have the 
potential to be packaged and serve as genomic RNA. In addition they are expressed to produce the 
8
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Gag and Gag-Pol polyproteins. Gag-Pol is generated by a ribosomal frameshift occurring at the 3´-
end of the gag gene. The frequency of this frameshift is approximately 5%. Gag and Gag-Pol 
polyproteins are substrates of the viral PR, that after cleavage yield the viral proteins MA, CA, p2, 
NC, p1, p6, PR (free form), RT and IN (reviewed in Ganser-Pornillos et al., 2008; Lee et al., 2012). 
Singly-spliced forms of viral RNA yield the Env polyprotein, separated in signal peptide (SP), gp120 
and gp41 after cleavage by a cellular protease known as furin. Finally, different spliced forms of the 
viral RNA result in the expression of accessory and regulatory proteins (i.e. Vif, Vpr, Vpu and Nef) 
(Fig 1B) (reviewed in Krogstad 2003; Nielsen et al., 2005). 
 HIV-1 primarily infects CD4
+
 T cells and macrophages (reviewed in Carter & Ehrlich, 2008; 
Koppensteiner et al., 2012). Viral infection initiates with the interaction between gp120 and the 
cellular surface receptor CD4, which produces a conformational change that allows the virus to 
interact with a second receptor (coreceptor), usually a chemokine receptor such as CCR5 or CXCR4 
(Fig 2). The attachment of the virus triggers rearrangements of the gp41 protein, leading to the fusion 
of cell membrane and the viral envelope, and thereby to viral uncoating. This phenomenon delivers 
the viral core into the cytoplasm. In addition, several host factors, such as the actin microtubules and 
cyclophilin A (CypA), are likely to play a role during this step, forming a structure known as the 
reverse transcription complex (Hottiger et al., 1995; reviewed in Nisole & Saïb, 2004; Gomez & 
Hope, 2005; Fassati, 2012). The maturation of this complex results in the pre-integration complex 
(PIC). HIV PICs are composed of dsDNA associated with several viral proteins (at least RT, MA, 
Vpr and IN), as well as host proteins (CypA and others). PICs travel to the nuclear membrane, where 
they associate with nuclear pore complexes. After docking to the nuclear pores, several cellular 
factors help the PIC to break into the nucleus (reviewed in Nisole & Saïb, 2004; Gomez & Hope, 
2005; Fassati, 2012). Viral dsDNA integration is catalyzed by the viral IN. The integration of viral 
DNA normally takes place within cellular genes (Schroder et al. 2002; Han et al., 2004). 
 HIV-1 can remain as a provirus for long periods of time. However, under certain conditions not 
well understood, HIV-1 “wakes up” and initiates the transcription process described above (reviewed 
in Colin & Van Lint, 2009; Siliciano & Greene, 2011). The process leading to the formation of the 
provirus starts with the association of Gag and Gag-Pol precursor polyproteins. Initially just a few 
Gag molecules bind two copies of the viral RNA genome and bind into assembly sites in the plasma 
membrane (Fig 2). This membrane binding event is facilitated by a post-translationally modification 
of the N-terminal domain of Gag (corresponding to the MA region) that contains a myristic acid (a 
fatty acid chain). Then, more Gag molecules are recruited and the interactions between the CA 
regions of different Gag proteins form a shell of Gag hexamers just beneath the viral envelope. Also, 
Env polyproteins are incorporated in the nascent virus during this step. This is thought to happen 
through the interaction of Env with the MA region of Gag (reviewed in Briggs & Kraüsslich, 2011; 
Ganser-Pornillos et al., 2012). While the immature viral capsid is being formed, virus budding 
occurs. This process is facilitated by the endosomal sorting complexes required for transport 
(ESCRT) machinery (reviewed in Weiss & Göttlinger, 2011). 
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Fig 2. HIV-1 viral life cycle. Representation of the different stages of the HIV-1 life cycle. Cellular receptors and immature 
viral polyproteins are indicated in the boxed legend. Cell cytoplasm is shown in white, while the nucleus is a gray circle with 
chromosomal DNA in light purple. Cellular restriction factors are highlighted in red at the specific step where they act. 
 As mentioned above, Gag-Pol precursors represent only 5% of total Gag products. It is believed 
that retroviral maturation requires the dimerization of two PR regions of Gag-Pol polyproteins to 
form an active protease that then initiates the proteolytic processing of the Gag and Gag-Pol 
polyproteins. This process results in the formation of the structural proteins MA, CA and NC. CA 
hexamers are rearranged to form the mature conical capsid of the virus, which is stabilized by the 
presence of 12 CA pentamers (Fig 1A). The NC proteins cover the two RNA strands, adopting a 
stable structure, while MA proteins remain attached to the inner surface of the virion lipid bilayer 
(reviewed in Ganser-Pornillos et al., 2008; Briggs & Kraüslich, 2011; Ganser-Pornillos et al., 2012; 
Lee et al., 2012). 
 An overwhelming number of cellular factors involved in HIV infection have been identified 
(Brass et al., 2008; König et al., 2008; reviewed in Friedrich et al., 2011). A few of them have been 
described as restriction factors (Fig 2). APOBEC is a family of proteins that catalyze DNA C-to-U 
deamination. APOBEC3G is the principal enzyme of the family and shows anti-HIV activity, driving 
the virus towards lethal mutagenesis, because it has the ability to be incorporated in the nascent 
virion, and then influence the reverse transcription of genomic RNA (Bishop et al., 2008). The viral 
Vif protein mediates the ubiquitinitation of the APOBEC family by promoting their degradation by 
cellular proteasomes (reviewed in Malim & Emerman, 2008; Harris et al., 2012). TRIM5α is another 
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restriction factor that acts by accelerating viral uncoating and therefore leads to abortive reverse 
transcription. Although the human TRIM5α is unable to inhibit HIV-1 infection, TRIM5α from Old 
World monkeys generally can (reviewed in Malim & Bieniasz, 2012). Tetherin is a membrane 
protein which acts as an anchor that traps the virion while it attempts to bud from the cell. HIV-1 
Vpu counteracts the effect of tetherin by reducing its level in the cell surface, either by retarding its 
progress through the secretory pathway or by causing its internalization (reviewed in Harris et al., 
2012; Malim & Bieniasz, 2012). Finally, SAMHD1 is a deoxynucleotide triphosphate (dNTP) 
hydrolase able to reduce the dNTPs levels to a point that abort viral reverse transcription (Hrecka et 
al., 2011; Laguette et al., 2011). Vpx proteins from HIV-2 and several SIVs, but not HIV-1 Vpr 
protein, can direct SAMHD1 to a proteasome pathway, rescuing viral infectivity (Goldstone et al., 
2011; Laguette et al., 2011; Powell et al., 2011; Lahouassa, et al., 2012; reviewed in Harris et al., 
2012; Laguette and Benkirane, 2012).  
1.2 HIV-1 integrase 
 HIV-1 IN is a 32-KDa protein containing 288 amino acids (Fig 3). It is composed of three 
domains including an N-terminal domain (NTD) (residues 1-49), that carries an HHCC motif, 
important on protein multimerization, a catalytic or central domain (CCD) (residues 50-212) 
implicated in the binding of viral DNA extremes and that bears a conserved (D, D-35, E) motif, 
responsible for the catalytic activity of the enzyme, and a C-terminal domain (CTD) (residues 213-
288), mainly implicated on DNA and protein binding (Krishnan & Engelman, 2012). The catalytic 
competent form of IN in vivo is called intasome, and in its minimal form it involves a tetramer (dimer 
of dimers) of IN proteins attached to viral DNA. In this conformation the inner IN subunits of each 
dimer establish extensive dimer-dimer contacts through their catalytic domains. These domains are 
responsible for all interactions with viral DNA and the IN catalytic activity. The outer IN subunits do 
not have interactions within proteins, nor with DNA and likely play a supporting role (Fig 3) (Hare et 
al., 2010a,b; Maertens et al., 2010; reviewed in Cherepanov et al., 2011). 
 
Fig 3. Intasome structure. Ribbon representation of prototype foamy virus (PFV) intasome prior to 3´-end processing. Inner 
subunits are colored blue and green, and outer chains in gray. The reactive and nonreactive viral DNA strands are depicted as 
yellow and orange cartoons, respectively. Visible subdomains are indicated (figure extracted from Hare et al., 2012). 
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 IN is a multifunctional enzyme with three different activities: 3´-end processing, strand transfer 
and disintegration (Fig 4). During the course of viral infection, the first activity carried out by the IN 
is 3´-end processing of viral DNA. Although an IN dimer is able to carry out this reaction in vitro, 
the in vivo process seems to involve the complete intasome (reviewed in Delelis et al., 2008; 
Krishnan & Engelman, 2012). Through this reaction IN cleaves the conserved C-A dinucleotides 
from both viral ends, creating the reactive ends needed in the subsequent strand-transfer reaction. 
Structural data of pre- and post-3´-end processed intasome of the related PFV allow a mechanistic 
interpretation of the process (Hare et al., 2012; reviewed in Cherepanov et al., 2011), showing a 
endonucleolytic reaction, involving two divalent cations (Mn
2+
 or Mg
2+
). The strand-transfer reaction 
involves simultaneously binding of processed viral ends and target (chromosomal) DNA. In this 
configuration the target DNA suffers a severe deformation, leading to a great expansion of its major 
groove. This phenomenon implies the insertion of the scissile phosphodiesters into the intasome 
binding site. Afterwards, a nucleophilic attack of the 3´-OH recessed viral ends on target DNA 
creates a gap of five nucleotides where viral DNA integrates. Therefore HIV-1 integration produces a 
duplication of five nucleotides at each provirus end (Hare et al., 2010b, 2012; reviewed in Krishnan 
& Engelman, 2012). Finally the chromosomal nicks created by IN are corrected by the cellular DNA 
repairing machinery (reviewed in Skalka & Katz, 2005). Although a disintegration activity has been 
described in vitro (Chow et al., 1992), its occurrence in vivo is unlikely (reviewed in Delelis et al., 
2008). The disintegration process is the strand transfer reaction run in reverse and only needs the 
central catalytic domain of IN to proceed (Chow et al., 1992). 
Inside the cell, IN interacts with the cellular lens epithelium-derived growth factor (LEDGF/p75) 
protein. LEDGF/p75 is a protein with chromatin binding properties that assists IN in several ways: 
promotes tetramerization of IN monomers, increases IN-DNA affinity, aids to integrate viral DNA on 
regions of active transcription, increases strand transfer activity and could also avoid IN degradation 
by cellular proteasomes (Kessl et al., 2011; reviewed in Poeschla, 2008).  
 Additionally, IN-RT interaction has been reported using pull-down, yeast-two hybrid and dot 
blot far Western assays (Wu et al., 1999; Tasara et al., 2001; Hehl et al., 2004; Zhu et al., 2004; 
Wilkinson et al., 2009). This interaction has been mapped to occur between the C-terminal domain of 
IN, implicating the region between residues 220-270 (Hehl et al., 2004; Zhu et al., 2004; Wilkinson 
et al., 2009), and two regions of RT: one located within residues 1-242 and the other between 
residues 387-422 (Hehl et al., 2004). The significance of this interaction is controversial. While some 
authors found that RT inhibits all IN activities (Tasara et al., 2001; Oz et al., 2002), others found that 
RT inhibits IN 3´-end processing but fosters the strand transfer activity (Hehl et al., 2004). In the 
case of RT activities, some reports found that the presence of IN had no effect on DNA polymerase 
or RNase H activities of the RT (Oz et al., 2002; Hehl et al., 2004), while others found significant 
inhibition of the DNA-dependent DNA polymerase activity (Tasara et al., 2001). Notably, two 
studies have reported an enhancer effect of IN on RT-DNA polymerase activity during initiation of 
reverse transcription (Dobard et al., 2007; Nishitsuji et al., 2009). This stimulating effect of IN on 
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RT activity could be mediated by another IN partner, the cellular protein Gemin2, by improving IN 
oligomerization, IN binding to the reverse transcription complex and by aiding RT association with 
the RNA (Hamamoto et al., 2006; Nishitsuji et al., 2009). 
 
Fig 4. HIV-1 integration. Schematic representation of the integration process, with important sequence features of both viral 
ends indicated. IN cleavages are indicated with red triangles. The chromosomal DNA is shown in green and the five 
nucleotides where IN creates the gap are represented in blue. Insertion of viral DNA leads to the duplication of these five 
nucleotides at both viral ends. 
1.3 HIV-1 RT 
 The RT is the enzyme responsible of the conversion of the viral single stranded RNA genome 
into a dsDNA complex in a process called reverse transcription.  
1.3.1 Reverse transcription 
 Although not well understood, the initiation of reverse transcription seems to be modulated by 
the exposition of the viral complex to a high dNTP concentration inside the cell, and by specific 
rearrangements in the viral RNA (Cobrinik et al., 1988; reviewed in Abbink & Berkhout, 2008). 
Reverse transcription is initiated from a tRNA primer, a feature common to all retroviruses. In HIV-1 
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the tRNA
Lys, 3
 used is present in the viral particle and is incorporated together with the lysyl-tRNA 
synthetase protein (LysRS) from a previously infected cell (reviewed in Abbink & Berkhout, 2008; 
Levin et al., 2010). This tRNA
Lys, 3 
 binds to the primer binding site (PBS), located downstream of the 
5´-end of genomic RNA (reviewed in Levin et al., 2010). 
 A representation of the different steps of reverse transcription is shown in Fig 5. Upon tRNA
Lys, 3
 
binding,  combined DNA polymerase and RNase H activities of the RT copy and degrade the 5´-end 
of the viral (+) RNA, generating the minus-strong-stop DNA ((-)ssDNA). By taking advantage of the 
sequence homology between both viral RNA ends, the newly copied DNA binds the 3´-end, in a 
process called (-) strand transfer. Then, the complete (-) strand DNA is synthesized, and the viral 
RNA is simultaneously degraded. However, the 3´- and central-polypurine tracts (PPTs) remain 
unaffected by the RNase H activity. Furthermore, these ribonucleotide segments serve as primers for 
the synthesis of the (+) strand DNA. The use of the central-PPT involves discontinuous DNA 
synthesis, generating a DNA flap, called central flap (later eliminated by cellular endonucleases), and 
the plus-strong-stop DNA ((+) ssDNA) product. The presence of the PBS sequence in the 3´-end of 
the (-) strand DNA supports the second or (+) strand transfer, therefore facilitating the annealing of 
both PBS segments. Finally, the elongation of the (+) and (-) strands of DNA leads to the synthesis of 
the complete double-stranded viral DNA, that is longer than the RNA genome and that contains the 
same U3-R-U5 sequence at each end (reviewed in Abbink & Berkhout, 2008, Matamoros et al., 
2011; Hu and Hughes, 2012; Le Grice, 2012). 
 Reverse transcription takes place in the cytoplasm of the infected cell. After entry, the viral core 
reorganizes and forms the reverse transcription complex. The cornerstones of this complex are the 
RT and the RNA genome. However, accumulating evidence reveals the contribution of additional 
viral and host factors. Among the viral factors, it has been shown that NC plays different roles during 
reverse transcription. For example, fostering the annealing of the tRNA and the PBS sequence, or 
facilitating (-) strand transfer (reviewed in Levin et al., 2010). Nef and Tat also interact with the RT 
and increase the efficiency of reverse transcription (Fournier et al., 2002; Apolloni et al., 2007). As 
discussed above, IN is also associated with the reverse transcription complex, stimulating the 
synthesis of reverse transcription products (Wu et al., 1999; Dobard et al., 2007). Other viral factors, 
such as MA, CA, Vif and Vpr, also constitute part of the reverse transcription complex, where they 
probably help to create a more favorable environment and/or recruit host factors (reviewed in 
Warrilow et al., 2009; Fassati et al., 2012). 
 A number of cellular factors have been implicated in reverse transcription. Examples are specific 
proteins, such as AKAP149, HuR, Top1 and Gemin2, although their precise role is not clear 
(Hamamoto et al., 2006; Lemay et al., 2008a,b; Ahn et al., 2010; reviewed in Warren et al., 2009). In 
addition, mammalian cell lysates as well as purified fractions stimulate also reverse transcription 
(Warrilow et al., 2008, 2010).  
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Fig 5. Reverse transcription process. The viral RNA is shown with a gray thin line. The tRNA
Lys, 3 is represented by a ocher 
bended arrow. The newly synthesized DNA is shown as a black thick line. RNase H-degraded RNA is shown with dashed 
lines, and specific RNase H cleavage sites that produce PPT primers and eliminate the tRNA
Lys, 3
 are represented by yellow 
triangles. 
 
1.3.2 HIV-1 RT structure 
 HIV-1 RT is a heterodimer composed of two subunits designated as p66 (560 amino acids) and 
p51 (440 amino acids) (Di Marzo Veronese et al., 1986). Only p66 has catalytic activity, and is 
composed of a DNA polymerase and a RNase H domain. The DNA polymerase domain is divided 
into four subdomains termed fingers (residues 1-85 and 118-155), palm (residues 86-117 and 156-
236), thumb (237-318) and connection (319-426). As all the other DNA polymerases, the RT DNA 
polymerase domain has a structure resembling a right hand (Fig 6A). The p51 subunit lacks the 
RNase H domain, is catalytically inactive and plays a pivotal role in stabilizing the heterodimer 
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(Chung et al., 2013). In both p66 and p51 the four polymerase subdomains fold similarly (Kohlstaedt 
et al., 1992; Jacobo-Molina et al., 1993). However, the spatial organization of the subdomains in p51 
differs from p66. 
 The HIV-1 RT heterodimer contains a nucleic acid binding-cleft, where the thumb of p51 and 
the connection of both subunits form the “floor”. In addition, the fingers, palm and thumb 
subdomains of p66 establish lateral and apical interactions with the nucleic acid (Jacobo-Molina et 
al., 1993; Rodgers et al., 1995; Hsiou et al., 1996). Interestingly, in the absence of a nucleic acid 
substrate, the thumb subdomain of p66 is folded down resulting in a partial occlusion of the nucleic 
acid binding cleft (Rodgers et al., 1995; Hsiou et al., 1996) (Fig 6B).  
 
Fig 6. HIV-1 RT structure and effects of template/primer and dNTP binding. (A) Ribbon representation of the structure of 
the HIV-1 RT bound to DNA/DNA and dNTP showing the fingers, palm and thumb subdomains of p66 in blue, red and green, 
respectively, the connection subdomain in yellow, the RNase H domain in orange, and p51 in grey. The template strand is 
shown in purple, the primer strand in cyan and the incoming dNTP as green spheres. Catalytic residues of the DNA 
polymerase active site (Asp-110, Asp-185 and Asp-186), as well as those of the RNase H active site (Asp-443, Glu-478, Asp-
498 and Asp-549) are shown with yellow and blue spheres, respectively. (B) Superposition of p66 thumb subdomains of RT 
bound to DNA/DNA (blue) and an unliganded RT (orange) showing the movement of the thumb subdomain upon nucleic acid 
binding. In addition, the closure of the fingers tips on the bound dNTP (represented as green spheres) is also shown. 
Coordinates of RT bound to DNA/DNA and the dNTP, and unliganded RT were taken from PDB files 1RTD and 1DLO, 
respectively. Structures were obtained with the PyMOL Molecular Graphics System (DeLano Scientific) software. 
 The catalytic residues of the polymerase activity (Asp-110, Asp-185 and Asp-186) are located in 
the palm subdomain of the p66 subunit (Fig 6A), facing the nucleic acid binding cleft (Smerdon et 
al., 1994). In addition to this catalytic triad, there are other important motifs implicated in RT 
activity, indicated in Table 1.  
 Structures of RT bound to double-stranded nucleic acids (Jacobo-Molina et al., 1993; Ding et 
al., 1998; Sarafianos et al., 2001) showed that the nucleic acid binding cleft can accommodate 17-18 
nucleotides between the polymerase and the RNase H catalytic sites. The most pronounced 
conformational change undertaken by the RT upon nucleic acid binding involves the movement of 
the p66 thumb to an extended conformation, away from the fingers subdomain, creating a space that 
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is filled by the nucleic acid (Fig 6B) (Jacobo-Molina et al., 1993; Rodgers et al., 1995). There are no 
big differences in the way RT binds DNA/DNA and RNA/DNA complexes. In both DNA/DNA and 
RNA/DNA complexes, nucleic acids undertake a transition from an A-type to a B-type conformation 
near the p66 thumb subdomain. In addition, a second bend of approximately 20º-30º entering the 
RNase H domain produces an increase in the width of the major groove of the RNA/DNA duplex 
(Lapkouski et al., 2013). Recent studies have pointed out that nucleic acid-RT interactions could be 
more complex, due to the ability of RT to “flip” on the nucleic acid substrate (Abbondanzieri et al., 
2008; Liu et al., 2008, 2010). 
 
Table 1. HIV-1 RT motifs and residues participating in nucleic acid interaction 
Motif name Subdomain Residues Role in RT function 
Primer grip p66 palm (β12-β13) 227-235 
Helps to position the 
primer 3´-OH in the 
priming site 
DNA polymerase 
catalytic site 
p66 palm Asp-110, Asp-185, Asp-186 
Nucleotide incorporation 
catalytic residues 
Helix clamp p66 thumb (αH-αI) 255-268 (αH)/278-286 (αI) 
Acts as a nucleic acid 
clamp 
RNase H primer grip 
p51 connection, p66 
connection, p66 RNase H 
358-361 (p66 connection), 
395-396 (p51 connection), 
473-476, 501, 505 (p66 
RNase H) 
Closely associated with 
the primer strand 
Template grip 
p66 fingers, p66 palm (β4, 
αB, β5, β8-αE) 
73-77 (β4), 78-83 (αE), 86-
90 (β5), 141-174 (β8-αE) 
Closely associated with 
the template strand 
RNase H catalytic site RNase H 
Asp-443, Glu-478, Asp-498, 
Asp-549 
RNA hydrolysis catalytic 
residues 
β3-β4 hairpin loop p66 fingers (β3-β4) 63-73 
Implicated in nucleotide 
incorporation, fidelity and 
processivity 
YMDD p66 palm 183-186 
Implicated in nucleotide 
incorporation 
 
 Binding of a dNTP (or a nucleotide analog) produces further conformational changes. The most 
important is the closure of the fingers tips (β3-β4 strands) over the palm subdomain creating a dNTP 
binding site (or N site) just in front of the primer 3´-OH site (or P site) (Fig 6B) (Huang et al., 1998; 
Tuske et al., 2004; Das et al., 2009, 2012; reviewed in Sarafianos et al., 2009). In the dNTP binding 
pocket, the nucleotide is stabilized by interactions with residues Lys-65, Arg-72, Asp-113, Ala-114 
and Gln-151. Tyr-115 acts as a “steric gate” discriminating between dNTPs and rNTPs (Martín-
Hernández et al., 1996; Cases-González et al., 2000). Nucleotide incorporation also requires the 
proper positioning of the primer 3´-OH, stabilized by the side-chains of Tyr-183 and Met-184 (part of 
the YMDD motif) (Huang et al., 1998).  The nucleophilic attack of the 3´-OH of the primer terminus 
on the α phosphate of the dNTP renders an elongated primer and a PPi molecule, which is released 
with one of the Mg
2+ 
ions that participates in the catalysis (Huang et al., 1998; Mendieta et al., 2008). 
Upon dNMP incorporation, the RT should translocate to continue the polymerization, positioning the 
primer terminus in the P-site and leaving the N-site free for the incorporation of a new dNTP. 
Structural data show that the YMDD motif (formed by Tyr-183, Met-184, Asp-185 and Asp-186) 
acts as a “springboard” supplying some of the energy required for translocation (Sarafianos et al., 
2002; reviewed in Singh et al., 2010). 
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1.3.3 HIV-1 RT activities 
 The RT is a multifunctional enzyme with DNA- and RNA-dependent DNA polymerization 
activities, as well as RNase H activity. 
1.3.3.1 DNA polymerase activity 
 Early biochemical work using pre-steady state kinetics showed that nucleotide incorporation is a 
two-phase reaction including a rapid burst phase followed by a linear phase (Kati et al., 1992; 
Reardon et al., 1992; Wöhrl et al., 1999), a behaviour shared by other DNA polymerases (Patel et al., 
1991). The rate limiting step in the reaction was identified as the fingers movement needed to 
properly position the dNTP prior to the nucleophilic attack (Sarafianos et al., 2009). However, the 
dissociation of the RT from the template/primer is the rate limiting step of the overall reaction when 
performed under steady-state conditions (Reardon & Miller, 1990; Kati et al., 1992; Jaju et al., 
1995). 
 The RT is able to use RNA/DNA, DNA/DNA and even RNA/RNA (during the initiation of 
reverse transcription) as substrates for nucleotide incorporation. However, RNA/DNA duplexes are 
more efficient substrates, as the dNTP dissociation constant (Kd) is lower on RNA/DNA than on 
DNA/DNA, and the nucleotide incorporation rate (kpol) is also slightly increased when RNA/DNA 
complexes are used (Kati et al., 1992). The processivity of the enzyme is also enhanced with 
RNA/DNA template/primers (Reardon & Miller, 1990). In addition, the RT affinity for nucleic acid 
complexes is higher for RNA/DNA complexes than for DNA/DNA duplexes, due to their lower 
dissociation rate (koff) (DeStefano et al., 1993a).  
1.3.3.2 RNase H activity 
 RNase H activity is critical to accomplish productive infection since RNase H-deficient viruses 
are non-infectious (Schatz et al., 1989). The RNase H domain acts as an endonuclease that 
hydrolyzes the RNA strand in (and only in) RNA/DNA heteroduplexes. The catalytic active site is 
composed of four acid residues: Asp-443, Glu-478, Asp-498 and Asp-549 (Fig 6A). Those amino 
acids coordinate two divalent metal cations (most probably Mg
2+
) required for the phosphodiester-
bond cleavage (Nowotny et al., 2007; reviewed in Schultz & Champoux, 2008; Champoux & 
Schultz, 2009; Sarafianos et al., 2009; Herschhorn & Hizi, 2010; LeGrice, 2012). Several residues 
from the thumb subdomain of the p51 subunit, especially Gln-294, are important modulators of the 
RNase H activity, probably through contacts with the RNase H domain (Sevilya et al., 2001, 2003). 
Also, some residues from the connection subdomain have an impact on the RNase H activity. For 
example, the amino acid substitution A361H impairs RNA cleavage (Julias et al., 2003) while the 
RNase H mutation Q509L also reduces the enzyme´s activity (Brehm et al., 2008). Substitutions 
P52G, P55G and S156A at the palm and fingers subdomains also impair RNase H activity (Gao et 
al., 1998).  
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 Depending on the position of the DNA polymerase and RNase H domains of the RT in relation 
to the RNA/DNA ends, three different types of RNase H cleavages have been reported (Fig 7). 
1) DNA 3´-end directed: In this type of cleavage, the DNA polymerase domain is positioned on the 
3´-end of the DNA strand, annealed to a longer RNA template (Liu et al., 2008). Biochemical 
evidences show that the RT is able to cleave the RNA between 15-20 nucleotides away from the 
recessed end (Furfine & Reardon, 1991; Schultz et al., 2009).  
2) RNA 5´-end directed cleavage: Here the polymerase domain of the RT is associated with an 
RNA 5´-end of a recessed RNA annealed to a DNA strand. The DNA polymerase domain is 
located towards the RNA 5´-end, and therefore the RNase H domain binds the RNA strand 13-
19 nucleotides away (DeStefano et al., 1993b; reviewed in Schultz & Champoux, 2008). This 
type of cleavage is predominant when RNA strands are used as primers on RNA/DNA 
heteroduplexes (Fuentes et al., 1995; Schultz et al., 2003).  
3) Internal cleavage: In this type of cleavage there is no strand-end recognition by the RT (Fuentes 
et al., 1995), and the most important determinant is the nucleotide sequence (Schultz et al., 
2004). 
 
Fig 7. RT RNase H cleavage modes. Schematic representation of the three modes of RT-associated RNase H cleavage. In 
all modes of association, heteroduplex substrates contain an RNA strand (blue) and a DNA strand (black). The 3´-termini are 
indicated by arrowheads. The RT is represented by an oval, indicating the DNA polymerase (gray circle) and RNase H (pink 
circle) active sites.  
 The PPT sequence (Fig 8) is resistant to RNase H cleavage (Huber & Richardson, 1990). The 
PPT structure has a U tract at its 5´-end, a central A tract (interrupted by a single G) and a run of Gs 
at its 3´-end. The RT carries out three specific cleavages in the PPT (Fig 8) (reviewed in Rausch & 
LeGrice, 2004). The first two cleavages take place during (-) strand DNA synthesis. One of them 
occurs at the 5´-end of the PPT, normally 15, 17 or 19 nucleotides away from the PPT-U3 junction, 
defining the length of the PPT primer (Huber & Richardson, 1990; Julias et al., 2002; Rausch & 
LeGrice, 2007). The other (-) strand DNA synthesis cleavage releases the viral genomic RNA at the 
PPT-U3 junction. The third specific cleavage takes place at the RNA-DNA junction during (+) strand 
DNA synthesis and results in the production of the U3 end of the viral DNA. Evidence obtained from 
in vitro and in vivo experiments have shown that the specific sequences of both PPT ends are the 
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most important determinants for RT cleavage. The central A tract has a stronger effect on the 
efficiency of the PPT-U3 cleavage relative to the PPT 5´-end cleavage (Huber & Richardson, 1990; 
Dash et al., 2004; McWilliams et al., 2003, 2006, 2008; Julias et al., 2004; Jones & Hughes, 2007).    
 Although RNA primers are not efficiently extended by the RT (Fuentes et al., 1995), the PPT 
primer is an exception. This special property has been associated with the presence of a consensus 3´-
end G tract (Fig 8) (Huber & Richardson, 1990; Powell & Levin, 1996; Götte et al., 1999; Schultz et 
al., 2003; Rausch & LeGrice, 2007). 
 
Fig 8. PPT usage. Representation of specific cleavages on the PPT. RNA and DNA strands are shown in blue and black, 
respectively, with the PPT sequence highlighted in red. Specific RNase H cleavages are represented by yellow triangles and 
the DNA polymerization direction is indicated by an arrow. 
 
 Finally, some thumb subdomain and RNase H primer grip residues have been shown to affect 
PPT usage (Powell et al., 1999; Julias et al., 2004; McWilliams et al., 2006; reviewed in Rausch & 
LeGrice, 2004).  
1.4  Antiretroviral treatment 
 RT inhibitors play a major role in current antiretroviral therapy. Licensed RT inhibitors are 
classified into two major groups, depending on their inhibitory mechanism: nucleos(t)ide reverse 
transcriptase inhibitors (NRTIs) and non nucleoside reverse transcriptase inhibitors (NNRTIs) (Fig 
9). 
 During the first years of the AIDS epidemic, the treatment of HIV-1 infection was limited to 
very few drugs and the appearance of resistance strains leading to treatment failure was a major 
problem in the clinical management of the disease (Larder et al., 1989; St Clair et al., 1991; 
Shirasaka et al., 1993; Lin et al., 1994; Shafer et al., 1994). The emergence of resistance was 
facilitated by the high replication capacity of the virus and its high rates of mutation and 
recombination (reviewed in Menéndez-Arias, 2002, 2009). 
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 However, in the mid 90´s, with the introduction of protease inhibitors, the use of combinations 
of three or more drugs has greatly reduced the morbidity and mortality of HIV-1 infection (reviewed 
in De Clercq, 2009a,b; Arts & Hazuda, 2012). These cocktails are referred to as HAART (highly 
active antiretroviral therapy). An example of this approach is represented by Atripla®, a pill 
containing tenofovir, emtricitabine and efavirenz, commonly used in developed countries.   
 
1.4.1 Nucleos(t)ides analogues (NRTIs) 
 At present, there are eight NRTIs approved for clinical use (Fig 9A). All NRTIs lack a 3´-OH 
group and use a common mechanism of inhibition, first described for AZT in 1986 (Furman et al., 
1986). This mechanism involves the competition between the NRTI and the natural substrate and the 
subsequent interruption of DNA synthesis due to the incorporation of the NRTI in the growing DNA 
strand. The absence of the 3´-OH group blocks the formation of new phosphodiester bonds with 
incoming nucleotides (Fig 10). Based on this mechanism, NRTIs are also defined as chain-
terminators (Menéndez-Arias, 2008; De Clercq, 2009b). 
 However, before their use by the RT, the effectiveness of NRTIs depends on several factors such 
as their entry efficiency inside the cells or their half-life (Cihlar & Ray, 2010). Nonetheless, the most 
important step required by a NRTI is its phosphorylation to an active triphosphate form: AZT 
triphosphate (AZTTP), d4T triphosphate (d4TTP), ddA (ddA is the active metabolite of ddI) 
triphosphate (ddATP), ddC triphosphate (ddCTP), 3TC triphosphate (3TCTP), FTC triphosphate 
(FTCTP), carbovir (carbovir is the active metabolite of abacavir) triphosphate (CBVTP) and 
tenofovir diphosphate (tenofovir-DP).  NRTI phosphorylation is carried out by cellular kinases (De 
Clercq, 2009a,b; Cihlar & Ray, 2010). 
Prolonged use of NRTIs may produce toxic side effects, like lactic acidosis, myopathy or 
pancreatitis. These toxic effects mainly include the inhibition of mitochondrial DNA polymerase γ, 
due to the inability of this enzyme to discriminate between NRTIs and natural dNTPs (Feng et al., 
2004; Anderson, 2010; reviewed in Lewis et al., 2003; Akanbi et al., 2012).  
 However, the main problem associated with the use of NRTIs is the development of resistance 
mutations. Classically, the mutations rendering resistant RTs are divided in two groups, depending if 
the decreased susceptibility relies on a discriminatory ability to distinguish between the NRTI and the 
natural dNTP, or on the excision of the NRTI from the blocked DNA strand.  
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Fig 9. NRTIs and NNRTIs currently approved for clinical use. (A) NRTIs are 3´-azido-2´,3´-dideoxythymidine (AZT); 2´,3´-
didehydro-2´,3´-dideoythymidine (d4T); didanosine, 2´,3´-dideoxyinosine (ddI);  (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-
purine-9-yl]-2cyclopentene-1-methanol (ABC); 2´-3´-dideoxycytidine (ddC); 2´,3´-dideoxy-3´-thiacytidine (3TC); (-)-β-L-3´-thia-
2´,3´-dideoxy-5-fluorocytidine (FTC) and [(R)-9-(2-phosphonylmethoxypropyl)adenine] disoproxil fumarate (tenofovir). (B) 
NNRTIs.  
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Fig 10. Chain termination and excision mechanism. Schematic representation of dNTP or AZTTP incorporation. The RT 
nucleotide binding site (N-site) and the priming site (P-site) are represented by blue and green circles, respectively. In the 
presence of dTTP and AZTTP, the RT can incorporate the natural substrate and the DNA synthesis continues. However, upon 
AZTMP incorporation, the RT can use a PPi donor (ATP and a PPi molecule are represented) to excise the AZTMP molecule. 
This process produces a free 3´-OH end to resume DNA synthesis and leads to the formation of AZTp4A (when ATP is the 
donor) or AZTTP (when PPi is the donor) molecule. The ATP-dependent excision reaction is favored when TAMs are present. 
However, the RT can also translocate along the blocked- T/P, positioning the 3´-inhibitor in the P-site. In this configuration the 
excision of the chain-terminator cannot take place. If RT further binds the next correct dNTP, a stable complex referred to as 
“dead-end-complex” (DEC) is formed. If such a thing happens, the RT is blocked in this position and therefore the DNA 
synthesis is abrogated. 
 
1.4.1.1 Resistance to NRTIs by a discriminatory mechanism 
 Through this mechanism the RT is able to favor the incorporation of the correct dNTP instead of 
the triphosphorylated NRTI. All of the mutations acting through this pathway exert a direct effect on 
the nucleotide/inhibitor incorporation step. Many mutations acting through this mechanism impair 
the viral replication capacity (reviewed in Menéndez-Arias et al., 2003).  
 Apart from major mutations described in Table 2, there are other less frequent mutations that 
also act through a discriminatory mechanism. For example, mutations K70E/Q, V75T, V118I, Y181I 
and the deletion at codon 69 (∆69) have been found to enhance the discriminatory ability of the RT 
(Hertogs et al., 2000; Selmi et al., 2001; Blanca et al., 2003; Girouard et al., 2003; Sluis-Cremer et 
al., 2007; Kisic et al., 2008, 2011; Hachiya et al., 2011).  
1.4.1.2 Resistance to NRTIs by an excision mechanism: 
 Mutations at positions 41 (M41L), 67 (D67N), 70 (K70R), 210 (L210W), 215 (T215F/Y) and 
219 (K219Q/E) were soon identified in patients failing treatment with AZT (Larder et al., 1989; St 
Clair et al., 1991; Kellam et al., 1992; Harrigan et al., 1996; Hooker et al., 1996). The resistance 
mechanism involved in the selection of these mutations was not related with discrimination between 
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AZTTP and dTTP (Reardon & Miller, 1990; Lacey et al., 1992; Carroll et al., 1994). A moderate 
enhancement of processivity and binding affinity for AZTMP-terminated primers had been invoked 
to explain the effect of AZT-resistance-associated mutations (Caliendo et al., 1996; Canard et al., 
1998). However, two different groups showed that the most relevant difference between wild-type 
and AZT-resistant RTs was the increased ability of the latter to excise 3´-terminal chain-terminator 
inhibitors from blocked DNA primers through phosphorolysis mediated by PPi or a PPi-donor (Arion 
et al., 1998; Meyer et al., 1998). The pyrophosphorolysis reaction results in the removal of AZTMP 
from the end of the primer and the production of a polyphosphate product containing the AZTMP 
molecule linked to the PPi donor substrate (Fig 10). Chemically, PPi-dependent excision process is 
the same that the nucleotide incorporation reaction, but run in reverse.  
Table 2. Major mutations that increase the RT´s ability to discriminate between NRTIs and dNTPs 
Mutation 
Enzyme 
resistant to 
Residue role on 
nucleotide 
incorporation 
Resistance 
mechanism 
Comments References 
K65R 
CBVTP,  
3TCTP, 
tenofovir-DP 
Interacts with the 
incoming 
nucleotide 
Reduces kpol 
Most frequently selected in subtype C viruses. 
The side-chain of Arg-65 stacks against the side-
chain of Arg-72, increasing the discriminatory 
ability of the RT 
1-23 
L74V 
CBVTP, 
ddGTP, 
ddATP 
Stabilizes the 
template 
nucleoside 
Reduces kpol 
Diminished RT capacity to synthesize early 
reverse-transcribed viral DNA 
5, 24-31 
Q151M 
All NRTIs 
except    
3TCTP    
and FTCTP 
Interacts with the 
incoming 
nucleotide 
Reduces kpol 
Preferred AZT resistance mutation in HIV-2. 
Frequently found associated with other mutations 
in the cluster A62V/V75I/F77L/F116V/Q151M, 
also known as the Q151M complex 
3, 28, 29, 
32-41 
M184I/V 
3TCTP, 
FTCTP 
Interacts with 
primer 3´-OH 
Increases Kd 
Part of the YMDD motif. M184I/V causes a steric 
hindrance with the β-L-oxathialone ring of 3TCTP 
7, 28, 29, 
39, 42-48 
References correspond to (1) Srinivas & Fridland, 1998, (2) Wainberg et al., 1999, (3) Ray et al., 2002, (4) White et al., 2002, 
(5) Deval et al., 2004, (6) Miller et al., 2004, (7) Stone et al., 2004, (8) Tuske et al., 2004, (9) White et al., 2005, (10) Wirden et 
al., 2005, (11) Brenner et al., 2006, (12) Doualla-Bell et al., 2006, (13) Margot et al., 2006, (14) Parikh et al., 2006, (15) Parikh 
et al., 2007, (16) Sluis-Cremer et al., 2007, (17) Murray et al., 2008, (18) von Wyl et al., 2008, (19) Brenner & Coutsinos 2009, 
(20) Coutsinos et al., 2009, (21) Das et al., 2009, (22) Invernizzi et al., 2009, (23) Das & Arnold, 2013, (24) St Clair et al., 
1991, (25) Larder. 1992, (26) Martin et al., 1993, (27) Lacey et al., 1994, (28) Ueno & Mitsuya, 1997, (29) Huang et al., 1998, 
(30) Ren et al., 1998, (31) Frankel et al., 2005, (32) Shafer et al., 1994, (33) Shirasaka et al., 1995, (34) Ueno et al., 1995, (35) 
Iversen et al., 1996,  (36) Kosalaraska et al., 1999, (37) Deval et al., 2002, (38) Deval et al., 2005, (39) Reid et al., 2005, (40) 
Boyer et al., 2006, (41) Frangeul et al., 2008, (42) Wainberg et al., 1996, (43) Wilson et al., 1996, (44) Sarafianos et al., 1999, 
(45) Chamberlain et al., 2002, (46) Stoeckli et al., 2002, (47) Whitcomb et al., 2003, (48) Ly et al., 2007.   
 The same mutations selected under AZT therapy are also found in virus isolated from patients 
treated with d4T (Coakley et al., 2000; Cozzi-Lepri et al., 2009). For this reason, these mutations are 
commonly referred as TAMs (thymidine analogue resistance mutations). TAMs appear usually in 
two different clusters known as TAM-1, composed of mutations M41L, L210W and T215Y and 
TAM-2, including D67N, K70R, K219Q, and sometimes T215F (Yahi et al., 1999; Cozzi-Lepri et 
al., 2005, 2009; Svicher et al., 2006). The TAM-1 cluster is more frequent and confers higher levels 
of resistance to AZT (Japour et al., 1995; reviewed in Menéndez-Arias, 2010). The selection of either 
TAM-1 or the TAM-2 pathway probably depends on the emergence of the K70R or T215Y as the 
first mutations selected under therapy (Cozzi-Lepri et al., 2009; Brehm et al., 2012). Individually, 
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those mutations confer low-level resistance to AZT (Lacey et al., 1994; Boyer et al., 2001; Radzio et 
al., 2010). 
 AZTMP, d4TMP and tenofovir are the best substrates of the excision reaction, while cytidine 
analogues are resistant to ATP-mediated excision (Isel et al., 2001; Naeger et al., 2002; Ray et al., 
2003; Boyer et al., 2004; White et al., 2004, 2005; Marchand et al., 2007; Parikh et al., 2007; 
Iyidogan & Anderson, 2012; reviewed in Goldschmidt et al., 2004). Purines are generally better 
substrates than pyrimidines as shown with 3´-azidopyrimidines and 3´-azidopurines (Sluis-Cremer et 
al., 2005; Meteer et al., 2011). Although WT and mutant RTs are equally efficient in PPi-dependent 
excision reactions, the use of bi- and tri-phosphorylated molecules as PPi donors (e.g nucleoside 
triphosphates (NTPs), nucleoside diphosphates (NDPs), dNTPs, etc) is favored by the presence of 
TAMs in the RT coding sequence. However, NTPs are the most efficient PPi donors of the reaction 
(Meyer et al., 1998, 1999, 2000; Boyer et al., 2001; reviewed in Sluis-Cremer et al., 2000). Use of 
PPi or a PPi donor depends on their relative concentration inside the cell, which is also regulated by 
the cellular activation state (Barshop et al., 1991; De la Rosa et al., 1991; Gribble et al., 2000; Smith 
et al., 2005; reviewed in Smith & Scott, 2006). Among all nucleoside-triphosphates, ATP is the only 
one with intracellular concentrations high enough to be readily use as PPi donor and therefore it is 
widely accepted that this is the relevant PPi donor in vivo. 
 A recent study determining the structure of wild-type and mutant 
M41L/D67N/K70R/T215Y/K219Q RTs bound to a dsDNA and a 3´-azido-3´-deoxythymidine-(5´)-
tetraphospho-(5´)-adenosine (AZTp4A) molecule provided a rational explanation for the role of 
TAMs in NRTI excision (Tu et al., 2010). AZTp4A is a product of the ATP-dependent excision 
reaction of primers terminated with AZTMP (Fig 10, 11). Tu and colleagues demonstrated that 
“primary” TAMs K70R and/or T215Y create a new ATP binding-site by interacting with the AMP 
(adenosine monophosphate) moiety of the molecule, while the other TAMs help to stabilize the 
molecule in its binding to the RT through hydrogen bonds (Fig 11). The new ATP binding-site 
facilitates the proper alignment of the molecule for the nucleophilic attack, producing the excision of 
the blocking inhibitor, rather than increasing the affinity for ATP (Ray et al., 2003; Selmi et al., 
2003). Interestingly, this AZTp4A product, as well as other polyphosphate molecules, such as 
dinucleoside tetraphosphates, can be more efficiently used as nucleotide analogues by RTs 
containing TAMs than by the wild-type enzyme (Meyer et al., 2006; Dharmasena et al., 2007; 
reviewed in Acosta-Hoyos & Scott, 2010; Das & Arnold, 2013). 
A number of factors have been shown to affect the excision reaction rate. For example, the 
RNA/DNA or DNA/DNA nature of the template/primer, the specific nucleic acid sequence or the 
Mg
2+
 concentration (Isel et al., 2001; Rigourd et al., 2002; Ray et al., 2003; Meyer et al., 2004; 
Goldschmidt et al., 2006; Iyidogan & Anderson, 2012; reviewed in Smith & Scott, 2006). However, 
the most important factor in vivo is the RT susceptibility to the next complementary nucleotide. 
Binding of the RT to the template/primer defines two different sites, i.e., the nucleotide binding site 
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(N-site) and the priming site (P-site) (Fig 10) (Boyer et al., 2001; Marchand & Götte, 2003).  For 
excision to occur, the inhibitor incorporated at the 3´-end should be located at the N-site, and forms a 
pre-translocation complex. However, movement of the RT along the template strand leaves the 
chain-terminator at the P-site, forming a post-translocation complex (Boyer et al., 2001; Sarafianos et 
al., 2002). This complex leaves a free N-site which can be occupied by the incoming nucleotide. In 
this case, the ternary RT-T/P-NRTI complex forms a stable aggregate known as the “dead-end-
complex” (DEC) which is resistant to the excision reaction (Tong et al., 1997; Meyer et al., 1999) 
(Fig 10).  
 
Fig 11. ATP-binding site. Surface representation of an AZT-resistant RT bearing mutations M41L/D67N/K70R/T215Y/K219Q 
(left, in green), and the WT RT (right, in wheat). TAM mutations are shown in cyan and the AZTp4A molecule is represented 
with sticks. The AMP moiety of the AZTp4A molecule (in orange) adopts a conformation that favors excision in the AZT-
resistant RT, stabilized by the side-chains amino acid residues Leu-41, Asp-67, Arg-70, Tyr-215 and Gln-219. In the WT RT 
structure, the AMP moiety (in red) is in a less favorable configuration for the excision reaction. Coordinates of the AZT-
resistant and WT RTs were obtained from PDB files 3KLF and 3KLE, respectively. Structures were generated with the PyMOL 
Molecular Graphics System (DeLano Scientific) software. 
 TAMs facilitate the excision of the inhibitor from the 3´-end of the primer, while favoring the 
formation of pre-translocated complexes (Meyer et al., 1999, 2000; Mas et al., 2002; Marchand & 
Götte, 2003; Selmi et al., 2003; White et al., 2004). Different NRTIs show different propensities to 
generate these complexes. Thus, excision of d4TMP or tenofovir is highly susceptible to inhibition 
by low concentrations of the next correct nucleotide (i.e., between 0.5 and 25 μM) (Meyer et al., 
1999, 2000; Ray et al., 2003; Marchand et al, 2007; Matamoros et al., 2009, reviewed in Smith & 
Scott, 2006). On the other hand, the high volume of the azido group impairs the incorporation of a 
subsequent nucleotide, facilitating AZTMP excision even in the presence of high concentrations of 
dNTP (e.g., > 200 μM) (Boyer et al., 2001). 
 Clinical, virological and biochemical data have shown that certain mutations impair TAM 
function (Table 3). However, the analysis of a large number of viral sequences has also allowed the 
identification of a number TAM-associated mutations that improve fitness of TAM-containing HIV-1 
strains (Table 4).  
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Table 3. Mutations that antagonize the effect of TAMs on ATP- or PPi-dependent excision 
Group Mutation Comments References 
NRTI resistance mutations 
involved in dNTP discrimination 
K65R Primary mutation involved in tenofovir resistance 1-7 
L74V ddI resistance mutation 8-11 
V75I Part of the Q151M complex 12 
M184V 3TC and FTC resistance mutation 5, 10, 11, 13, 14 
Foscarnet (phosphonoformic 
acid) 
W88G/S, E89K, 
L92I, S156A, 
Q161L 
Rarely found in patients, since foscarnet is not 
currently prescribed for HIV-1 treatment  
15-18 
NNRTI resistance mutations 
I132M 
Rare nevirapine and delavirdine resistance 
mutation. Reduces RT´s ability to discriminate 
between NRTIs and dNTPs 
19,20 
Y181C Nevirapine resistance mutation 9, 21 
Others R172K 
Impairs NRTI and NNRTI resistance in different 
sequence contexts 
22, 23 
References correspond to (1) Parikh et al., 2006, (2) Ly et al., 2007,  (3) Parikh et al., 2007, (4) Sluis-Cremer et al., 2007, (5) 
Zelina et al., 2008, (6) Das et al., 2009, (7) Xu et al., 2009, (8) St Clair et al., 1991, (9) Larder, 1992, (10) Frankel et al., 2005, 
(11) Miranda et al., 2005, (12) Matamoros et al., 2009, (13) Boyer et al., 2002a, (14) von Wyl et al., 2010, (15) Mellors et al., 
1995, (16) Tachedjian et al., 1996, (17) Tramontano et al., 1998, (18) Meyer et al., 2003a, (19) Nissley et al., 2007, (20) 
Ambrose et al., 2009, (21) Selmi et al., 2003, (22) Hachiya et al., 2012, (23) Menéndez-Arias, 2013. 
 In addition, several connection and RNase H mutations have been associated with antiretroviral 
treatment failure: E312Q (Nikolenko et al., 2007; Hachiya et al., 2009), G333E (Hachiya et al., 
2009), G335C/D (Nikolenko et al., 2007; Delviks-Frankenberry et al., 2008, 2013; Hachiya et al., 
2009), N348I (Nikolenko et al., 2007; Yap et al., 2007; Delviks-Frankenberry et al., 2008, 2013; 
Ehteshami et al., 2008; Hachiya et al., 2008; Gupta et al., 2010; Radzio et al., 2010; Sluis-Cremer et 
al., 2010; Von Wyl et al., 2010; Lengruber et al., 2011; Radzio & Sluis-Cremer, 2011), A360I/V/T 
(Nikolenko et al., 2007; Delviks-Frankenberry et al., 2008; Ehteshami et al., 2008; Brehm et al., 
2012), V365I (Nikolenko et al., 2007; Delviks-Frankenberry et al., 2008; Hachiya et al., 2009), 
A371V (Hachiya et al., 2009; Lengruber et al., 2011; Delviks-Frankenberry et al., 2013), A376S 
(Nikolenko et al., 2007; Delviks-Frankenberry et al., 2008, 2013; Hachiya et al., 2009), A400T (Von 
Wyl et al., 2010; Delviks-Frankenberry et al., 2009; 2013) and Q509L (Brehm et al., 2008). 
Although not all of these mutations have been mechanistically characterized, several of them are 
thought to act by reducing the RNase H activity of the enzyme, giving RT more time to remove the 
chain-terminator inhibitor before RNA degradation (reviewed in Götte, 2007; Ehteshami & Götte, 
2008; Delviks-Frankenberry et al., 2010) (Fig 12). Biochemical data have shown that mutations 
N348I, Q509L and the combination N348I/A360V reduced RT RNase H activity while increasing 
AZTMP excision on RNA/DNA complexes, but not on DNA/DNA complexes (Nikolenko et al., 
2007; Yap et al., 2007; Brehm et al., 2008; Delviks-Frankenberry et al., 2008; Ehteshami et al., 
2008; Hachiya et al., 2008; Radzio et al., 2010). These mutations impair RNase H activity, especially 
the secondary cleavages responsible for the generation of RNA oligonucleotides of less than 13 
bases, a length insufficient to serve as excisable substrate if blocked with an NRTI at their 3´-end 
(Brehm et al., 2008; Radzio & Sluis-Cremer 2008).  
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Table 4. TAMs associated mutations located in the fingers, palm and thumb subdomains of HIV-1 RT 
Mutation/s Comments References 
E40F 
When combined with M41L/T215Y, this substitution increases AZT resistance in phenotypic 
assays. It also reduces viral fitness 
1 
K43E 
Although this mutation does not affect viral AZT resistance, addition of K43E to 
E40F/M41L/T215Y mutations restores viral replication capacity 
1 
E44D 
Addition of E44D mutation improves 3TCMP excision efficiency of the mutant 
M41L/D67N/L210W/T215Y enzyme 
2 
V118I 
When combined with T215Y it increases by 2-fold the IC50 for d4T. In enzymatic assays the 
presence of V118I alone or combined with different TAMs increases AZT, 3TC and ddA 
resistance by reducing NRTI incorporation. V118I reduces AZTMP and 3TCMP excision both 
on a wild-type and on mutated M41L/E44D/D67N/L210W/T215Y background 
2, 3 
 
Q207D 
Virus carrying M41L/D67N/K70R/Q207D/H208Y/T215Y/K219Q has an IC50 for AZT that is 2.7-
fold higher than the IC50 for the mutant virus M41L/D67N/K70R/H208Y/T215Y/K219Q  
4 
H208Y 
When combined with T215Y it increases by 2-fold the IC50 for d4T while decreasing viral 
fitness. Further addition of V118I increases the IC50 by 3.3-fold 
3 
F214L 
Polymorphism negatively associated with the TAM-1 pathway but positively associated with 
TAM-2 mutations 
5, 6 
References correspond to (1) Huigen et al., (2008), (2) Girouard et al., (2003), (3) Clark et al., (2006),  (4) Lu et al., (2005), (5) 
Svicher et al., 2006, (6) Puertas et al., 2009. Additional clinical and epidemiological data supporting the association of these 
mutations with antiretroviral treatment and/or TAMs can be found in Garriga et al., 2009 (H208Y), Chen et al., 2004 (V118I), 
Ceccherini-Silberstein et al., 2005 (K43E, E44D, V118I, H208Y), Cane et al., 2007 (K43E, H208Y), von Wyl et al., 2010 
(K43E, E44D, V118I, H208Y), Saracino et al., 2006 (K43E, H208Y), Stürmer et al., 2003 (H208Y), Romano et al., 2002 (K43E, 
E44D, V118I, H208Y), Svicher et al., 2006 (K43E, H208Y), Nebbia et al., 2007 (H208Y), Shulman et al., 2004 (found V118I 
and H208Y associated with NNRTI hypersusceptibility), Stoeckli et al., 2002 (E44D, V118I, Q207D, H208Y), Masquelier et al., 
2004 (E44D, V118I), Melikian et al., 2012 (E40F, K43E, V118I, H208Y). Finally, Gonzales et al., 2003 found mutations at 
positions 43, 44, 118 and 208 associated with increased exposure to NRTIs. 
 
Fig 12. Mechanisms proposed to explain enhanced NRTIs resistance mediated by connection subdomain mutations. 
(A) Reduced RNase H activity gives RT more time to excise the 3´-end inhibitor before synthesis abrogation. RNA and DNA 
strands are blue and dark, respectively and the 3´-end inhibitor is represented by a red square. RT (grey oval) posses a 
RNase H and a DNA polymerase active sites, illustrated by red and grey circles, respectively. (B) Similarly, reduced ability to 
produce secondary cleavages rendering RNA/DNA duplexes less than 13 nucleotides long, limits the amount of non-excisable 
substrates. 
 Interestingly, another connection subdomain mutation, G333D has been found to compensate for 
the excision impairment produced by the presence of the M184V mutation together with TAMs 
(Kemp et al., 1998). Addition of G333D on a background of M41L/M184V/L210W/T215Y 
mutations compensates AZTMP excision by increasing the affinity of the RT for the blocked 
complex (Zelina et al., 2008). 
 Finally, associated with the presence of TAMs, a number of changes in the β3-β4 hairpin loop of 
RT fingers subdomain, including dipeptide insertions between codons 69-70 (sometimes 
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accompanied by mutations T69S and A62V), and the deletion of codon 67 (together with mutations 
T69G and K70R) (i.e., the ∆67 complex), have been described as enhancers of the excision reaction 
(Mas et al., 2000, 2002; Boyer et al., 2002b; Meyer et al., 2003b; Matamoros et al., 2004; White et 
al., 2004; Cases-González et al., 2007; Kisic et al., 2011; reviewed in Menéndez-Arias et al., 2006).  
1.4.2 Resistant to non-nucleoside RT inhibitors (NNRTIs) 
 There are five NNRTIs currently approved for clinical use: the dipyrodiazepinone nevirapine 
(NVP), the bis(heteroaryl)piperazine (BHAP) derivative delavirdine (DLV), the benzoxazinone 
efavirenz (EFV) and the most recently approved diarylpyrimide (DAPY) analogues etravirine (ETR, 
formerly known as TMC125) and rilpivirine (RPV, formerly known as TMC278) (Fig 9B). Unlike 
NRTIs, NNRTIs do not need further modifications inside the cell to be active. In addition, all 
approved NNRTIs share the same inhibitory mechanism. All act as allosteric inhibitors binding to a 
pocket situated approximately 10 Å away from the dNTP binding site (Fig 13A) (Kohlstaedt et al., 
1992; Smeardon et al., 1994). This pocket is formed upon NNRTI binding and involves the 
movement of the side-chains of Tyr-181 and Tyr-188 from a down configuration (as observed in the 
unliganded RT) to an upper configuration (Rodgers et al., 1995; Hsiou et al., 1996; reviewed in Ren 
& Stammers, 2008; Singh et al., 2010). Inside the binding pocket, NNRTIs establish a number of 
stacking interactions that could vary depending on the specific inhibitor (Fig 14). 
NNRTI binding produces a number of rearragments in the RT structure (Fig 13B, C), including 
the hyperextension of the thumb subdomain, which coupled with a movement of the 3´-end of the 
primer strand, relocate the 3´-end in a non-catallytically position. In addition, there is a change in the 
conformation of the β3-β4 structure of the fingers subdomain, that impairs the productive binding of 
the dNTP (Fig 13C) (Das et al., 2012). Kinetic studies have shown that NNRTIs inhibit the chemical 
step of dNTP incorporation, but not the conformational change (Spence et al., 1995, 1996). 
Furthermore, NNRTI binding enhances the RT affinity for dNTPs in a metal-dependent way (Xia et 
al., 2007). In addition, apart from the polymerase inhibitory effect, NNRTIs also impact the RNase H 
activity, producing an enhancement of the hydrolytic activity (Palaniappan et al., 1995; Shaw-Reid et 
al., 2005; Hang et al., 2007; Radzio & Sluis-Cremer 2008; Biondi et al., 2010; reviewed in Sluis-
Cremer & Tachedjian, 2008). 
 Studies from different groups have shown that efavirenz, etravirine and in a lesser extend 
nevirapine promote RT dimerization (Tachedjian et al., 2001; Figueiredo et al., 2006; Braz et al., 
2010a,b; reviewed in Sluis-Cremer & Tachedjian, 2008). This behavior can be explained by the 
strong tendency of NNRTIs to bind the p66 monomer. Interestingly, binding of EFV to the RT 
structure in the Gag and Gag-Pol precursos may lead to the formation of RT dimers, but also protease 
dimers, producing the premature cleavage of the Gag and Gag-Pol polyproteins (Figueiredo et al., 
2006; Chiang et al., 2009; Sudo et al., 2013; reviewed in Sluis-Cremer & Tachedjian, 2008).  
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Fig 13. Effects of NNRTI binding on RT structure. (A) Ribbon representation of the RT bound to NVP (PDB code 3HVT). 
Structure showing the p66 and p51 subunits in blue and gray, respectively. NVP is shown as green dots, and polymerase 
catalytic aspartic acids Asp-110, Asp-185, Asp-186 are shown as orange spheres. (B) Comparison of the conformation of the 
thumb subdomain in the unliganded RT (PDB file 1HMV), in red, RT bound to DNA/DNA (PDB file 2HMI), in cyan, and RT-
NVP binary complex (PDB file 3HVT), in brown. (C) Superposition of  RT-DNA/DNA-NVP (PDB file 3V81) and RT-DNA/DNA-
AZTTP (PDB file 3V4I) complexes, in green and red, respectively. The primer 3´-end of each structure is shown in the same 
color code. NVP binding produces a relocation of the primer 3´-end as well as the movement of fingers tip β3-β4 loop. 
Structures were obtained with the PyMOL Molecular Graphics System (DeLano Scientific) software. 
  NNRTI resistance mutations (Fig 15) are classified in three groups according with their 
mechanism of resistance. Thus, mutations such as Y181C/I or Y188C/L eliminate specific stacking 
interactions between the NNRTI and the RT (Kohlstaedt et al., 1992; Smeardon et al., 1994; Ren et 
al., 2001; Das et al., 2007). Other mutations, such as L100I and G190A/S introduce a steric 
hindrance, decreasing the space available for the NNRTI to bind the RT (Hsiou et al., 1998; Ren et 
al., 2004; Das et al., 2008). Finally, mutations such as K101E and K103N prevent the entry of the 
NNRTI by altering hydrogen bond interactions in the NNRTI binding site (Maga et al., 1997; Hsiou 
et al., 2001; Ren et al., 2006). Interestingly, combinations of at least two of these classical NNRTI 
resistance mutations are needed to show phenotypic resistance to the newly developed NNRTIs 
etravirine and rilpivirine (Ghosn et al., 2009; Alcaro et al., 2011). These drugs were designed to have 
high flexibility, to facilitate their accommodation inside the binding pocket. Structural studies have 
shown the ability of these drugs to reorient and reposition into the pocket through conformational 
changes designated as “wiggling” and “jiggling” (Das et al., 2004, 2008; Lansdon et al., 2010). 
Although etravirine and rilpivirine were expected to have a higher genetic barrier to resistance (i.e., 
30
                                                                                                                   Introduction 
 
required 2 or 3 amino acid substitutions for high-level resistance), epidemiological and virological 
studies have reported the quick appearance of the E138K substitution in patients treated with those 
drugs (Tambuyzer et al., 2009; Asahchop et al., 2011; Hu & Kuritzkes 2011; Xu et al., 2011, 2012, 
2013; Singh et al., 2012). 
 
 
Fig 14. Structure of nevirapine, efavirenz, etravirine and rilpivirine binding pockets and resistance-associated 
mutations. Panels show the binding pockets of four inhibitors, using a mesh representation. NNRTIs are represented with 
blue, purple, orange and yellow sticks for nevirapine, efavirenz, etravirine and rilpivirine, respectively. Major interactions for 
each NNRTI are indicated. For nevirapine, residues Leu-100, Lys-103, Val-106, Tyr-181, Tyr-188, Gly-190, Phe-227, Trp-229, 
Leu-234, Pro-236 and Tyr-318 are shown in yellow. For efavirenz, residues Leu-100, Lys-101, Lys-103, Val-106, Val-179, Tyr-
181, Tyr-188, Phe-227, Trp-229 and Tyr-318 are shown in green. In etravirine and rilpivirine complexes, residues Leu-100, 
Val-106, Val-179, Tyr-188, Pro-225, Phe-227, Trp-229, Leu-234, Pro-236 and Tyr-318 (in red) and residues Phe-227, Trp-229 
and the p51 residue Glu-138 (in blue), respectively, are highlighted. Coordinates were taken from PDB files 3HVT (NVP), 
1FK9 (EFV), 3MEC (ETR) and 3MEE (RPV). Structures were obtained with the PyMOL Molecular Graphics System (DeLano 
Scientific) software. 
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Fig 15. NNRTI resistance-associated mutations.  
 In addition, connection subdomain mutations E312Q, Y318F, G333D/E, G335C, N348I, K358R, 
G359S, A360I/V, V365I, T369I/V, A371V, I375V, A376S, T377M, T386A, I393L and E399D, as 
well as the RNase H domain mutation Q509L have been found associated with NNRTI resistance 
(Pelemans et al., 1998; Harrigan et al., 2002; Vingerhoets et al., 2005; Yap et al., 2007; Zhang et al., 
2007; Hachiya et al., 2008, 2009; Gupta et al., 2010, 2011; Sluis-Cremer et al., 2010; Lengruber et 
al., 2011; McCormick et al., 2011; Paredes et al., 2011; Delviks-Frankenberry et al., 2013; reviewed 
in Menéndez-Arias et al., 2011). Biochemical studies carried out with RTs bearing the mutation 
Y318F or Y318W, showed that they conferred resistance to DLV (Y318F) and NVP (Y318W) 
(Pelemans et al., 1998). It has been shown that the A376S mutation alone confers 3.8-fold resistance 
to NVP, due to a reduced NVP binding affinity and an improved affinity for DNA/DNA complexes 
(Paredes et al., 2011). However, for the most studied mutation (N348I), four different mechanism 
have been proposed to explain the observed phenotypic resistance to NVP. Thus, this mutation could 
act by (i) reducing NVP binding to the inhibitor binding pocket, (ii) decreasing the affinity of the RT 
for the template/primer in the presence of the NNRTI, (iii) diminishing the RT RNase H activity, and 
(iv) affecting the orientation of the RT relative to the nucleic acid substrate, a property relevant for 
PPT-RNA primer removal during (+) strand DNA synthesis (Fig 16) (Yap et al., 2007; Biondi et al., 
2010; Nikolenko et al., 2010; Schuckmann et al., 2010; Radzio & Sluis-Cremer 2011; reviewed in 
Menéndez-Arias et al., 2011). Interestingly, while the N348I substitution in the p51 subunit is the 
responsible for the reduced RNase H activity (Schuckmann et al., 2010; Radzio & Sluis-Cremer, 
2011), the reduced NVP affinity conferred by this amino acid substitution seems to rely on the 
presence of N348I in the p66 subunit (Schuckmann et al., 2010). 
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Fig 16. Potential mechanisms to explain NNRTI resistance mediated by N348I. (A) Behavior of wild-type and N348I 
mutant RTs with a heteropolymeric RNA/DNA. RT mutation can affect interactions with the NNRTI and the RNA/DNA 
template/primer and therefore, the balance between the RNA-dependent DNA polymerase and RNase H activities of the 
enzyme during DNA elongation. (B) Proposed effect of the N348I mutation on initiation of (+) strand DNA synthesis is based 
on the reduced tendency of N348I RT to bind on an RNase H-dependent orientation. Therefore, the PPT-RNA primer is not 
degraded and gives RT more time to dissociate from the NNRTI and resume the synthesis. 
 
 Finally, simultaneous usage of NRTIs and NNRTIs produces a synergistic action, where 
NNRTIs antagonize the effects of TAMs on NRTI excision from blocked template/primers 
(Basavapathruni et al., 2004, 2006; Radzio & Sluis-Cremer, 2008).  
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2. Objectives 
1. To determine the role of RT thumb subdomain polymorphisms Pro-272, Arg-277 and Thr-
286 associated with thymidine analogue resistance mutations (TAMs) in resistance to 
nucleoside analogues inhibitors. 
2. To characterize the molecular mechanism underlying the selection of the RT thumb 
subdomain substitution R284K under treatment with NRTIs, in the presence of TAM-1 
pathway mutations (i.e., M41L, L210W and T215Y). 
3. To study the mechanism by wich H208Y contributes to the selection of NRTI-resistant 
strains containing mutations of the TAM-1 pathway. 
4. To determine the effects of different RT connection subdomain mutations in resistance to 
nevirapine and other non-nucleoside RT inhibitors and to analyze their contribution to PPT 
removal in reverse transcription during (+) strand DNA synthesis 
5. To determine the effect of HIV-1 integrase in the RNase H activity of the RT in the 
processing of the PPT during reverse transcription and in the hydrolysis of heteropolymeric 
RNA/DNA complexes. 
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3. Materials & Methods 
3.1 Site-directed mutagenesis 
In this work several RTs bearing different combination of amino acids substitutions have been 
used. To obtain these mutant enzymes the “QuickChangeTM Site-Directed Mutagenesis Kit” of 
Stratagene was used according to the manufacturer’s instructions. 
Plasmid pRT66B (Fig 17) contains the sequence of the RT-coding region from the HIV-1 wild-
type BH10 strain (group M, subtype B). This plasmid was used as template to introduce mutations 
M41L, H208Y, T215Y, P272A, R277K, R284K, T286A, N348I, M357T, T369I, T369V and T376S. 
Additionally, a derivative of the pRT66B plasmid containing the mutations M41L/T215Y 
(pRT66BLY) and obtained during this project, was used to introduce mutations 
P272A/R277K/T286A, H208Y and L210W. In addition, the pRT66BLWY plasmid, containing 
mutations M41L/L210W/T215Y was used to introduce mutations H208Y, R284K and M357T. 
Another variant of the pRT66B plasmid containing the sequence of a mutated RT bearing a Ser-Ser 
insertion between codons 69 and 70 and mutations M41L, A62V, T69S, K70R, and T215Y was also 
used (Matamoros et al., 2004 ). 
 
Fig 17. Plasmids used in RT purification. Left, plasmid pRT66B (Boretto et al., 2001). This plasmid codifies the p66 subunit 
of RT and derives from plasmid pTcr99A (Amersham Bioscience). The plasmid pTcr99A was modified by introducing the p66 
coding sequence and a six-histidine tag in sites generated by MscI and HindIII endonucleases. Right, plasmid pATPR, 
codifying HIV-1 protease. The plasmid pATPR (Boretto et al., 2001) derived from pAT contained an ATG codon followed by 
the protease coding sequence in the ribosome binding site (RBS) of T7g10, flanked by EcoRI and BamHI endonuclease 
restriction sites. pRT66B and pATPR are expressed simultaneously to produce p66/p51 heterodimers resulting from cleavage 
of p66 by the viral protease.  
 
Mutagenesis reactions were carried out using plasmids pRT66B, pRT66BLY and pRT66BLWY as 
templates and the mutagenic primers shown in Table 5. Table 6 shows a list with all of the mutant 
RTs purified (derived from the HIV-1 group M subtype B BH-10 strain) in this work and their 
sequence differences in comparison to the wild-type HIV-1 (BH-10 strain) RT. 
41
                                                                                                     Materials & Methods 
 
Mutagenesis reactions were carried out in 50 μl of 20 mM Tris-HCl pH 8.8 buffer, containing 10 
mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1% (w/v) Triton X-100, 0.1 mg/ml bovine serum 
albumin (BSA), 125 ng of each of the corresponding mutagenic primers, around 50 ng of the 
template plasmid, 500 μM of each of the four dNTPs and 2.5 U of Pfu Turbo DNA polymerase 
(Stratagene). The polymerase chain reaction (PCR) was started with an incubation of 2 min at 95ºC 
followed by 20 cycles each one including incubations of 30 s at 95ºC, 1 min at 55ºC and 12 min at 
68ºC. The obtained product was treated with 10 U of DpnI (Stratagene) for 1 hour at 37ºC. DpnI is an 
endonuclease that specifically degrades the methylated or hemimethylated DNA, leaving undigested 
the newly synthesized DNA with the desired mutations. The template plasmids used in the reaction 
are methylated because they are amplified in an E. coli dam
+
 strain. 
 
Table 5. Primers used in mutagenesis reactions 
Mutation(s) Primer sequence 
M41L 
5´ GTAGAAATTTGTACAGAACTGGAAAAGGAAGGGAA  3´ 
3´ CATCTTTAAACATGTCTTGACCTTTTCCTTCCCTT  5´ 
  
H208Y  
5´ GGAGCTGAGACAATATCTGTTGAGGTGGGG  3´ 
3´ CCTCGACTCTGTTATAGACAACTCCACCCC  5´ 
  
H208Y
a
 
5´ GGAGCTGAGACAATATCTGTGGAGGTGGGG  3´ 
3´ CCTCGACTCTGTTATAGACACCTCCACCCC  5´ 
  
L210W 
5´ GCTGAGACAACATCTGTGGAGGTGGGGACTTACC  3´ 
3´ CGACTCTGTTGTAGACACCTCCACCCCTGAATGG  5´ 
  
T215Y 
5´ TGAGGTGGGGATTTTACACACCAGACAAA  3´ 
3´ ACTCCACCCCTAAAATGTGTGGTCTGTTT  5´ 
  
P272A/R277K 
5´ CAAGTCAGATTTACGCAGGGATTAAAGTAAAGCAATTATGTAAAC  3´ 
3´ GTTCAGTCTAAATGCGTCCCTAATTTCATTTCGTTAATACATTTG  5´ 
  
R284K 
5´ GTAAACTCCTTAAAGGAACCAAAGCACTAAC  3´ 
3´ CATTTGAGGAATTTCCTTGGTTTCGTGATTG  5´ 
  
T286A 
5´ CTCCTTAGAGGAGCCAAAGCACTAACAGA  3´ 
3´ GAGGAATCTCCTCGGTTTCGTGATTGTCT  5´ 
  
N348I 
5´ CAAGAGCCATTTAAAATTCTGAAAACAGGAAAATATGCAAGAATGAGG 3´ 
3´ GTTCTCGGTAAATTTTAAGACTTTTGTCCTTTTATACGTTCTTACTCC 5´ 
  
M357T 
5´ GGAAAATATGCAAGAACGAGGGGTGCCCAC  3´ 
3´ CCTTTTATACGTTCTTGCTCCCCACGGGTG  5´ 
  
T369I 
5´ CTAATGATGTAAAACAATTAATAGAGGCAGTGCAAAAAATAACCAC 3´ 
3´ GATTACTACATTTTGTTAATTATCTCCGTCACGTTTTTTATTGGTG 5´ 
  
T369V 
5´ CACTAATGATGTAAAACAATTAGTAGAGGCAGTGCAAAAAATAACCACAG  3´ 
3´ GTGATTACTACATTTTGTTAATCATCTCCGTCACGTTTTTTATTGGTGTC  5´ 
  
T376S 
5´ CAGAGGCAGTGCAAAAAATATCCACAGAAAGCATAGTAATATGGGG  3´ 
3´ GTCTCCGTCACGTTTTTTATAGGTGTCTTTCGTATCATTATACCCC  5´ 
Left column indicates the mutation(s) introduced in the RT. Mutagenized codons are shown in red. The sequence of RTs 
obtained after the mutagenesis reactions were confirmed by DNA sequencing.  
a 
 H208Y mutation introduced in a M41L/L210W/T215Y background. Underlined sequence indicates the triplet encoding for the 
L210W mutation. 
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E. coli DH5α [F-, φ80dlacZΔM15, Δ(lacZYAargF),U169, recA1, endA1, hsdR17 (rK- mK+), 
phoA, supE44, λ-, thi-1, gyrA96, relA1] competent cells were then transformed with 3 μl of the 
product of the mutagenesis reaction, and ampicillin-resistant colonies were selected. 
The integrity of the entire RT sequence, as well as the presence of the desired mutations, were 
confirmed by sequencing of the plasmidic DNA extracted with the “Wizard Plus SV Minipreps” kit 
(Promega). The sequencing reactions were carried out in Macrogen Korea (Seoul, South Korea). The 
sequences were analyzed using the Seqman 4.0 (DNAstar Inc.) software. Once the presence of the 
mutation was confirmed, the plasmids were used to transform the E. coli XL1-Blue PR strain. This 
strain derives from E. coli XL1-Blue, previously transformed with the pATPR plasmid (Fig 17), that 
contains the nucleotide sequence encoding the HIV-1 protease (Boretto et al., 2001). 
 
Table 6. Purified recombinant RTs  
RT 41 62 69 70 208 210 215 272 277 284 286 348 357 369 376 
WT (BH10) M A T K H L T P R R T N M T T 
M41L/H208Y/L210W/T215Y L    Y W Y         
M41L/H208Y/T215Y L    Y  Y         
M41L/L210W/T215Y L     W Y         
M41L/L210W/T215Y/R284K L     W Y   K      
M41L/L210W/T215Y/R284K/M357T L     W Y   K   T   
M41L/T215Y L      Y         
M41L/T215Y/P272A/R277K/T286A L      Y A K  A     
H208Y     Y           
P272A/R277K/T286A        A K  A     
R284K          K      
N348I            I    
N348I/T369I            I  I  
T369I              I  
T369V              V  
T376S               S 
MAK_SSSY L V SSS R   Y         
Left column indicates the name of the RT, while the amino acid substitution found in RT sequence of the different mutants are 
shown on the right. The second row on the top shows the amino acid sequence of the wild-type (BH10 strain) HIV-1 RT at 
relevant positions.  
 
 
3.2 RT purification 
RT purification relies on the coexpression of the large subunit of the RT (p66) and the HIV-1 
protease in E. coli, previously transformed with plasmids pRT66B and pATPR (Fig 17) (Boretto et 
al., 2001; Matamoros et al., 2005). 
3.2.1 RT expression 
Twenty ml of LB medium containing ampicillim (100 μg/ml) and kanamicin (50 μg/ml) were 
inoculated with 5-10 μl of a glycerol-containing stock of E. coli XL1-Blue strain cells previously 
transformed with the pRT66B plasmid (which contains the sequence of the p66 subunit of the RT 
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with the desired mutations) and the pATPR plasmid (codifying the viral PR). This culture was grown 
overnight at 37ºC under constant stirring. Then, the obtained culture (20 ml) was added to 300 ml of 
the same medium and grown for another 4 hours under the same conditions. After this step, we 
prepared three flasks of one liter each with fresh LB medium containing ampicillin (100 μg/m) and 
kanamicin (50 μg/ml). To each flask we added 100 ml of the bacterial culture obtained in the 
previous step. These cultures were maintained under constant agitation at 37ºC until the optical 
density at 600 nm was around 0.7. Then, isopropyl β-D-1-thiogalactopyranoside (IPTG) was added 
to a final concentration of 0.6 mM to produce the p66 subunit of the RT and the PR encoded within 
the plasmids and the culture was left at 37ºC for another 24 hours. Then, the cells were harvested by 
centrifugation at 3000 rpm at 4ºC for 30 min using a rotor JLA 10.500 and an Avanti J-26 XP 
centrifuge (Beckman Coulter). 
3.2.2 Lysis of bacteria 
The bacterial pellet obtained (roughly 4 g) was resuspended in 20 ml of 40 mM Tris-HCl pH 8.0 
buffer, containing 25 mM EDTA, 10% (w/v) sucrose, 1 mM phenylmethylsulfonyl fluoride (PMSF), 
2 mM benzamidine, and 1 mg/ml lysozyme, and stirred at 4ºC for 15 min. Then, another 20 ml of a 
solution containing 0.8% (w/v) NP-40, 20 mM dithiothreitol, 1 mM PMSF and 2 mM benzamidine 
were added and again mixed at 4ºC for 15 min. Finally, we added NaCl to a final concentration of 0.5 
M and the mixture was sonicated at an amplitude of 24 microns for 1 min using a Labsonic M 
sonifier (Sartorius). Then, the sample was centrifuged at 15000 g at 4ºC for 15 min using a rotor JA 
25.50 and an Avanti J-26 XP centrifuge (Beckman Coulter). The supernatant obtained was diluted in 
7 volumes of 50 mM sodium phosphate pH 6.8 buffer and stored at 4ºC. 
3.2.3 Cation-exchange chromatography  
First, a cellulose-phosphate column (P11 cellulose phosphate, Whatman) of around 5 ml was 
packed according to manufacturer’s instructions in 50 mM sodium phosphate pH 6.8 buffer, leaving 
the column at the same pH. The sample was passed through the column and then washed with 10 
volumes of the equilibrating buffer. 
The bound enzyme was eluted from the column using a gradient prepared with 40 ml of 50 mM 
sodium phosphate pH 6.8 buffer, containing 30 mM NaCl, and 40 ml of the same buffer, containing  
1 M NaCl. Fractions of 2 ml were collected and the presence of enzyme was checked by measuring 
the absorbance at 280 nm of all fractions. The enzyme-enriched fractions were pooled and subjected 
to affinity chromatography. 
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3.2.4 Affinity chromatography 
The pooled sample collected after the cation-exchange chromatography step was loaded in a 2 
ml-column of Ni
2+
-nitriloacetic-agarose (ProBond
TM
, Invitrogen), previously equilibrated in 50 mM 
sodium phosphate pH 6.8 buffer containing 30 mM NaCl. Then, the column was washed with 100 ml 
of 50 mM sodium phosphate pH 6.0 buffer containing 0.5 M NaCl. 
The RT bound to the Ni
2+
 column was eluted with a gradient prepared with 20 ml of 50 mM 
sodium phosphate pH 6.0 buffer containing 0.5 M NaCl, and another 20 ml of the same buffer 
containing 0.5 M NaCl and 0.5 M imidazole. Fractions of 2 ml were collected and their absorbance at 
280 nm was determined. The RT-enriched fractions were pooled and subjected to dialysis using 
Visking 20/32 dialysis bags of 16 mm diameter in a 50 mM Tris-HCl pH 7.0 buffer, containing 25 
mM NaCl, 1 mM EDTA and 10% (w/v) glycerol. Pooled fractions (around 20 ml) were usually 
dialyzed against 250 ml of dialysis buffer each time, and four changes of the dialysis solution were 
made. Finally, the sample was concentrated to a final volume of 1-2 ml by ultracentrifugation using 
Centiprep-30 (Millipore) and following manufacturer’s instructions. The concentrated RT aliquots 
obtained were stored at -20ºC. 
The purity of the heterodimers obtained was determined by SDS-polyacrylamide gel 
electrophoresis. The enzyme concentration was determined by using the RT molar extinction 
coefficient at 280 nm (ε280 = 260450 M
-1
 cm
-1
) (Kati et al., 1992).  
3.3 Nucleotides and Inhibitors 
Stock solutions (100 mM) of dNTPs, ddATP and rNTPs were obtained from GE Healthcare. 
AZT triphosphate (AZTTP) was purchased from Moravek Biochemicals (Brea, CA) and TriLink 
Biotechnologies (San Diego, CA). Carbovir triphosphate (CBVTP) and tenofovir diphosphate 
(tenofovir-DP) were obtained from Moravek Biochemicals (Brea, CA). Stavudine triphosphate 
(d4TTP) was purchased from Sierra Bioresearch (Tucson, AZ). 
The NNRTIs nevirapine (NVP), efavirenz (EFV), etravirine (ETR) and rilpivirine (RPV) were 
obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, 
NIH (Rockville, Maryland, USA). In the case of rilpivirine and etravirine, drugs were contributed to 
the Program by Tibotec Pharmaceuticals, Inc. 
3.4 Preparation of template/primers 
In this work, we used several DNA/DNA and RNA/DNA complexes. Their sequences are given 
in Table 7.  
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3.4.1 Heteropolymeric nucleic acid complexes 
M13mp2 oligonucleotide ssDNA was available in the laboratory from previous studies and was 
obtained as decribed in Bebenek & Kunkel (1995). Synthetic PPT17r8d (composed of 17 
deoxyribonucleotides and 8 ribonucleotides) was obtained from Sigma-Aldrich (MO, USA). All 
other RNA and DNA oligonucleotides used in this work were supplied by Invitrogen Life 
Technologies (CA, USA).  
3.4.1.1 Labeling of RNA and DNA oligonucleotides 
DNA oligonucleotides, including the PPT17r8d primer (2 pmol) and RNA oligonucleotides (3 
pmol) were labeled at their 5´-end by using 1 μCi of [γ32P]ATP (Perkin Elmer) and 5 U of T4 
polynucleotide kinase (Promega). The labeling reaction included an incubation with [γ32P]ATP, the 
oligonucleotide and the polynucleotide kinase at 37ºC during 45 min, in 70 mM Tris-HCl pH 7.5 
buffer, containing 10 mM MgCl2 and 5 mM dithiothreitol. Then, the polynucleotide kinase was heat-
inactivated by incubating the reaction at 90ºC for 10 min. The correct incorporation of the radioactive 
phosphorous was confirmed by thin-layer chromatography in PEI-cellulose plates (TLC, 20x20 cm, 
Merck) and using 0.5 M disodium phosphate as mobile phase. 
Before annealing, labeled RNA templates, as well as the PPT17r8d chimeric RNA-DNA primer 
were subjected to a purification step using mini Quick Spin 764 columns (Roche) by following the 
manufacturer’s  instructions. Since part of the RNA could be lost at this step, the RNA was 
chromatographed in PEI-cellulose plates (TLC, 20x20 cm, Merck) using 0.5 M disodium phosphate 
as mobile phase. The PEI-cellulose sheets were exposed to phosphoroimaging plates (Fujifilm BAS-
MP 2040S) and the intensity of the RNA samples before and after the using the mini Quick Spin 764 
column was determined by phosphoroimaging with a BAS 1500 scanner (Fujifilm), and using the 
software TINA 2.09 (Raytest Isotopenmessgerate GmbH, Staubenhardt, Germany). This method was 
used to estimate the final RNA concentration. 
3.4.1.2 DNA/DNA and RNA/DNA duplexes annealing 
The DNA/DNA and RNA/DNA duplexes containing a labeled DNA primer strand were 
obtained by heating a roughly 5-fold excess concentration of unlabeled template over the primer at 
100ºC for 4 min in a solution containing 150 mM NaCl and 150 mM magnesium acetate (pH 7.0), 
followed by slowly cooling at room temperature. The obtained DNA/DNA and RNA/DNA 
complexes were then diluted to the desired concentration in 550 mM Hepes pH 7.0 buffer, containing 
150 mM NaCl and 150 mM magnesium acetate. 
The RNA/DNA complexes containing a labeled RNA template strand were obtained by heating 
a roughly 5-fold excess of the unlabeled DNA primer strand over the labeled-RNA template at 100ºC 
46
                                                                                                     Materials & Methods 
 
for 4 min in 50 mM Tris-HCl pH 8.0 buffer containing 50 mM KCl, followed by slowly cooling at 
room temperature. Then, the RNA/DNA duplexes were diluted to a 200 nM final concentration in 50 
mM Tris-HCl pH 8.0 buffer, containing 50 mM KCl and 2.5 U of rRNAsin® Plus (Promega).  
Finally, the complex T57d/PPT17r8d was obtained by heating a roughly 5-fold excess of 
unlabeled T57d template over the primer at 100ºC for 4 min in 50 mM Tris-HCl pH 8.0 buffer 
containing 50 mM KCl, followed by slowly cooling at room temperature. Then, the RNA/DNA 
duplexes were diluted to a 200 nM final concentration in 50 mM Tris-HCl pH 8.0 buffer containing 
50 mM KCl. 
 
 
Table 7. Heteropolymeric template/primer complexes used 
Name Sequence 
D38 
25PGA 
3´  ACCATCCCGATATGTAAGAACGTCCATTCTTTCCTGGG 5´ 
5´  TGGTAGGGCTATACATTCTTGCAGG              3´ 
D38C 
25PGA 
3´  ACCATCCCGATATGTAAGAACGTCCCTTATTTCCTGGG 5´ 
5´  TGGTAGGGCTATACATTCTTGCAGG              3´ 
D38T 
25PGA 
3´  ACCATCCCGATATGTAAGAACGTCCTAACTTTCCTGGG 5´ 
5´  TGGTAGGGCTATACATTCTTGCAGG              3´ 
ssM13mp2
a 
ProLac110 
3´  --ACGACGTTCCGCTAATTCAACCCATTGCGGTCC-- 5´ 
5´             GCGATTAAGTTGGGT            3´     
C120 
C220 
3´  TACACCTTTTAGAGATCGTCA 5´ 
5´  ATGTGGAAAATCTCTAGCAGT 3´ 
C120 
B2-1 
3´  TACACCTTTTAGAGATCGTCA 5´ 
5´  ATGTGGAAAATCTCTAGCA   3´ 
Dumbbell
b 
5´  TGCTAGTTCTAGCAGGCCCTTGGGCCGGCGCTGCGCC 3´ 
PPT30DNA 
PPT29RNA 
3´     AAATTTTCTTTTCCCCCCTGACCTTCCCGA 5´ 
5´  CUUUUUAAAAGAAAAGGGGGGACUGGAAG     3´ 
PPT29DNA 
PPT29RNA 
3´      AATTTTCTTTTCCCCCCTGACCTTCCCGA 5´ 
5´  CUUUUUAAAAGAAAAGGGGGGACUGGAAG     3´ 
PPT28DNA 
PPT29RNA 
3´      AATTTTCTTTTCCCCCCTGACCTTCCCGA 5´ 
5´  CUUUUUAAAAGAAAAGGGGGGACUGGAAG     3´ 
D38rna 
25PGA 
5´  GGGUCCUUUCUUACCUGCAAGAAUGUAUAGCCCUACCA 3´ 
3´               GGACGTTCTTACATATCGGGATGGT 5´         
D38Crna 
25PGA 
5´  GGGUCCUUUAUUCCCUGCAAGAAUGUAUAGCCCUACCA 3´ 
3´               GGACGTTCTTACATATCGGGATGGT 5´ 
D38Trna 
25PGA 
5´  GGGUCCUUUCAAUCCUGCAAGAAUGUAUAGCCCUACCA 3´ 
3´               GGACGTTCTTACATATCGGGATGGT 5´ 
D31rna 
25PGA 
5´  GGGUCCUUUCUUACCUGCAAGAAUGUAUAGC        3´   
3´               GGACGTTCTTACATATCGGGATGGT 5´ 
T57d 
PPT17r8d 
3´  AGAATCGGTGAAAATTTTCTTTTCCCCCCTGACCTTCCCGATTAAGTGAGGGTTGC 5´ 
5´              UUAAAAGAAAAGGGGGGACTGGAAG                    3´ 
PPT29DNA 
PPT17r 
3´      AATTTTCTTTTCCCCCCTGACCTTCCCGA 5´ 
5´      UUAAAAGAAAAGGGGGG             3´ 
T35rna 
PR26 
5´  AGAAUGGAAAAUCUCUAGCAGUGGCGCCCGAACAG  3´ 
3´            TAGAGATCGTCACCGCGGGCTTGTCC 5´  
31Trna 
21P 
5´ UUUUUUUUUAGGAUACAUAUGGUUAAAGUAU 3´ 
3´           CCTATGTATACCAATTTCATA 5´ 
a 
Dashes in the ssM13mp2 DNA strand indicate the sequence continues. 
b 
The dumbbell strand is self-complementary.  
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3.4.2 Primers blocked with carbovir monophosphate (CBVMP) or d4T 
monophosphate (d4TMP)  
Terminal transferase (Roche) was used to block 25PGA primers with CBVMP and d4TMP (the 
terminal transferase marketed by Roche is also known as terminal deoxynucleotidyl transferase, or 
TdT). These blocked oligonucleotides were used to determine the ATP-dependent excision of wild-
type and mutant RTs. The reaction was initiated by incubating the 25PGA primer with a 2-fold 
excess concentration of d4TTP or CBVTP and 150 U of recombinant terminal transferase (Roche) in 
25 mM Tris-HCl pH 6.6 buffer, containing 250 mM potassium cacodylate, 0.25 mg/ml BSA and 1 
mM MnCl2 at 37 ºC for 1 hour. Then, the enzyme was heat-inactivated by incubating the sample at 
90ºC for 10 min. The blocked-primer obtained was precipitated with sodium acetate and 98% ethanol 
and diluted in 60 μl of water. However, the precipitation step does not eliminate all the free d4TTP 
and CBVTP present in the media. Therefore, the blocked-primer was subjected to a second 
purification step using mini Quick Spin 764 columns (Roche). The sample was passaged through the 
columns until the absorbance at 260 nm remained unchanged, indicating that all of the free 
triphosphorylated NRTI molecules had been eliminated. 
Then, the purified primers were labeled using the same protocol described in section 3.4.1.1. 
Finally, the labeled 25PGA
d4TMP
 or 25PGA
CBVMP
 blocked-primers were annealed to their 
corresponding templates by incubating each one with a 2-fold excess of template strand in water at 
100ºC for 4 min, followed by slowly cooling at room temperature. 
3.4.3 Primers blocked with AZT monophosphate (AZTMP) or tenofovir  
  The terminal transferase is unable to incorporate AZTTP or tenofovir-DP at the 3´-end of a 
primer. Therefore, an alternative method was developed. This method is based on the production of 
template/primer (T/P) complexes containing a blocked primer, instead of the synthesis of a blocked 
primer that was later annealed to the corresponding template. The process initiates with the 
production of the corresponding nucleic acid duplex following the protocol described in section 
3.4.1.2.  
For AZTTP and tenofovir-DP incorporation reactions, the labeled T/P (4.6 μM) was 
preincubated with wild-type RT (4 μM) in 65 μl of 50 mM Hepes pH 7.0 buffer, containing 15 mM 
NaCl, 15 mM magnesium acetate, 130 mM potassium acetate, 1 mM dithiothreitol, and 5% (w/v) 
polyethyleneglycol 6000 for 10 min at 37°C. Then, 35 μl of 6 mM AZTTP or tenofovir-DP (diluted 
in the preincubation buffer) were added and incubated for another 30 min at 37°C to ensure that the 
primer was blocked completely. The RT was inactivated by heating the mixture for 10 min at 90°C. 
After slowly cooling the sample at room temperature, it was passaged several times through mini 
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Quick Spin columns (Roche) to eliminate the free inhibitor. Tests carried out previously in the 
laboratory demonstrated that complete elimination of free AZTTP or tenofovir-DP as well as salt 
traces was achieved after four successive passages through these columns. Finally, the blocked-T/P 
was precipitated with sodium acetate and 98% ethanol, and diluted in 50 μl of 550 mM Hepes pH 7.0 
buffer, containing 150 mM NaCl and 150 mM magnesium aspartate.  
The final T/P concentration was calculated after thin-layer chromatography in PEI-cellulose 
plates (TLC, 20x20 cm, Merck) using 0.5 M disodium phosphate as mobile phase, by comparing the 
intensity of the labeled-T/P before and after the purification process. For this purpose, the PEI-
cellulose sheet used in the chromatography was exposed to phosphoroimaging plates (Fujifilm BAS-
MP 2040S) and the intensity of each point was measured in the phosphoroimaging scanner BAS 
1500 (Fujifilm) using the TINA 2.09 software (Raytest Isotopenmessgerate GmbH, Staubenhardt, 
Germany). This method yields approximately a 40-50% of the initial product. 
 
3.5 Active enzyme titration 
Active site titration of all RTs was carried out with the T/P D38/25PGA (prepared as described 
in section 3.4.1.2). The assay was performed in 20 μl of 100 mM Hepes pH 7.0 buffer, containing 30 
mM NaCl, 30 mM magnesium acetate, 130 mM potassium acetate, 1 mM dithiothreitol, 5% (w/v) 
polyethyleneglycol 6000, 30 nM D38/25PGA, 500 μM dTTP and the corresponding RT at different 
concentrations.  
Aliquots of 4 μl were removed 10, 20, 30 and 40 s after starting the reaction and mixed with 4 μl 
of stop solution (10 mM EDTA, 90% formamide, with 3 mg/ml xylene cyanol and 3 mg/ml 
bromophenol blue). Products were resolved on a denaturing 20% polyacrylamide/8 M urea gel, and 
primer elongation was quantified by phosphorimaging with a BAS 1500 scanner (Fuji), using the 
software TINA version 2.09 (Raytest Isotopenmessgerate Gmbh, Staubenhardt, Germany). Kinetic 
parameters were obtained by adjusting the total amount of primer elongated at each time point to the 
equation y = ax + b, where y is the percentage of elongated primer, x is the time and b represents the 
percentage of RT-T/P bound at time zero. This number, corrected with the T/P concentration used in 
the assay yields the active enzyme concentration of the sample (Kati et al., 1992). 
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3.6 Rescue assays 
This assay has been developed to study the efficiency of the RT in removing NRTIs from 
blocked primers and resume DNA synthesis, using DNA/DNA and RNA/DNA complexes with a 
blocked 3´-end (rescue assay). A list of RTs and the inhibitors used in these assays is given in Table 
8. All T/P duplexes were prepared as described in section 3.4.1.2. 
Prior to their use, all dNTPs, rNTPs and NRTIs were subjected to treatment with 
pyrophosphatase (Roche) for 1 hour at 37ºC, in order to eliminate any trace of pyrophosphate (PPi) 
that could interfere with the assay. Then, pyrophosphatase was removed by centrifugation at 14000 
rpm for 20 min at 4ºC using Amicon® Ultra-0.5 ml Ultracel® 10K centrifugal filters (Millipore), or 
by centrifugation at 7500g for 30 min at 4ºC using Amicon® Ultra Ultracel® 10K centrifugal filters 
(Millipore). 
RT-catalyzed DNA/DNA rescue reactions were carried out in 55 mM Hepes pH 7.0 buffer, 
containing 15 mM NaCl, 15 mM magnesium acetate, 130 mM potassium acetate, 1 mM dithiothreitol 
and 5% (w/v) polyethyleneglycol 6000 (Fig 18).  First, 25 μl of a mixture containing the 
phosphorylated T/Ps (75 nM) was preincubated with the RT (60 nM) for 10 minutes at 37°C. Then, 
25 μl of the same preincubation buffer containing 50 μM AZTTP, d4TTP, ddATP, CBVTP or 
tenofovir-DP were added and incubated for another 10 min under the same conditions. Rescue 
reactions were triggered by adding 10 μl of  a mixture of all dNTPs at final concentrations of 100 μM 
each and depending on the assay ATP, CTP, GTP or inosine triphosphate (ITP) at final 
concentrations ranging from 3.2 to 9.6 mM. The final concentration of the next complementary 
dNTP (dATP or dTTP under our assay conditions) was kept at 1 μM in order to minimize its 
inhibitory effect on the rescue reaction, due to the formation of a “dead-end” complexes (DEC). 
 
Table 8. Nucleic acid substrates and NRTIs tested in rescue reactions with each RT 
RT 
DNA/DNA RNA/DNA 
AZT d4T ddA CBV Tenofovir AZT d4T ddA CBV Tenofovir 
WT √ √ √ √ √ √ √ √ √ √ 
M41L/H208Y/L210W/T215Y √ √ x x √ √ √ x x √ 
M41L/H208Y/T215Y √ √ x x x √ √ x x x 
M41L/L210W/T215Y √ √ x x √ √ √ x x √ 
M41L/L210W/T215Y/R284K √ √ x x √ √ √ x x √ 
M41L/T215Y √ √ √ √ x √ √ √ √ x 
M41L/T215Y/P272A/R277K/T286A √ √ √ √ x √ √ √ √ x 
H208Y √ √ x x √ √ √ x x √ 
P272A/R277K/T286A √ √ √ √ x √ √ √ √ x 
R284K √ √ x x √ √ √ x x √ 
MAK_SSSY √ √ √ √ x √ √ √ √ x 
“√” is used to indicate that rescue assays under the specific conditions described have been carried out. If not, this is indicated 
with an “x”. 
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Fig 18. RT catalyzed rescue reactions. Schematic representation of the rescue reaction catalyzed by the RT. The 
template/primer is depicted in black lines, with a 
32
P-labeled 5´-end, while the RT is represented by a blue oval with a grey 
circle inside, indicating the location of the DNA polymerase domain. RT and T/P preincubation at 37ºC allows the formation of 
the binary complex. Further addition of a triphosphorylated NRTI leads to the blockage of the nucleic acid. Incubation of the 
complex with ATP allows rescue-proficient enzymes to excise the inhibitor and resumes DNA elongation. On the contrary, 
enzymes lacking rescue activity are not able to remove the inhibitor and DNA synthesis remains blocked. 
 
Assays with RNA/DNA complexes were carried out as above, but the primer was blocked with 
triphosphorylated nucleoside analogues at a 50 μM final concentration (2-fold more concentrated 
than in assays carried out with DNA/DNA complexes). The dNTP concentrations in the extension 
reactions were kept at 200 μM, except for the next complementary dNTP (dATP or dTTP under our 
assay conditions) that was supplied at 2 μM.  
Rescue and extension reactions were incubated for 30 or 60 min (depending on the assay) at 
37°C, with aliquots being removed at appropriate times. Reactions were stopped by adding an equal 
amount of stop solution. Products were analyzed by denaturing polyacrylamide gel electrophoresis 
and phosphoroimaging quantification as described in section 3.5. 
This assay was modified in order to determine the inhibitory effect of the next corresponding 
nucleotide (dATP). For this purpose, dATP ranging from 0 to 200 μM was supplied to the rescue 
reaction and aliquots were removed at different times ranging from 15 to 40 min, depending on the 
RT used in the assay. In all cases, incubation times were within the linear range of the corresponding 
time course experiment. Reactions were stopped by adding an equal amount of stop solution. 
Products were resolved on 20% polyacrylamide/8 M urea gels, and data quantified as described 
above. The percentage of rescue reaction inhibition was plotted against the dATP concentration and 
the resulting slope was adjusted to a hyperbolic equation, to obtain the corresponding IC50 value.  
The Michaelis-Menten constants for the PPi donors in rescue reactions were calculated by using 
a modified assay. For this purpose, rescue reactions were carried out in the presence of ATP, CTP, 
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GTP and ITP under steady-state conditions as described above. Rescue rates were determined with 
concentrations of NTP ranging from 0.4 to 12 mM and in the presence of 100 μM of each of four 
dNTPs (except dATP, the next complementary nucleotide, which was supplied at 1 μM). Reactions 
were stopped after 10 or 20 min, depending on the PPi-donor used, by adding an equal amount of 
stop solution. Products were resolved on 20% polyacrylamide/8 M urea gels, and data quantified as 
described above. The catalytic constants Km and kcat were obtained after fitting the rescue results to 
the Michaelis-Menten equation: 
V0 = Vmax
[NTP]
Km+[NTP]
 
where Vmax is the maximum NRTI-MP excision rate and Km  is the Michaelis-Menten constant for the 
PPi donor. 
3.7 Chain terminator excision assays 
Pre-steady-state kinetics of the ATP-dependent excision of AZTMP, d4TMP, CBVMP and 
tenofovir were determined using heteropolymeric T/Ps D38/25PGA
d4TMP
, D38rna/25PGA
d4TMP
, 
D38/25PGA
AZTMP
, D38T/25PGA
tenofovir
 and D38Crna/25PGA
CBVMP
. Complexes were prepared as 
described in sections 3.4.2 and 3.4.3. The wild-type and mutant RTs P272A/R277K/T286A, 
M41L/T215Y, M41L/T215Y/P272A/R277K/T286A, R284K, H208Y, M41L/L210W/T215Y, 
M41L/H208Y/L210W/T215Y, M41L/L210W/T215Y/R284K and MAK_SSSY, were tested in these 
assays.  
Single-turnover conditions were used to study the excision of d4TMP, AZTMP, tenofovir and 
CBVMP. Solutions containing from 24 to 420 nM RT and 60 nM of the corresponding blocked-T/P 
in 110 mM Hepes pH 7.0 buffer, containing 30 mM NaCl, 30 mM magnesium acetate, 130 mM 
potassium acetate, 1 mM dithiothreitol, and 5% (w/v) polyethyleneglycol 6000 were preincubated at 
37ºC for 10 min. Then, those samples were mixed with equal volumes of a solution containing 130 
mM potassium acetate, 1 mM dithiothreitol, 5% (w/v) polyethyleneglycol 6000 and 6.4 mM ATP. 
Excision reactions were carried out for 0 to 60 min at 37°C. Aliquots were removed at different 
times, quenched with stop solution, heated at 90ºC for 10 min and then the products were analyzed 
by denaturing polyacrylamide gel electrophoresis and phosphoroimaging quantification as described 
in section 3.5 
The formation of product (concentration of product [P]) over time was fitted to a single 
exponential decay equation: 
 [P] = A x e
-kobs x t
 
where kobs is the apparent kinetic constant of the excision reaction.  
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A linear regression was used to fit the data when the excision rates were low. In those cases, we 
assumed that the amount of active RT was identical to the T/P concentration in the assay, since these 
reactions were carried out with a large excess of RT relative to the RNA/DNA duplex. 
A variation of this assay was used to determine the Km and Vmax values for M41L/L210W/T215Y 
and M41L/H208Y/L210W/T215Y RTs, for the excision reaction using the D38/25PGA
AZTMP
 T/P. 
For this purpose, assays were carried out as described above, maintaining a fixed RT concentration of 
21 nM and using a T/P concentration ranging from 2.5 to 200 nM. Aliquots were removed at 
different times between 5 and 30 min and the reaction rates obtained at each T/P concentration were 
fitted to a Michaelis-Menten equation to obtain the Km and Vmax values. 
3.8 Nucleotide incorporation assays 
Two different types of kinetic constants can be calculated: the steady-state kinetic parameters Km 
and kcat, as well as the catalytic efficiency (kcat/Km), and the pre-steady-state kinetics constants kobs 
and Kd. The difference between both types of determinations lies in that steady-state rates are 
dominated by the slowest step of the polymerization reaction (i.e., dissociation of the RT-DNA 
complex), while pre-steady-state kinetics can monitor nucleotide incorporation directly.  
3.8.1 Steady-state kinetics of nucleotide or nucleotide analogue 
incorporation 
Nucleotide incorporation reactions under steady-state conditions were carried out for mutant RTs 
M41L/L210W/T215Y and M41L/L210W/T215Y/R284K as well as the wild-type enzyme. For this 
purpose D38/25PGA and D38T/25PGA heteropolymeric complexes were prepared as described in 
section 3.4.1.2. A mix of 10 μl containing the RT and the T/P in a preincubation solution of 110 mM 
Hepes pH 7.0 buffer, containing 30 mM NaCl, 30 mM magnesium acetate, 130 mM potassium 
acetate, 1 mM dithiothreitol, and 5% (w/v) polyethyleneglycol 6000 was preincubated at 37ºC for 10 
min. Active RT and T/P were present at concentrations of 7–20 nM and 60 nM, respectively. Then, 
an equal volume of a solution containing 130 mM potassium acetate, 1 mM dithiothreitol, 5% (w/v) 
polyethyleneglycol 6000 and dATP or dTTP at different concentrations was added. Aliquots of 4 μl 
were removed and the reaction was quenched after 20 s by adding the same amount of stop solution. 
Elongation rates were determined in the presence of dTTP concentrations ranging from 0.05 to 20 
μM or with dATP concentrations ranging from 12 nM to 10 μM. Catalytic constants kcat and Km were 
determined after fitting the elongation data to the Michaelis–Menten equation, as described in section 
3.6. 
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A variation of this assay was used to determine the inhibition constants (Ki) for AZTTP and 
tenofovir-DP. Assays were carried out in the same conditions described above, but in the presence of 
0, 2, 5 or 10 μM of the corresponding nucleotide analogue. To distinguish between the incorporation 
of the natural nucleotide or the nucleotide analogue, a concentration of 1 to 2 μM of the nucleotide 
corresponding to position +2 (dTTP or dATP under our assay conditions) was included in the 
reaction. Products were resolved on 20% polyacrylamide/8 M urea gels, and data quantified as 
described above. The percentage of +2 product formation was plotted against time for each NRTI 
concentration, fitting these data to a Michaelis-Menten equation, and the apparent Km were then 
calculated. The Km values obtained were fitted to the equation: 
 Apparent Km = Km x (1+ 
 I 
Ki
) 
where apparent Km is the Km for the dNTP obtained in the presence of the analogue NRTI, Km is the 
Michaelis-Menten constant obtained in the absence of the NRTI and Ki is the apparent inhibition 
constant.  
3.8.2 Pre-steady-state kinetics of nucleotide incorporation 
Pre-steady-state kinetics for dTTP incorporation were determined for M41L/L210W/T215Y and 
M41L/L210W/T215Y/R284K mutant enzymes using the heteropolymeric T/P D38/25PGA, prepared 
as described in section 3.4.1.2. Assays were carried out in a quench-flow instrument, model QFM-
400 (Bio-Logic Science Instruments, France). 
Reactions were carried out at high dTTP concentration (80 μM) with incubation times ranging 
from 25 to 6000 ms. Reactions were started by the addition of 12 μl of 160 μM dTTP diluted in a 50 
mM Tris-HCl pH 8.0 buffer, containing 50 mM KCl and 25 mM MgCl2 to 12 μl of a mix consisting 
in the same solution without MgCl2, but containing 140 nM of active enzyme and 200 nM of 
D38/25PGA complex. 
Reactions were stopped by the addition of 12 μl of 0.9 M EDTA. After mixing the product with 
the same volume of stop solution, samples were heated at 90ºC for 10 min and analyzed by 
denaturing polyacrylamide gel electrophoresis and phosphoroimaging as described in section 3.5 
The appearance of product ([P]) over time (t) was adjusted to the following equation: 
[P] = A x (1-e
-kobs x t
) + kss x t 
where A is the amplitude, kobs the apparent phosphodiester bond formation constant and kss is the 
enzyme turnover rate. 
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3.8.3 Determination of dissociation equilibrium constants (Kd) for 
DNA/DNA and RNA/DNA complexes 
The determination of the affinity of wild-type and mutant enzymes for nucleic acid complexes 
was carried out using D38/25PGA DNA/DNA and D31rna/25PGA RNA/DNA complexes.  
RTs were preincubated with increasing concentrations (2 to 60 nM) of the labeled D38/25PGA 
complex or D31rna/25PGA duplex (prepared as described in section 3.4.1.2) for 10 min at 37°C in 
10 μl of 100 mM Hepes pH 7.0 buffer, containing 30 mM NaCl, 30 mM magnesium acetate, 130 mM 
potassium acetate, 1 mM dithiothreitol, and 5% (w/v) polyethyleneglycol 6000. Reactions were 
initiated by the addition of 10 μl of 1 mM dTTP to 10 μl of the solution indicated above, and 
incubated at 37°C. In these experiments, the active RT concentration was around 3 nM. Samples of 4 
μl were then removed at 10, 20, 30, and 40 s and quenched with stop solution. Products were 
analyzed by denaturing polyacrylamide gel electrophoresis and phosphoroimaging quantification as 
described in section 3.5 
The burst amplitudes (RT bound to T/P at time zero) were plotted as a function of the T/P 
concentration, and the data were fitted to the following quadratic equation: 
[E·T/P] = 0.5 x [(Kd + ET + T/P) -  (Kd + ET + T/P)
2
 – (4 x ET x T/P)] 
where ET and T/P are the total active enzyme and T/P concentration, respectively, and Kd is the 
dissociation equilibrium constant for RT binding to T/P. 
3.8.4 Determination of dissociation rate constants (koff) 
Dissociation rate constants for T/Ps were determined using the D38/25PGA complex with 
M41L/L210W/T215Y and M41L/L210W/T215Y/R284K mutant RTs. Assays were carried out in 
Tris-HCl pH 8.0 buffer, containing 100 mM KCl, 2 mM dithiothreitol and 6 mM MgCl2.  
RTs (120 nM final concentration) were preincubated with the D38/25PGA substrate (at 8 nM 
final concentration) for 10 min at 37ºC. Then, 3 μl of sodium heparin (Serva 24590) trap (3 mg/ml 
final concentration) were added to 7 μl of the preincubated sample, and the incubation was continued 
for 0-60 s, before adding 10 μl of 200 μM dTTP. Elongation reactions were stopped after 7 s by 
addition of equal volume of stop solution. Products were resolved on a denaturing 20% 
polyacrylamide/8 M urea gel, and results were quantified by phosphorimaging with a BAS 1500 
scanner (Fuji), using the software TINA version 2.09 (Raytest Isotopenmessgerate Gmbh, 
Staubenhardt, Germany).  
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The production of elongated primer ([P]) was fitted to the single exponential decay:  
[P] = e
(-koff x t)
 
where koff is the dissociation rate constant and t is the time of incubation with the trap (in seconds). 
3.9 DNA polymerization assays 
DNA polymerization assays were carried out to determine primer elongation efficiencies of 
wild-type and mutant enzymes using heteropolymeric T/Ps. 
3.9.1 Primer extension assays 
We determined the ability of M41L/T215Y and M41L/T215Y/P272A/R277K/T286A mutant 
RTs to extend the 25PGA primer in the D38rna/25PGA complex, as well as the efficiency of 
M41L/L210W/T215Y and M41L/L210W/T215Y/R284K RTs in extending the primer in 
D38/25PGA complexes. Labeled T/P was prepared as described in section 3.4.1.2. 
First, 25 μl of a sample containing 3 or 20 nM of the appropriate T/P and 3 nM RT in 55 mM 
Hepes pH 7.0 buffer, containing 15 mM NaCl, 15 mM magnesium acetate, 130 mM potassium 
acetate, 1 mM dithiothreitol and 5% (w/v) polyethyleneglycol 6000 was incubated at 37ºC for 10 
min. Then, 25 μl of a solution with the four dNTPs (200 μM each) diluted in the same buffer was 
added and aliquots of 4 μl were removed at different times (1 to 10 min). The reaction was then 
stopped by adding an equal volume of stop solution. Products were resolved on a denaturing 20% 
polyacrylamide/8 M urea gel, and the elongated primer quantified by phosphorimaging with a BAS 
1500 scanner (Fuji), using the software TINA version 2.09 (Raytest Isotopenmessgerate Gmbh, 
Staubenhardt, Germany).  
3.9.2 Processivity assays 
The processivity of wild-type and M41L/L210W/T215Y, M41L/L210W/T215Y/R284K, and 
M41L/L210W/T215Y/R284K/M357T RTs was assessed with a complex made of M13mp2 single-
stranded DNA as template and ProLac110 as primer, as well as with the 38/25-mer D38/25PGA.  
RTs and T/P (both at 60 nM concentration) were preincubated at 37°C for 10 min in 12 μl of 50 
mM Tris-HCl pH 8.0 buffer, containing 50 mM KCl. Reactions were initiated by adding 12 μl of 
preincubation buffer containing 12 mM MgCl2 and a mixture of the four dNTPs (at 100 μM each) 
with or without 10 mg/ml sodium heparin. A control to confirm the validity of the trap was also 
introduced. In this control, the RT was preincubated with sodium heparin before the addition of the 
T/P and the dNTPs. Aliquots of 4 μl were removed after 5, 15, 30 and 45 min and quenched with an 
equal volume of sample loading buffer. Products were resolved on a denaturing 20% 
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polyacrylamide/8 M urea gel, and the elongated primer was quantified by phosphorimaging with a 
BAS 1500 scanner (Fuji), using the software TINA version 2.09 (Raytest Isotopenmessgerate Gmbh, 
Staubenhardt, Germany). 
3.10 RNase H activity determination 
The endonuclease activity of the RT (RNase H activity) was studied using different 
heteropolymeric RNA/DNA complexes with wild-type RT and mutant enzymes. 
3.10.1 Cleavage of heteropolymeric T/Ps 
The RNase H cleavage activity of the wild-type and mutant enzymes H208Y, R284K, N348I, 
T369I, T369V, T376S, N348I/T369I, M41L/T215Y/P272A/R277K/T286A, P272A/R277K/T286A, 
M41L/L210W/T215Y, M41L/T215Y, M41L/H208Y/L210W/T215Y and 
M41L/L210W/T215Y/R284K was determined with RNA/DNA complexes 31Trna/21P, 
D38rna/25PGA, D38Trna/25PGA, T35rna/PR26, T57d/PPT17r8d, PPT29RNA/PPT29DNA, 
PPT29RNA/PPT28DNA, PPT29RNA/PPT30DNA and PPT29DNA/PPT17r. In these assays, 
heteropolymeric complexes were prepared as described in section 3.4.1.2.  
Assays were carried out in 50 mM Tris-HCl pH 8.0 buffer, containing 50 mM KCl (or 50 mM 
NaCl), 50 nM RT and 50 nM T/P (or 125 nM RT and 25 nM T/P in the case of the T57d/PPT17r8d 
complex). Reactions were initiated by adding MgCl2 to a final concentration of 5 mM. Aliquots of 4 
μl were removed at appropriate times (normally between 20 s and 5 min) and quenched with an equal 
volume of stop solution. Products were analyzed by denaturing polyacrylamide gel electrophoresis 
and quantified by phosphoroimaging as described in section 3.5. The amount of cleavage product 
generated over time was fitted to a single exponential decay as described in section 3.7 and the 
apparent kinetic constant of RNase H cleavage (kobs) was determined. 
3.10.2 Cleavage of AZTMP-blocked complexes 
RNase H activity of wild-type RT and P272A/R277K/T286A, M41L/T215Y and 
M41L/T215Y/P272A/R277K/T286A mutant enzymes was measured using the T35rna/PR26 
complex. After obtaining the labeled RNA/DNA duplex as described in section 3.4.1.2, a mutant 
HIV-1 group O RT containing the V75I/E478Q mutations (O_V75I/E478Q) was used to block the 
complex with AZTMP. Mutation E478Q completely inactivates the RNase H activity of the enzyme 
(Álvarez et al., 2009), thus avoiding undesired cleavage events that would occur during the AZTTP 
incorporation step. The reaction was carried out for 1 hour at 37 ºC in Tris-HCl pH 8.0 buffer, 
containing 50 mM KCl, 10 mM MgCl2, 80 nM of labeled T35rna/PR26 complex, 30 nM 
O_V75I/E478Q mutant enzyme and 60 μM AZTTP. The RT was inactivated by heating the sample 
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for 10 min at 90ºC, and the T35rna/PR26
AZTMP
 complex was then purified with mini Quick spin 
columns (Roche). 
T35rna/PR26
AZTMP
 RNase H cleavage reactions were carried out at 37°C in 50 mM Tris-HCl pH 
8.0 buffer, containing 50 mM KCl, 10 mM MgCl2, 0.3 mM ATP, 20 nM labeled RNA/DNA complex 
and the corresponding RT at 200 nM active site concentration. Aliquots of 4 μl were removed at 
different times between 10 and 180 min and then quenched by using an equal volume of stop 
solution. Finally, samples were analyzed by denaturing polyacrylamide gel electrophoresis and 
quantified by phosphoroimaging as described in section 3.5. 
3.11 RT inhibition by NNRTIs  
The half maximal inhibitory concentration (IC50) for NEV, EFV, ETR and RPV was determined 
using the D38/25PGA complex, prepared as described in section 3.4.1.2, with wild-type, and mutant 
RTs bearing amino acids substitutions N348I, T369I, T369V, T376S and N348I/T369I. 
A preincubation mix (5 μl) of RT (from 14.4 to 36 nM) and T/P (72 nM) was maintained at 37ºC 
for 10 min in 120 mM Hepes pH 7.0 buffer, containing 24 mM NaCl, 24 nM MgCl2 208 mM 
potassium acetate, 1.6 mM dithiothreitol, and 8% (w/v) polyethyleneglycol 6000, and then mixed 
with 3 μl of the corresponding NNRTI at an appropriate concentration and diluted in 4% (w/v) 
dimethyl sulfoxide. Then the sample was incubated for 10 min at 37ºC. Four μl of a solution 
containing 100 μM dTTP, diluted in 130 mM potassium acetate, 1 mM dithiothreitol, and 5% (w/v) 
polyethyleneglycol 6000 was added and the reaction was then stopped after 20 s by mixing and 
aliquot of 4 μl with equal volume of stop solution and heating at 90ºC for 10 min. Samples were 
analyzed by denaturing polyacrylamide gel electrophoresis and quantified by phosphoroimaging as 
described in section 3.5. 
NNRTI inhibition was determined as the percentage of dTTP-incorporation inhibited in the 
presence of a specific NNRTI concentration, when compared with dTTP incorporation in the absence 
of the drug. Data were fitted to a dose-response slope and the IC50 value determined. 
 
3.12 Purification of HIV-1 integrase 
A recombinant IN corresponding to the group M subtype B NL4-3 strain was purified. This 
recombinant enzyme had a polyhistidine tag at its N-terminus. 
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3.12.1 IN expression 
One-hundred ml of LB medium containing ampicillim (80 μg/ml) and kanamicin (34 μg/ml) 
were inoculated with 5-10 μl of a glycerol stock of E. coli BL21 strain cells containing the pT7-7IN 
plasmid (which contains the sequence encoding for the full-length HIV-1 IN protein) (gift of Dr S.A. 
Chow, University of California, Los Angeles, USA). This culture was grown overnight at 37ºC under 
constant stirring. Next, 40 ml of this preculture were added to 1 liter of the same medium and grown 
at 32ºC until the optical density at 600 nm was around 0.8. Then, IPTG was added to a final 
concentration of 0.4 mM to trigger the expression of the sequence encoding the IN. After 3 hours at 
32ºC, cells were harvested by centrifugation at 5100 rpm for 25 min at 4ºC using a centrifuge TJ-25 
(Beckman-Coulter) and a swinging bucket rotor TS-5-1-500. 
3.12.2 Lysis of bacteria 
The bacterial pellet obtained was resuspended in 40 ml of 20 mM Hepes pH 7.5 buffer, 
containing 5 mM β-mercaptoethanol, 1 M NaCl, 10% (w/v) glycerol, 10 mM imidazole, 50 μM 
EDTA and 0.5% (w/v) NP-40. Just before using this lysis buffer, four pills of protease inhibitors 
(Completa®, Roche) were added, and once the pills had been diluted, we added lysozyme at a final 
concentration of 0.3 mg/ml. The bacterial solution was kept at 4ºC for one hour without agitation. 
Cells were then sonicated using a Branson 450 sonifier at power level 5 and 45% duty cycle for 
one min, seven times each cycle. Then, the sample was centrifuged at 12000 rpm for one hour at 4ºC, 
using a rotor JA 25.50 and an Avanti J-26 XP centrifuge (Beckman Coulter). The supernatant 
obtained was stored at 4ºC. 
3.12.3 Affinity chromatography 
The supernatant collected in the bacterial lysis step was applied to a 5-ml Ni
2+
-Sepharose-
agarose medium column (His-trap HP columns, GE Healthcare) adapted to a BioRad BioLogic 
station (BioRad).  
The IN bound to the Ni
2+
-agarose column was eluted using 200 ml of 20 mM Hepes pH 7.5 
buffer, containing 5 mM β-mercaptoethanol, 1 M NaCl and 0.1% (w/v) NP-40 and 50 ml of 20 mM 
Hepes pH 7.5 buffer, containing 5 mM β-mercaptoethanol 1 M NaCl, 0.1% (w/v) NP-40 and 500 
mM imidazole, following the process described in Table 9. Fractions of 1 ml were collected and the 
presence of enzyme was monitored by measuring the absorbance at 280 nm. The purity of the 
samples was determined by SDS-polyacrylamide gel electrophoresis. The enzyme-enriched fractions 
were pooled in 1-ml fractions and subjected to overnight dialysis using SnakeSkin tubing (Thermo 
Scientific) dialysis bags, against 900 ml of 20 mM Hepes pH 7.5 buffer, containing 5 mM                 
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β-mercaptoethanol, 0.5 M NaCl, 10 mM CHAPS and 20% (w/v) glycerol. Finally, the sample 
concentration was determined using a Bradford assay and BSA of known concentration as reference. 
The IN aliquots obtained were stored at -20ºC. 
 
Table 9. HPLC program to purify HIV-1 IN  
Step Vol (ml) Description Parameters 
1 3 Isocratic Flow 
Buffer A 
Buffer B 
98% 
2% 
Volume: 3 ml 
Flow: 1 ml/min 
2 10 Isocratic Flow 
Buffer A 
Buffer B 
90% 
10% 
Volume: 10 ml 
Flow: 1 ml/min 
3 25 Linear Gradient 
Buffer A 
Buffer B 
90% - 0% 
10% - 100% 
Volume: 25 ml 
Flow: 1  ml/min 
4 3 Isocratic Flow 
Buffer A 
Buffer B 
0% 
100% 
Volume: 3 ml 
Flow: 1 ml/min 
Buffer A is composed of 20 mM Hepes pH 7.5, containing 5 mM β-mercaptoethanol, 1 M NaCl and 0.1% (w/v) NP-40 and 
buffer B of 20 mM Hepes pH 7.5, containing 5 mM β-mercaptoethanol, 1 M NaCl, 0.1% (w/v) NP-40 and 500 mM imidazole. 
 
3.13 IN activity determination 
The three different main activities that HIV-1 IN has (3´-end processing, strand transfer and 
disintegration) were measured biochemically using 
32
P-labeled DNA complexes and recombinant 
HIV-1 IN proteins purified as described above (Chow, 1997). 
3.13.1 Preparation of nucleic acid complexes 
Three different DNA complexes were used in the characterization of IN activities: C220/C120, 
C120/B2-1 and the dumbbell single stranded DNA (Table 7, Fig 19). C220, B2-1 and dumbbell were 
labeled following a method similar to those described in section 3.4.1.1, but before annealing the 
32
P-
labeled DNA obtained (20 μl at 2.5 μM) was diluted in final volume of 97.5 μl of 10 mM Tris-HCl 
pH 7.5 buffer, containing 1 mM EDTA and 100 mM NaCl. The DNA/DNA duplexes C220/C120 
and C120/B2-1 were prepared by the addition of a 3-fold excess (2.5 μl at 75 μM) of unlabeled 
template strand (C120 in both cases) followed by heating at 100ºC for 4 min and finally by slowly 
cooling at room temperature.  
 
3.13.2 3´-end processing activity 
Determination of the 3´-end processing activity of IN (Fig 19) was performed using the 
C220/C120 complex, prepared as described above.  
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The reaction was carried out in a final volume of 20 μl, and under two different conditions: 
1) 5 nM C220/C120 and 200 nM IN in a 22 mM Hepes pH 7.5 buffer, containing 10 mM 
MnCl2, 43.3 mM NaCl, 10.1 mM dithiothreitol, 1 mM Tris-HCl pH 7.5 and 0.11 mM EDTA. 
2) 5 nM C220/C120 and 200 nM IN in a 50 mM Tris-HCl pH 8.0 buffer, containing 22 mM 
Hepes pH 7.5, 50 mM NaCl, 10 mM MgCl2 and 1.8 mM dithiothreitol.   
The 3´-end processing reactions were incubated for 1 hour at 37ºC. Aliquots of 4 μl were 
removed at appropriate times and reactions were stopped by adding 4 μl of stop solution and 
incubating the sample at 90ºC for 4 min. Products were resolved on denaturing 15% 
polyacrylamide/8 M urea gels, and DNA processing was quantified by phosphorimaging using a 
Typhoon scanner (Amershan Bioscience) and the software ImageQuant® version 5.0 (Molecular 
Dynamics). 
3.13.3 Strand transfer activity 
The determination of the strand transfer activity of IN (Fig 19) was carried out with the 
C120/B2-1 complex, prepared as described in section 3.13.1. Strand transfer reactions were carried 
out by incubating 5 nM C120/B2-1 with 200 nM IN, in 22 mM Hepes pH 7.5 buffer, containing 10 
mM MnCl2, 43.3 mM NaCl, 10.1 mM dithiothreitol, 1 mM Tris-HCl pH 7.5 and 0.11 mM EDTA at 
37ºC. Aliquots of 4 μl were removed at 20, 40 and 60 min and quenched by mixing with equal 
volume of stop solution. Strand transfer events were analyzed by denaturing polyacrylamide gel 
electrophoresis and phosphoroimaging quantification as described in section 3.13.2. 
3.13.4 Disintegration activity 
The determination of the disintegration activity of IN (Fig 19) was performed using the 
dumbbell single stranded DNA, prepared as described in section 3.13.1. The dumbbell strand is able 
to associate with itself producing a double-stranded DNA region that is substrate for the 
disintegration activity of IN. Disintegration reaction was carried out at 37ºC in the presence of 5 nM  
dumbbell substrate and 200 IN, in 22 mM Hepes pH 7.5 buffer, containing 10 mM MnCl2, 43.3 mM 
NaCl, 10.1 mM dithiothreitol, 1 mM Tris-HCl pH 7.5 and 0.11 mM EDTA at 37ºC. Aliquots of 4 μl 
were removed at 10, 20, 40 and 60 min and quenched by mixing with an equal volume of stop 
solution. Resulting products were analyzed by denaturing polyacrylamide gel electrophoresis and 
phosphoroimaging quantification as described in section 3.13.2. 
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Fig 19. Integrase in vitro reactions. Schematic representation showing the substrates and reaction schemes of the 3´-end 
processing (A), strand transfer (B) and disintegration (C and D) activities carried out by HIV-1 integrase. The 
32
P-labeled 5´-
end is indicated by a red star. Figure adapted from Chow et al (1997). Sequence of the C120/B2-1 complex is given in Table 
7. 
 
3.14 RT RNase H activity in the presence of IN 
The RNase H activity of the wild-type RT was determined in the presence of HIV-1 IN protein, 
obtained as described in section 3.12 and using the 31Trna/21P heteropolymeric complex and 
PPT29RNA/PPT29DNA and T57d/PPT17r8d heteroduplexes. 
RT (50 nM) and IN (at different concentrations ranging from 50 nM to 1 μM), together with 
31Trna/21P, PPT29RNA/PPT29DNA or T57d/PPT17r8d complex (50 nM) were preincubated in 50 
mM Tris-HCl pH 8.0 buffer, containing 50 mM NaCl for 10 min at 37ºC. Cleavage activity was 
triggered by the addition of 5 mM MgCl2. Aliquots of 4 μl were removed at 20 s, 40 s and 1, 2 and 4 
min. Products were resolved on denaturing 15% polyacrylamide/8 M urea gels, and DNA processing 
was quantified by phosphorimaging with a Typhoon scanner (Amershan Bioscience), using the 
software ImageQuant® version 5.0 (Molecular Dynamics). The apparent kinetic constant of RNase H 
cleavage (kobs) was determined as described in section 3.10.1. 
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4.Results 
4.1 Amino acid substitutions in the HIV-1 RT thumb subdomain 
associated with TAM-1 mutations and their role in resistance to 
NRTIs 
4.1.1 Molecular mechanisms favoring the selection of RT thumb 
subdomain polymorphisms A272P/K277R/A286T associated with 
nucleoside analogue therapy failure 
 Extended use of RT inhibitors as well as the increased complexity of antiretroviral treatments 
facilitates the accumulation of resistance mutations. Classical HIV-1 genotypic assays do not provide 
RT sequence information beyond residues 250-300. Therefore, while mutations located in the palm-
fingers subdomains are routinely detected, mutations outside these regions remain unidentified in 
most cases. However, recent reports have implicated thumb and connection subdomains, as well as 
the RNase H domain in drug resistance.  
 In an effort to identify mutations associated with antiretroviral therapy failure found outside the 
classical DNA polymerase region (residues 40-240), an epidemiological study was carried out 
previously, where thumb subdomain mutations were identified in patients failing antiretroviral 
therapy (Garriga et al., 2009). In this study, thumb subdomain polymorphisms Pro-272, Arg-277 and 
Thr-286 were found to be selected under therapy with several combinations of two NRTIs: 
d4T/abacavir, d4T/ddI, ddI/abacavir, d4T/3TC and d4T/tenofovir. The largest levels of statistical 
significance were obtained for the d4T/abacavir and d4T/ddI combinations. Of note, correlated pairs 
of substitutions at positions 272 and 277 and at positions 272 and 286 were also reported in HIV-1 
pol sequences from patients failing therapy with d4T and ddI. Interestingly, in most cases, 
polymorphisms were associated with TAMs, especially with the TAM-1 cluster, consisting of 
mutations M41L, L210W and T215Y. In order to determine the molecular mechanisms involved in 
the selection of these polymorphisms, we carried out a biochemical characterization of recombinant 
RTs bearing TAM-1 mutations M41L/T215Y with or without RT thumb subdomain polymorphisms. 
4.1.1.1 Rescue of DNA/DNA complexes containing primers blocked with AZTMP, 
d4TMP, CBVMP and ddAMP 
 An association between TAM-1 pathway mutations and the presence of Pro-272, Arg-277 and 
Thr-286 was found in viruses from patients failing therapy (Garriga et al., 2009). Therefore, we 
reasoned that thumb subdomain substitutions could be implicated in NRTI resistance through the 
excision mechanism, since TAMs have a major role in drug resistance acting as NRTI-excision 
enhancer mutations. To test this possibility, rescue assays using heteropolymeric template/primers 
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(T/P) blocked with AZT monophosphate (AZTMP), d4T monophosphate (d4TMP), ddA 
monophosphate (ddAMP) and carbovir monophosphate (CBVMP) were carried out. 
 A schematic representation of the standard rescue assay employed is shown in Fig 20. Rescue 
assays involve two different phases. After blocking the DNA primer with the corresponding NRTI, a 
PPi donor is supplied together with a mixture of dNTPs. If the RT has excision activity, the inhibitor 
can be removed from the 3´-end of the primer and the resulting DNA extended to obtain a full-length 
product. 
                  
Fig 20. Schematic representation of the rescue reaction. A representative gel obtained in rescue assays together with a 
scheme of the T/P complexes formed during the assay are shown. The [
32
P]-labeled-primer end is indicated by the presence 
of a red “p”. First, the inhibitor was incorporated at position +1 (black box) of the 25-nucleotide primer (lane P) to generate a 
26-nucleotide product (lane B). Excision of the inhibitor and further extension of the primer in the presence of a PPi donor and 
a mixture of dNTPs led to the formation of a fully extended 38-nucleotide product. A representative time course experiment of 
a primer rescue reaction is shown in lanes 1 to 9, which correspond to aliquots removed 2, 4, 6, 8, 10, 12, 15, 20, and 30 min 
after the addition of the PPi donor. 
 
 In our study the HIV-1 group M subtype B BH10 strain was used as wild-type (WT) reference. 
This strain has proline, arginine and threonine at positions 272, 277 and 286, respectively. Thumb 
subdomain polymorphisms P272A, R277K and T286A were introduced in the sequence context of 
the WT BH10 RT. The WT and P272A/R277K/T286A RTs were used, in addition to RTs with 
mutations M41L/T215Y/P272A/R277K/T286A and M41L/T215Y. As a control, a multidrug-
resistant RT bearing M41L/A62V/T69SSS/K70R/T215Y mutations (MAK_SSSY) was used. This 
enzyme was used as positive control due to its high rescue activity (Matamoros et al., 2004). 
 T/P complexes D38/25PGA
AZTMP
, D38/25PGA
d4TMP
, D38C/25PGA
CBVMP
 and D38T/25PGA
ddAMP 
were used (sequences shown in Fig 21). In the presence of 3.2 mM ATP, MAK_SSSY showed 
efficient rescue activity on primers blocked with AZTMP, d4TMP, CBVMP and in a lesser extend 
with primers terminated with ddAMP (Fig 21). In contrast, rescue activity of WT and 
P272A/R277K/T286A enzymes was almost negligible, independently of the inhibitor used in the 
assays. Mutant RTs M41L/T215Y and M41L/T215Y/P272A/R277K/T286A showed detectable 
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rescue activity on primers terminated with thymidine analogues or CBVMP, but were unable to 
excise ddAMP. Thumb subdomain mutations P272A, R277K and T286A had no effect when 
introduced in a WT sequence or in the presence of TAM-1 mutations. When 200 μM PPi was used, 
all RTs showed very high rescue efficiency with all tested NRTIs (Fig 22). It is important to note that 
unlike the ATP-dependent excision reaction, pyrophosphorolysis (PPi-mediated) is the 
polymerization reaction run in reverse. Therefore, it was not surprising to find out that the WT 
enzyme was very efficient in excising NRTIs in the presence of PPi. 
           
Fig 21. Rescue DNA polymerization initiated from AZTMP-, d4TMP-, ddAMP- and CBVMP-terminated primers annealed 
to a DNA template. Reactions were carried out with D38/25PGA, D38C/25PGA or D38T/25PGA complexes (sequences given 
below). First the inhibitor was incorporated at the 3´-end of the primer. Then, excision of the inhibitor, followed by extension of 
the primer was achieved after adding a mixture containing 3.2 mM ATP and the four dNTPs. Time course experiments of 
primer rescue reactions initiated from inhibitor-terminated primers are shown. All dNTPs in the assays were supplied at 100 
μM, except for dATP or dTTP (depending on the reaction) whose concentration was 1 μM. T/P and active RT concentrations in 
these assays were 30 and 24 nM, respectively. The values (mean ± standard deviations [error bars]) were obtained from three 
independent experiments. 
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Fig 22. Rescue DNA polymerization in the presence of 200 μM PPi. AZTMP and d4TMP rescue assays were carried out 
by using the D38/25PGA heteroduplex, while the D38C/25PGA complex was used in CBVMP rescue assays. Reaction 
conditions were the same described for ATP-dependent rescue assays, but were carried out in the presence of 200 μM PPi. 
Time points were taken at 1, 2, 3, 4, 5, 6, 7, 8 and 10 min. The values (mean ± standard deviations [error bars]) were obtained 
from three independent experiments. 
 
4.1.1.2 Rescue of RNA/DNA complexes blocked with AZTMP, d4TMP, CBVMP and 
ddAMP 
 As described for DNA/DNA complexes, rescue activity of MAK_SSSY was much higher than 
for the other RTs when assayed on T/Ps D38rna/25PGA
AZTMP
, D38rna/25PGA
d4TMP
 and 
D38Crna/25PGA
CBVMP 
(Fig 23). In addition, AZTMP and d4TMP were more efficiently rescued than 
CBVMP. Interestingly, mutant RTs M41L/T215Y and M41L/T215Y/P272A/R277K/T286A showed 
higher rescue activity on RNA/DNA complexes than on DNA/DNA duplexes. While this behavior 
was also observed with the WT enzyme, mutant P272A/R277K/T286A showed negligible rescue 
activity on RNA/DNA complexes (Fig 23). Interestingly, the M41L/T215Y RT showed higher rescue 
activity on primers terminated with AZTMP than the M41L/T215Y/P272A/R277K/T286A RT (Fig 
23). In addition, none of the enzymes were able to rescue T/P complexes blocked with ddAMP (data 
not shown). Also, as in the case of DNA/DNA complexes, PPi-dependent rescue activity on d4TMP-
blocked complexes was similar for all tested RTs (data not shown). 
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Fig 23. Rescue DNA polymerization initiated from AZTMP-, d4TMP-, and CBVMP-terminated primers annealed to an 
RNA template. Time course experiments of rescue reactions were carried out in the presence of 3.2 mM ATP. The nucleotide 
sequences of T/Ps used are given on the right lower panel. All dNTPs in the assays were supplied at 200 μM, except for dATP 
whose concentration was 2 μM. T/P and active RT concentrations in these assays were 10 and 30 nM, respectively. 
Represented values (mean ± standard deviation [error bars]) were obtained from three independent experiments. 
 
4.1.1.3 RNase H activity of WT and mutant RTs 
 The RNase H activity of the RT produces the degradation of the RNA strand of RNA/DNA 
duplexes. Two different types of substrates were used in RNase H activity measurements. 
RNase H activity and primary cleavage 
 D38rna/25PGA and 31Trna/21P complexes were used to determine the RNase H activity of WT 
and mutant RTs (Fig 24). Cleavage rates were similar for WT and mutant RTs when using 
31Trna/21P as substrate. Primary cleavage products correspond to a fragment of 26 nucleotides (Fig 
24). This cleavage occurred after RT polymerase active site bound the 3´-end of the 21P primer, with 
the RNase H active site located 16 nucleotides upstream of the dNTP binding site. No secondary 
cleavages were observed with this T/P under our assay conditions. As a control, an RNase H-
deficient mutant (RNase H(-) RT) was used. This enzyme is an HIV-1 group O RT with mutations 
V75I/E478Q (Álvarez et al., 2009).  
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 The T/P complex D38rna/25PGA was used to assay the RNase H activity of the RTs in the same 
sequence context used in rescue assays. As in the case of 31Trna/21P, the kinetics of the reactions 
were essentially the same for all tested enzymes (Fig 24). A single processed product of 31 
nucleotides was detected. This product corresponds to a 3´-end DNA-directed cleavage of the 
template strand at position -18. However, catalytic rate constants were higher for D38rna cleavage 
than for 31Trna cleavage (Fig 24). Student´s t tests carried out using the obtained kobs values showed 
that differences between WT and P272A/R277K/T286A RTs and between 
M41L/T215Y/P272A/R277K/T286A and M41L/T215Y RTs were not significant (p > 0.05) 
   
Fig 24. RNase H activity of WT and mutants RTs M41L/L210W/T215Y and M41L/L210W/T215Y/R284K. (A) [
32
P]RNA/DNA 
substrates (50 nM) were cleaved at 37°C in the presence of the corresponding RT at 100 nM concentration. T/P sequences 
are shown below the corresponding gels. Arrows in the template sequences indicate the cleavage sites. For D38rna/25PGA, 
the time points were taken after incubating the samples for 10, 20, 30 and 40 s, while for 31Trna/21P time points correspond 
to 1-, 2-, 4- and 8-min incubations. (B) Apparent rate constants for the cleavage of D38rna and 31Trna were obtained from 3 
or 4 independent experiments. RTs LY, AKA, LYAKA and RNase H(-) RT correspond to mutant enzymes M41L/T215Y, 
P272A/R277K/T286A, M41L/T215Y/P272A/R277K/T286A and HIV-1 group O RT with mutations V75I/E478Q, respectively. 
RNase H secondary cleavages  
 RNase H secondary cleavages generated by WT and mutant RTs in excision-competent 
complexes were determined by using the T35rna/PR26
AZTMP
 complex in the presence of 0.3 mM 
ATP (Fig 25). As shown in Fig 25, all tested enzymes were able to degrade the RNA to produce 
RNA fragments resulting from cleavages at positions -15, -12 and -10. However, while 
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M41L/T215Y/P272A/R277K/T286A, P272A/R277K/T286A and M41L/T215Y RTs had similar 
kinetics of formation of the -10 cleavage product (Fig 25), the WT RT was 1.6-fold faster than the 
others. Interestingly, a slightly higher amount of -10 cleavage product was obtained for all RTs in the 
absence of ATP in comparison with reactions carried out in the presence of 0.3 mM ATP (Fig 25).  
 
 
Fig 25. RNase H cleavage activity of WT and mutant RTs during ATP-mediated AZTMP excision. Assays were 
performed with the T/P shown below the gel (at 20 nM) in the presence of 200 nM RT. Aliquots were removed at 10, 20, 30, 
45, 60, 90, 120, 150, and 180 min. Cleavage sites are indicated above the template sequence. The labeled 5´-ends of the 
templates are marked with asterisks. Time courses of RNase H cleavage reactions carried out in the presence (left) or 
absence (right) of 0.3 mM ATP are shown below. RTs LY, AKA and LYAKA, correspond to mutants M41L/T215Y, 
P272A/R277K/T286A and M41L/T215Y/P272A/R277K/T286A, respectively. The gel shown is a representative example of 
kinetics carried out in the presence of 0.3 mM ATP. 
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4.1.1.4 Pre-steady-state kinetics of the ATP-dependent excision reaction 
 As described above, rescue assays involve different steps. One of them is the excision of the 
inhibitor from the blocked DNA primer. Direct measurements of this reaction can be obtained by 
using pre-blocked T/P complexes and incubating them in the presence of a PPi donor and RT. For 
this purpose, 25PGA primers were blocked with d4TMP or CBVMP by using the recombinant 
terminal transferase enzyme as described in Material and Methods, and annealed to D38rna or 
D38Crna templates, respectively. Assays performed in the presence of 3.2 mM ATP showed that 
d4TMP was removed most efficiently by MAK_SSSY, but also by the other RTs containing TAM-1 
mutations (Fig 26). Interestingly, while the excision rates were similar for both M41L/T215Y and 
M41L/T215Y/P272A/R277K/T286A RTs (kobs around 0.08 min
-1
), the presence of 
P272A/R277K/T286A in a WT sequence background reduced d4TMP excision by 2.3-fold (kobs of 
0.0032 min
-1
 and 0.0014 min
-1
, respectively). These results were consistent with those obtained in 
RNA/DNA dependent rescue assays that revealed differences in rescue efficiencies between the WT 
RT and the mutant P272A/R277K/T286A RT (Fig 23). As observed in rescue assays, CBVMP was a 
poor substrate of the excision reaction, and only the excision-proficient MAK_SSSY RT was able to 
remove it efficiently (Fig 26). The excision activities of M41L/T215Y/P272A/R277K/T286A and  
M41L/T215Y RTs were relatively low (kobs around 0.0036 min
-1
). On the other hand, WT and 
P272A/R277K/T286A enzymes were devoid of excision on CBVMP-terminated primers.  
 
Fig 26. Kinetics of the ATP-dependent excision of d4TMP and CBVMP from RNA/DNA T/Ps. Time course experiments 
for the excision reaction of d4TMP- or CBVMP-terminated primers (26-mers) annealed to their corresponding 38-nucleotide 
RNA templates (30 nM) were determined in the presence of 3.2 mM ATP. The excision reaction was catalyzed by WT and 
mutant RTs (250 nM). The calculated kobs values for the d4TMP excision reaction were 0.0032 ± 0.0003 min
-1
 for WT RT, 
0.0014 ± 0.0002 min
-1
 for mutant P272A/R277K/T286A RT, 0.0810 ± 0.0025 min
-1
 for mutant M41L/T215Y RT, 0.0782 ± 
0.0044 min
-1
 for mutant M41L/T215Y/P272A/R277K/T286A RT, and 0.153 ± 0.018 min
-1
 for the MAK_SSSY RT. For the 
excision of CBVMP, the kobs values for mutants M41L/T215Y, M41L/T215Y/P272A/R277K/T286A, and MAK_SSSY RTs were 
0.0038 ± 0.0003 min
-1
, 0.0035 ± 0.0002 min
-1
, and 0.0629 ± 0.0138 min
-1
, respectively. 
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4.1.1.5 Determination of the half maximal inhibitory concentration (IC50) of the 
excision reaction by the next complementary dNTP 
 The incorporation of an NRTI to the 3´-end of the primer and its translocation to the priming (P) 
site leaves the nucleotide binding (N) site free for binding an incoming nucleotide. If this occurs, and 
a dNTP complementary to template position +1 binds the N-site of the RT, a “dead-end-complex” 
(DEC) constituted by the RT, the T/P and the complementary dNTP is formed. DECs are not 
substrates of the excision reaction, but inhibit NRTI excision (Fig 10). In order to gain further 
insights on the contribution of this mechanism to the effects produced by P272A/R277K/T286A in 
rescue reaction efficiency, we determined the 50% inhibitory concentration (IC50) by the next 
complementary nucleotide. As shown in Table 10, M41L/T215Y and 
M41L/T215Y/P272A/R277K/T286A RTs were equally susceptible to dATP, in rescue reactions 
carried out with D38rna/25PGA
d4TMP
 complexes, showing IC50 values around 4 μM. IC50 values 
obtained for MAK_SSSY were about two-fold higher (Table 10). When the reactions were carried 
out with heteropolymeric DNA duplexes such as D38/25PGA
d4TMP
, we obtained essentially the same 
values than with RNA/DNA complexes, thereby suggesting a minimal impact of the type of template 
(i.e., RNA vs DNA) on the inhibition by the next complementary dNTP. 
 
Table 10. Ability of the next complementary dNTP to inhibit ATP-dependent rescue of primers terminated 
with d4TMP in RNA/DNA duplexes by mutant RTs.  
RT IC50 (μM) 
M41L/T215Y   4.4 ± 1.6 
M41L/T215Y/P272A/R277K/T286A   3.9 ± 1.0 
MAK_SSSY 
10.6 ± 4.8 
 (7.8 ± 0.3)
a
 
Assays were carried out in the presence of 3.2 mM ATP. All dNTPs in these assays were supplied at 100 μM, except dATP 
that was supplied from 1 to 200 μM depending on the assay. Active enzyme concentrations in these assays were in the range 
of 10-20 nM, and the concentration of D38rna/25PGA T/P was 30 nM. Samples were incubated for 0-15 min depending on the 
assay. In all cases, incubation times were within the linear range of the corresponding time course. The percent inhibition was 
plotted against the concentration of dATP, and the data were fitted to a hyperbola to obtain the IC50 for each enzyme. 
Reported values were obtained from 2-3 experiments and are given as mean values ± standard deviations.  
a 
Value obtained under the same conditions, but with the heteropolymeric DNA/DNA substrate D38/25PGA. 
 
4.1.1.6 Determination of T/P binding affinity of WT and mutant enzymes. 
 The effects on T/P binding of substituting Ala-272, Lys-277 and Ala-286 for Pro-272, Arg-277 
and Thr-286, respectively, were determined from the dissociation equilibrium constants (Kd) for 
DNA/DNA and RNA/DNA duplexes. D38/25PGA T/P was selected to determine DNA/DNA 
binding affinity as this was the complex used in rescue assays. However, 31rna/25PGA was chosen 
instead of D38rna/25PGA to measure RNA/DNA binding affinity (Table 11). The 31rna/25PGA 
complex results from primary RNase H cleavage using the T/P D38rna/25PGA, and represents the 
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predominant T/P form present in the rescue assays, since almost all template strands in the 
D38rna/25PGA complex are expected to be cleaved after only 30 s in the presence of RT (Fig 24). 
As shown in Table 11, thumb subdomain polymorphisms did not affect the DNA/DNA binding 
affinity. All Kd values were around 2-3 nM. In contrast, WT and M41L/T215Y RTs showed around 
two-fold higher binding affinity for 31rna/25PGA complexes in comparison to RTs bearing the 
P272A/R277K/T286A substitutions (Table 11). Thus, WT and M41L/T215Y RTs have Kd values of 
1.23 ± 0.33 nM and 1.14 ± 0.30 nM, respectively, while mutants P272A/R277K/T286A and 
M41L/T215Y/P272A/R277K/T286A showed Kd values in the range of 2.09 to 2.76 nM. 
  
Table 11. Dissociation equilibrium constants for WT and mutant HIV-1 RTs and DNA/DNA and RNA/DNA 
T/Ps. 
RT 
Apparent Kd (nM) 
D38/25PGA 31rna/25PGA 
WT 2.19 ± 0.34 1.23 ± 0.33 
P272A/R277K/T286A 1.75 ± 0.44 2.76 ± 0.45 
M41L/T215Y 3.13 ± 0.04 1.14 ± 0.30 
M41L/T215Y/P272A/R277K/T286A 2.77 ± 0.31 2.09 ± 0.46 
Sequences of D38/25PGA and 31rna/25PGA are: 
D38    5´ GGGTCCTTTCTTACCTGCAAGAATGTATAGCCCTACCA  3´ 
25PGA  3´              GGACGTTCTTACATATCGGGATGGT  5´ 
31rna  5´ GGGUCCUUUCUUACCUGCAAGAAUGUAUAGC         3´ 
25PGA  3´              GGACGTTCTTACATATCGGGATGGT  5´  
Data reported are mean values ± standard deviations obtained from three independent experiments. 
 
4.1.1.7 DNA polymerization and RNase H activity of WT and mutant RTs in the 
presence of low concentrations of T/P 
 The differences in the Kd values for RNA/DNA versus DNA/DNA could have a significant 
impact in the DNA polymerase and RNase H activities of the RT. We have carried out assays with 
WT and mutant RTs in the presence of limiting concentrations of T/P to evaluate their efficiencies in 
these conditions. 
RNase H activity at limiting T/P concentration 
 RNase H reactions were carried out in the presence of 1.5 nM D38rna/25PGA. This 
concentration was chosen because it was intermediate between the Kd for RNA/DNA of WT and 
M41L/T215Y RTs (Kd around 1.2 nM) and those of P272A/R277K/T286A and 
M41L/T215Y/P272A/R277K/T286A RTs (Kd around 2.4 nM). RT concentration was maintained at 3 
nM in these assays. We found that thumb subdomain polymorphisms had a minor influence on the 
RNase H cleavage rates (Fig 27). In general, differences were not significant between WT and 
M41L/T215Y RTs and their homologs bearing thumb subdomain mutations. However, the mutant 
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M41L/T215Y/P272A/R277K/T286A RT showed slightly reduced RNase H activity in comparison 
with the M41L/T215Y RT suggesting that thumb subdomain polymorphisms could impair usage of 
T/P at low concentrations. 
 
Fig 27. RNase H activity of WT and mutant RTs determined under limiting concentration of T/P. The labeled-RNA/DNA 
substrate D38rna/25PGA (1.5 nM) was cleaved at 37ºC in the presence of the corresponding RT at 3 nM (active enzyme 
concentration). Time points were obtained after incubating the samples for 20 s, 40 s, 1.5, 3, 5 and 8 min, respectively. A 
representative autoradiogram of the RNase H cleavage activity of WT and mutant RTs is shown, as well as the time courses of 
the RNase H cleavage reactions carried out with WT and mutant RTs. Represented values (mean values ± standard 
deviations [error bars]) were obtained from three independent experiments. RTs AKA, LYAKA and LY, correspond to mutant 
enzymes P272A/R277K/T286A, M41L/T215Y/P272A/R277K/T286A and M41L/T215Y, respectively. 
Primer extension ability of WT and mutant RTs at limiting T/P concentration 
 Primer extension reactions were carried out in the presence of 3 nM active RT, with an excess of 
dNTPs (200 μM), with the exception of dATP which was supplied at 2 μM. In these assays, the 
31rna/25PGA complex was added at a limiting concentration (1 nM) and also at 10 nM to directly 
compare RT DNA polymerization under different conditions. Interestingly, while at 10 nM T/P 
differences were not significant, at 1 nM concentration there was an approximately two-fold increase 
in the rate of formation of 38-nucleotide product by the M41L/T215Y mutant in comparison with the 
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M41L/T215Y/P272A/R277K/T286A RT (Fig 28). Notably, these differences are consistent with the 
higher RNA/DNA affinity reported for the M41L/T215Y enzyme (Table 11).  
 
 
 
 
Fig 28. Extension of unblocked DNA primer 25PGA by WT and mutant RTs in the presence of an RNA template. 
Reactions were carried out with 31rna/25PGA concentrations of 1.5 and 10 nM, in the presence of 3 nM RT and 100 μM of 
each dNTP. P, primer; F, full length product. 
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4.1.2 Mechanistic insights into the association of the amino acid 
substitution R284K in the RT thumb subdomain and the TAM-1 pathway 
mutations M41L, L210W and T215Y 
RT thumb subdomain mutation R284K has been identified in several studies associated with 
NRTI treatment (Cane et al., 2007; Waters et al., 2009; Von Wyl et al., 2010). To further 
characterize the role of thumb subdomain substitutions on NRTI resistance and based on published 
evidence, we decided to study the molecular mechanism involved in the selection of R284K mutation 
under antiretroviral treatment. RT sequence analysis of viral isolates obtained from patients failing 
treatment with NRTIs showed a significant correlation between the presence of R284K and TAM-1 
mutations M41L, L210W and T215Y (Cane et al., 2007). Therefore, we characterized the WT (BH10 
strain) RT, and mutant RTs R284K, M41L/L210W/T215Y and M41L/L210W/T215Y/R284K. 
 
4.1.2.1 Rescue of DNA/DNA complexes blocked with AZTMP, d4TMP and tenofovir 
The rescue ability of WT and mutant RTs was tested using DNA/DNA complexes blocked with 
AZTMP, d4TMP or tenofovir (Fig 29). After incorporation of the corresponding NRTI, we added a 
mixture of the four dNTPs and 3.2 mM ATP to facilitate excision and resume DNA polymerization. 
The mutant M41L/L210W/T215Y/R284K RT was able to rescue a significantly larger amount of 
blocked DNA than the M41L/L210W/T215Y RT with all three studied NRTIs (Fig 29). These 
differences were higher for primers blocked with thymidine-analogues than for primers blocked with 
tenofovir. However, R284K  alone had no effect on the rescue activity of the WT enzyme (Fig 29). 
Unlike in the case of reactions carried out in the presence of ATP, D38/25PGA
AZTMP
 rescue 
assays carried out in the presence of 9.6 mM GTP showed relatively minor differences between 
M41L/L210W/T215Y and M41L/L210W/T215Y/R284K RTs. This was due to the increase in rescue 
efficiency observed in reactions catalyzed by M41L/L210W/T215Y RT, relative to those carried out 
with M41L/L210W/T215Y/R284K RT (Fig 30). In the presence of 200 μM PPi, differences between 
M41L/L210W/T215Y and M41L/L210W/T215Y/R284K RTs were not significant (Fig 30). Under 
these conditions both mutant enzymes were less efficient than the WT in rescuing primers terminated 
with AZTMP.  
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Fig 29. ATP-mediated excision of AZTMP-, d4TMP-, and tenofovir-terminated DNA/DNA T/Ps by WT and mutant RTs. 
Reactions were carried out with 38/25-mer DNA/DNA heteropolymeric complexes (sequences shown in the upper part of the 
figure). First, the inhibitor was incorporated at position +1 (indicated with an asterisk) of the 25-nucleotide primer (lane P) to 
generate a 26-nucleotide product (lane B). Excision of the inhibitor and further extension of the primer in the presence of 3.2 
mM ATP and a mixture of dNTPs led to the formation of a fully extended 38-nucleotide product. A representative time course 
experiment of a primer rescue reaction is shown in lanes 1 to 9, which correspond to aliquots removed 2, 4, 6, 8, 10, 12, 15, 
20, and 30 min after the addition of 3.2 mM ATP (gel on the right in the top panel). Graphs of time course experiments of 
primer rescue reactions initiated from inhibitor-terminated primers are given below. All dNTPs in the assays were supplied at 
100 μM, except for dATP or dTTP (depending on the assay) whose concentration was 1 μM. T/P and active RT concentrations 
in these assays were 30 and 24 nM, respectively. Mean values ± standard deviations [error bars] were obtained from three 
independent experiments. 
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Fig 30. Rescue of AZTMP-blocked complexes in the presence of GTP or PPi. AZTMP rescue assays were carried out with 
the D38/25PGA DNA/DNA complex. Reaction conditions were the same described for ATP-dependent rescue assays, but 
using 9.6 mM GTP (left) or 200 μM PPi (right). Time points were taken at 2, 4, 6, 8, 10, 12, 15, 20, and 30 min after the 
addition of GTP or at 1, 2, 3, 4, 5, 6, 7, 8 and 10 min, after the addition of PPi. Mean values ± standard deviations [error bars] 
were obtained from three independent experiments. 
 
 
4.1.2.2 Rescue of RNA/DNA complexes blocked with AZTMP, d4TMP and tenofovir 
D38rna/25PGA and D38Trna/25PGA RNA/DNA complexes were used to measure AZTMP-, 
d4TMP- and tenofovir-terminated primer rescue efficiencies (Fig 31). In contrast with the results 
obtained with DNA/DNA complexes, we did not detect any significant differences between 
M41L/L210W/T215Y and M41L/L210W/T215Y/R284K RTs (Fig 31). Although both enzymes had 
remarkable ATP-dependent phosphorolytic activity, slightly higher than on DNA/DNA T/Ps, the 
presence of R284K had a minimal impact on rescue efficiency. The R284K mutant and the WT RT 
also showed higher NRTI-excision activity than on DNA/DNA, especially in the case of tenofovir 
(Fig 31).  
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Fig 31. ATP-mediated rescue of AZTMP-, d4TMP-, and tenofovir-terminated primers in RNA/DNA duplexes by WT and 
mutant RTs. Time course experiments of excision reactions were carried out in the presence of 3.2 mM ATP. T/Ps used are 
indicated above corresponding graphs. All dNTPs in the assays were supplied at 200 μM, except dATP or dTTP (depending 
on the assay) whose concentration was 2 μM. T/P and active RT concentrations in these assays were 30 and 24 nM, 
respectively. Mean values ± standard deviations [error bars] were obtained from three independent experiments. 
4.1.2.3 RNase H activity of WT and mutant RTs 
The endonucleolytic activity of WT and mutant RTs was determined by using the 
heteropolymeric complexes 31Trna/21P and D38Trna/25PGA. D38Trna/25PGA was one of the T/Ps 
used in rescue assays with RNA/DNA complexes. We found no differences between the 
endonucleolytic activities of the M41L/L210W/T215Y RT and the WT enzyme, independently of the 
substrate used (Fig 32). Interestingly, RNase H kinetics obtained with these enzymes showed similar 
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cleavage rates between them on both tested T/Ps (catalytic rate constants around 0.35 min
-1
). The 
M41L/L210W/T215Y/R284K RT showed higher endonucleolytic activity than the WT and the 
M41L/L210W/T215Y enzymes. Thus, when 31Trna/21P was used as substrate, mutant 
M41L/L210W/T215Y/R284K showed a 2.5-fold increased catalytic rate in comparison with the WT 
RT (Fig 32). A similar increase was observed with D38Trna/25PGA that showed a catalytic rate 
constant that was roughly 3.3 times higher for the M41L/L210W/T215Y/R284K RT than for the WT 
and M41L/L210W/T215Y RTs (Fig 32). Thus, while approximately 35% of the 31Trna/21P remains 
uncleaved after 3 min of incubation in the presence of WT and M41L/L210W/T215Y RTs, this value 
was < 8% in the presence of M41L/L210W/T215Y/R284K RT. 
 
Fig 32. RNase H activity of WT and mutant RTs. [
32
P]RNA/DNA substrates (50 nM) were cleaved at 37°C in the presence of 
the corresponding RT at 50 nM (active enzyme concentration). The T/P sequences used are shown below the corresponding 
gel. For D38Trna/25PGA, the time points were obtained after incubating the samples for 20 s, 40 s and 1, 2 and 4 min. For 
31Trna/21P, aliquots were removed at 20 s, 40 s and 1, 2, 3 and 4 min. Catalytic rate constants for the cleavage of D38Trna 
were 0.34 ± 0.15 min
-1
, 0.39 ± 0.18 min
-1
 and 1.16 ± 0.54 min
-1
 for WT, and mutant RTs M41L/L210W/T215Y and 
M41L/L210W/T215Y/R284K, respectively. For 31Trna the catalytic rate constant of the WT enzyme was 0.33 ± 0.05 min
-1
. 
Rate constants for mutants M41L/L210W/T215Y and M41L/L210W/T215Y/R284K were 0.35 ± 0.03 min
-1
 and 0.87 ± 0.12   
min
-1
, respectively. 
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Interestingly, an increased frequency of RNase H secondary cleavages was also detected with 
the D38Trna/25PGA complex in reactions carried out with the M41L/L210W/T215Y/R284K RT 
(data not shown). However, this cleavage, corresponding to position -16 of the template strand, could 
not be measured accurately. Taken together, those results suggest that the reduced stability of the 
RNA template in reactions catalyzed by the M41L/L210W/T215Y/R284K RT could affect the 
elongation efficiency of unblocked DNA primers on rescue assays.  
 
4.1.2.4 Kinetics of ATP-dependent excision of AZTMP and d4TMP from DNA/DNA 
blocked-complexes 
In order to determine whether the improved DNA/DNA rescue efficiency displayed by the 
M41L/L210W/T215Y/R284K RT could be attributed to an increased chain-terminator excision 
activity, excision rates for WT and mutant RTs were determined under single-turnover conditions. 
 
Preparation of NRTI-blocked DNA primers annealed to DNA templates 
For the determination of the ATP-dependent excision activity of WT and mutant RTs, we 
obtained DNA/DNA complexes blocked with d4TMP, AZTMP and tenofovir. Primers terminated 
with d4TMP were obtained by using the terminal transferase enzyme (see section 4.1.1.4 and 
Material and Methods). It was known that AZTTP was a poor substrate of the terminal transferase 
(Mas et al., 2002). However, it was not known whether tenofovir-DP could be used as substrate by 
the terminal transferase enzyme. Our assays revealed some incorporation of tenofovir by the terminal 
transferase on 25PGA (Fig 33A). However, catalytic incorporation rates calculated for d4TTP and 
tenofovir-DP showed that d4TTP incorporation was around 18 times faster than tenofovir-DP 
incorporation (Fig 33B). Use of CoCl2 instead of MnCl2 did not improve AZTTP or tenofovir-DP 
incorporation. In order to obtain complexes with primers blocked with AZTMP or tenofovir, we used 
the WT RT to incorporate AZTTP and tenofovir-DP on preformed D38/25PGA or D38T/25PGA 
complexes, respectively (Fig 33C). Once the NRTI was incorporated, the WT RT was heat-
inactivated and the sample slowly cooled down at room temperature to allow T/P re-association. 
Finally the T/P was purified by gel-filtration chromatography and alcohol precipitation. This method 
yielded 40-50% of final purified product.  
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Fig 33. AZTTP, d4TTP and tenofovir-DP incorporation to the 3´-end of 25PGA and formation of T/Ps containing 
blocked DNA primers. (A) AZTTP, d4TTP and tenofovir-DP incorporation in 25PGA primers using the terminal transferase 
enzyme. The amount of enzyme used (in activity units) is shown below the gel. (B) Time courses of d4TTP and tenofovir-DP 
incorporation reactions carried out with the terminal transferase enzyme. Catalytic rate constants for the incorporation of 
d4TTP and tenofovir-DP were 4.59 ± 0.74 min
-1
 and 0.26 ± 0.03 min
-1
, respectively. (C) Schematic representation of the 
methodology employed in the production of D38/25PGA
AZTMP
 complexes. First, the primer was blocked in the presence of 
template, WT RT and a large excess of AZTTP (represented as a red Z). The RT was heat-inactivated (10 min, 90ºC) and the 
T/P re-associated by slowly cooling to room temperature. Free AZTTP molecules were eliminated by gel-filtration 
chromatography and finally the T/P further purified and concentrated by ethanol precipitation. 
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ATP-dependent excision of d4TMP- and AZTMP-terminated primers 
WT and mutant RTs R284K, M41L/L210W/T215Y and M41L/L210W/T215Y/R284K were 
incubated with D38/25PGA
d4TMP
 and D38/25PGA
AZTMP
 complexes in the presence of 3.2 mM ATP 
and the kinetics of the excision reaction were monitored by measuring the formation of free 25PGA. 
Two groups of mutations could be easily identified based on their excision activity. While WT and 
R284K RTs showed low-level activity on primers terminated with AZTMP or d4TMP, 
M41L/L210W/T215Y and M41L/L210W/T215Y/R284K RTs showed measurable levels of excision 
activity (Fig 34). Addition of R284K mutation to a M41L/L210W/T215Y background did not 
improve excision ability of the enzyme containing TAM-1 mutations. Notably, excision rate 
constants were roughly similar for both NRTIs (Fig 34). 
 
 
Fig 34. Kinetics of ATP-dependent excision of AZTMP and d4TMP from NRTI-terminated DNA/DNA T/Ps. Excision 
reactions of AZTMP- and d4TMP-terminated primers (26-mers) annealed to their corresponding 38-nucleotide DNA templates 
(30 nM) were initiated by the addition of 3.2 mM ATP. The active RT was 210 nM. The calculated kobs values for the AZTMP 
were 2.82 ± 0.15 x 10
-3
 min
-1
, 2.42 ± 0.12 x 10
-3
 min
-1
, 4.69 ± 0.17 x 10
-2
 min
-1
 and 3.64 ± 0.31 x  10
-2
 min
-1
 for WT, R284K, 
M41L/L210W/T215Y and M41L/L210W/T215Y/R284K RTs, respectively. For d4TMP excision, catalytic rate of the WT enzyme 
was 3.37 ± 0.19 x 10
-3
 min
-1
, while kobs for mutants R284K, M41L/L210W/T215Y and M41L/L210W/T215Y/R284K were 2.62 ± 
0.14 x 10
-3
 min
-1
, 3.72 ± 0.16 x 10
-2
 min
-1
 and 3.70 ± 0.23 x 10
-2
 min
-1
, respectively. 
 
4.1.2.5 DNA/DNA binding affinity of WT and mutant RTs 
We determined the DNA/DNA dissociation equilibrium constant (Kd) of WT and mutant RTs for 
the D38/25PGA complex used in rescue assays. The obtained Kd values were essentially the same 
(around 2 nM) for all tested RTs (Table 12), and similar to DNA/DNA binding affinities reported for 
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RTs M41L/T215Y, M41L/T215Y/P272A/R277K/T286A and P272A/R277K/T286A (Table 12). 
These results suggest a negligible impact of the DNA/DNA binding affinity on the higher rescue 
efficiency shown by the M41L/L210W/T215Y/R284K RT. 
 
Table 12. Dissociation equilibrium constants for WT and mutant HIV-1 RTs and DNA/DNA T/Ps. 
RT Kd (nM) 
WT 1.65 ± 0.48 
R284K 1.94 ± 0.42 
M41L/L210W/T215Y 2.37 ± 0.65 
M41L/L210W/T215Y/R284K 1.71 ± 0.21 
The nucleotide sequence of the T/P was: 
D38    5´ GGGTCCTTTCTTACCTGCAAGAATGTATAGCCCTACCA  3´ 
25PGA  3´              GGACGTTCTTACATATCGGGATGGT  5´ 
Reported data are mean values ± standard deviations obtained from three independent experiments. 
 
4.1.2.6 AZTTP and tenofovir-DP inhibition constants (Ki) for WT and mutant RTs 
As described previously, the addition of the R284K substitution did not improve the excision 
activity of the M41L/L210W/T215Y RT. Following primer unblocking, the RT has to extend the 
primer strand to generate the full length product of the rescue reaction. However, the free 
triphosphorylated inhibitor present in the sample (or even the polyphosphate product resulting from 
the ATP-mediated excision) could be incorporated at the same position instead of the corresponding 
dNTP and block the primer again. In order to check if the presence of R284K could affect the ability 
of M41L/L210W/T215Y RT to incorporate AZTTP or tenofovir-DP, inhibition constants for both 
inhibitors were determined. As shown in Table 13, AZTTP and tenofovir-DP Ki values for WT, 
M41L/L210W/T215Y and M41L/L210W/T215Y/R284K RTs were broadly similar and around 2.5 
μM in all cases. The only exception was the WT RT, which showed a 1.7-fold increase in Ki for 
tenofovir-DP in comparison with AZTTP. Taken together, these results suggest a minimal effect of 
amino acid substitutions of the TAM-1 cluster or R284K in AZTTP or tenofovir-DP discrimination. 
 
 
Table 13. Inhibition constants for AZTTP and tenofovir-DP incorporation. 
RT 
Ki (μM) 
AZTTP Tenofovir-DP 
WT 2.10 ± 0.38 3.59 ± 0.26 
M41L/L210W/T215Y 2.18 ± 0.17 2.63 ± 0.64 
M41L/L210W/T215Y/R284K 2.32 ± 0.74 2.54 ± 0.55 
D38/25PGA and D38T/25PGA were used as substrates for AZTTP and tenofovir-DP incorporation, respectively. Reported 
values are the mean values ± standard deviations, obtained from at least three independent experiments.  
 
85
                                                                                                                          Results 
 
4.1.2.7 Steady-state kinetic parameters of nucleotide incorporation of WT and mutant 
RTs 
As discussed above, efficient DNA elongation after primer unblocking is important to complete 
the rescue reaction. Therefore, the ability of M41L/L210W/T215Y/R284K and 
M41L/L210W/T215Y/ RTs to incorporate nucleotides in the growing DNA chain was determined. 
For this purpose, D38/25PGA and D38T/25PGA complexes were obtained and the incorporation of 
dTTP or dATP was monitored. Kinetic parameters such as the catalytic rate of nucleotide 
incorporation (kcat), the Michaelis-Menten constant (Km) and the catalytic efficiency (kcat/Km) for each 
nucleotide are given in Table 14. The kcat values for dTTP and dATP incorporation by the 
M41L/L210W/T215Y/R284K RT were around 1.7- and 3-fold higher, respectively, than those 
obtained with the WT and the M41L/L210W/T215Y RTs, respectively. However, the higher kcat of 
dNTP incorporation obtained with RTs bearing the R284K mutation resulted in a higher catalytic 
efficiency only in the case of dATP, since the Km value for dTTP incorporation shown by the 
M41L/L210W/T215Y/R284K RT was also 1.6-fold higher than the corresponding values obtained 
with the WT and M41L/L210W/T215Y enzymes (Table 14).  
Table 14. Steady-state kinetic parameters of nucleotide incorporation catalyzed by WT and mutant RTs. 
Nucleotide RT   kcat (min
-1
) Km (nM) kcat/Km (μM
-1
 min
-1
) 
dTTP WT   3.14 ± 0.55 108.3 ± 12.9   30.9 ± 4.7 
M41L/L210W/T215Y   3.53 ± 0.09 117.4 ± 21.9   30.8 ± 6.0 
M41L/L210W/T215Y/R284K   5.66 ± 0.23 184.5 ± 6.1   30.7 ± 2.3 
dATP WT   3.87 ± 0.99   25.8 ± 6.7 172.0 ± 27.7 
M41L/L210W/T215Y   5.70 ± 0.87   32.1 ± 9.6 243.9 ± 51.1 
M41L/L210W/T215Y/R284K 10.09 ± 1.47   15.9 ± 2.5 639.6 ± 101.2 
D38/25PGA and D38T/25PGA were used as T/Ps for dTTP and dATP incorporation, respectively. Reported data are the mean 
values ± standard deviations, obtained from at least three independent experiments. 
4.1.2.8 Pre-steady-state kinetics of dTTP incorporation 
Although the M41L/L210W/T215Y/R284K RT showed increased steady-state rates of 
nucleotide incorporation, it should be noted that these rates are dominated by the slowest step of the 
polymerization reaction (i.e., dissociation of the RT-DNA complex). Therefore, differences in 
dissociation rate constants (koff) could have a large influence on the kcat values obtained. However, 
this does not seem to affect the comparison of M41L/L210W/T215Y and 
M41L/L210W/T215Y/R284K RTs, since both RTs showed similar koffs in assays carried out with the 
D38/25PGA complex (0.215 ± 0.030 s
-1
 and 0.201 ± 0.033 s
-1
 for M41L/L210W/T215Y and 
M41L/L210W/T215Y/R284K RTs, respectively). Further evidence in support of these results was 
obtained by determining the pre-steady-state kinetics of single-nucleotide incorporation with the 
D38/25PGA T/P (Fig 35). These assays were performed in the presence of high dTTP concentrations 
(80 μM) to ensure optimal binding of dNTP. Under these conditions, the M41L/L210W/T215Y RT 
showed a nucleotide incorporation rate (kobs) of 21.5 ± 4.4 s
-1
 while the kobs value of the 
M41L/L210W/T215Y/R284K RT was 38.8 ± 9.4 s
-1
. These results gave additional support to the role 
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of the R284K mutation as an enhancer of nucleotide incorporation efficiency when added to 
M41L/L210W/T215Y RT. 
 
 
Fig 35. Pre-steady-state kinetics of single-nucleotide incorporation by RTs in the presence of high concentrations of 
dNTP. (A) Graphic representation of a complete time course reaction. Assays were carried in the presence of high dTTP 
concentration (80 μM), RT (70 nM) and D38/25PGA T/P (100 nM). Mean values ± standard deviations [error bars] were 
obtained from three independent experiments. (B) Close-up of nucleotide incorporation kinetics covering the first 500 ms of the 
reaction. 
 
4.1.2.9 Polymerization ability of WT and mutant RTs 
DNA primer extension assays as well as processivity measurements were also carried out with 
WT and mutant RTs. 
Primer extension assays 
Ability of WT and mutant RTs to extend the unblocked D38/25PGA DNA/DNA complex was 
determined in the presence of excess dNTPs (i.e. 100 μM each) and at 1, 5 and 10 nM T/P. In assays 
carried out with 10 nM D38/25PGA, the mutant RT M41L/L210W/T215Y/R284K showed increased 
ability to extend the DNA primer, in comparison with the WT and M41L/L210W/T215Y RTs (Fig 
36). This increase in primer extension was mitigated at lower T/P concentrations. Interestingly, when 
the R284K mutation was introduced in a WT background also produced an increase on primer 
elongation (Fig 36). Consistent with the results obtained with the M41L/L210W/T215Y/R284K RT, 
this effect was clearly observed at the highest T/P concentration (i.e., 10 nM). 
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Fig 36. Extension of unblocked primers in heteropolymeric DNA/DNA D38/25PGA complex by WT and mutant RTs. 
Reactions were carried out in the presence of 1.5, 5 and 10 nM T/P concentrations, 3 nM RT and 100 μM of each dNTP. 
Represented values shown in the plots below were mean values ± standard deviations [error bars], obtained from three 
independent experiments. 
Processivity assays 
Processivity is defined as the number of nucleotides that the RT is able to incorporate in a 
growing DNA chain before dissociation (i.e., the number of nucleotides incorporated in a single 
cycle of DNA synthesis). To ensure that only one synthesis cycle is taking place, the presence of an 
RT trap is essential. One of the most common traps used in RT biochemical assays is sodium 
heparin. Heparin acts by sequestering all free RT present in the media. Therefore, as soon as the RT 
dissociates from the preformed RT-T/P binary complex, the heparin will bind the enzyme, thus 
avoiding further polymerization events. Although processivity assays are usually carried out with 
large templates, we first assessed WT and mutants RTs processivity with the D38/25PGA complex 
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used in rescue assays. In the presence of 5 mg/ml heparin, M41L/L210W/T215Y/R284K RT showed 
higher processivity than the M41L/L210W/T215Y enzyme (Fig 37A, B). These results were highly 
consistent with data obtained in primer extension and nucleotide incorporation assays, further 
supporting the role of R284K in DNA polymerization efficiency when this amino acid substitution 
was accompanying the M41L/L210W/T215Y set of mutations. In additional experiments, processive 
synthesis of WT and mutant RTs were evaluated using a long template, corresponding to the 
M13mp2 single-stranded DNA in complex with the 15-mer ProLac110 in the presence of 5 mg/ml 
heparin. Under these conditions accurate measurements of primer extension were limited by high 
frequency of bands corresponding with primers whose elongation was not completed (Fig 37C). 
However, there was a clear tendency to produce longer extension products in reactions catalyzed by 
RTs bearing R284K compared with their counterparts without this mutation. This is particularly 
evident for WT and R284K enzymes (as indicated with asterisks in Fig 37C). 
 
Fig 37. Processivity of WT and mutant RTs. (A) Processivity assays carried out with M41L/L210W/T215Y and 
M41L/L210W/T215Y/R284K RTs and the heteropolymeric T/P D38/25PGA. Elongation reactions were carried out in the 
presence of heparin (5 mg/ml) as an enzyme trap. After formation of the binary complex of RT and T/P (D38/25PGA), 
reactions were initiated by adding a mixture of all four dNTPs (50 μM final concentration), with or without heparin (indicated 
above the gel with plus and minus signs, respectively). Lanes 1 to 4 represent samples taken 5, 15, 30 and 45 min after 
initiating the polymerization reaction. Asterisks in panels (A) and (C) indicate bands that are significantly more intense in the 
reactions catalyzed by the M41L/L210W/T215Y/R284K RT. (B) Shows the amount of extended primer in reactions carried out 
with D38/25PGA in the presence of trap. (C) Processivity assays using the M13mp2 single-stranded DNA as template. Assays 
were carried out in the same conditions described above for D38/25PGA. P stands for primer, and C represents control 
reactions where the heparin trap was added before the enzyme. The oligonucleotide ProLac110 (5’- GCGATTAAGTTGGGT-
3’) is complementary to positions 105-119 of the lacZα coding sequence. 
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4.1.2.10 Connection subdomain substitution M357T: a possible R284K associated 
mutation 
In order to identify possible partners of the R284K mutation, a rational search of new mutations 
was carried out. Firstly, the RT-DNA/DNA-dNTP ternary complex (Huang et al., 1998) was 
analyzed to identify residues in the vicinity of Arg-284. Structural data revealed that connection 
subdomain residues 355-357 as well as the side-chain of Arg-284 interact with the same template 
region (nucleotides -12 and -13 of template strand). Therefore an extensive search on the Stanford 
University HIV drug resistance database (http://hivdb.stanford.edu/) was performed in order to 
identify possible associations between R284K and mutations at positions 355, 356 and 357. 
Sequences from HIV-1 group M subtype B HIV-1 isolates bearing R284K, M41L/L210W/T215Y or 
M41L/L210W/T215Y/R284K mutations, as well as the WT strain were identified. While Ala-355 is 
highly conserved in all sequence contexts (around 97% of HIV-1 isolates), the residue at position 356 
is polymorphic, with Arg-356 being the most frequently found amino acid. The R356K substitution 
had the same frequency (around 10%) in all sequence contexts bearing the R284K mutation. 
Interestingly, in genotypes lacking the R284K mutation (i.e., in the WT and the 
M41L/L210W/T215Y backgrounds) the substitution R356K was found around 2 times more 
frequently (Table 15). Notably, the M357T substitution was found in 34% and 42.7% of viruses 
bearing the R284K and M41L/L210W/T215Y/R284K mutations, respectively. On the other hand, 
M357T was found in 25.8% of the viruses bearing the M41L/L210W/T215Y set of mutations, and in 
23% of the WT viruses (Table 15). Therefore, the frequency of M357T was about two-thirds higher 
in virus having M41L/L210W/T215Y/R284K than in virus having only the TAM-1 cluster of 
mutations. Furthermore, if we extend the analysis of other mutations at position 357 (e.g., M357I and 
M357V), the observed increase is even larger (Table 15). These results suggested that 
polymorphisms at position 357 could be related with mutations M41L/L210W/T215Y only when the 
R284K mutation was present. 
Table 15. Frequency of connection subdomain mutations R356K and M357T found in different sequence 
backgrounds. 
Sequence background R356K (%) M357T (%) 
WT 18.0 23.6 
R284K 9.7 34.0 
M41L/L210W/T215Y 24.6 25.8 (31.1)
a 
M41L/L210W/T215Y/R284K 10.7 42.7 (60.0)
a 
a
 Frequency of mutations M357I/T/V 
Data obtained from the Stanford University HIV drug resistance database (http://hivdb.stanford.edu/).  
Effects of M357T on rescue activity and processivity in the presence of TAMs and R284K 
Based on the evidence described above, we purified a mutant RT with the combination of amino 
acid substitutions M41L/L210W/T215Y/R284K/M357T. Rescue assays with DNA/DNA and 
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RNA/DNA complexes containing an AZTMP-blocked primer, carried out in the presence of 3.2 mM 
ATP, showed that mutant M41L/L210W/T215Y/R284K/M357T had significant ATP-dependent 
phosphorolytic activity, but similar to the M41L/L210W/T215Y/R284K RT (Fig 38A).  
 
Fig 38. Effect of M357T in the presence of the mutational complex M41L/L210W/T215Y/R284K ATP-dependent rescue 
activity and processivity. (A) Time course experiments with D38/25PGA
AZTMP
 (up) and D38rna/25PGA
AZTMP
 (down) were 
carried out in the presence of 3.2 mM ATP. T/P concentration was 30 nM, while RT was present at 24 nM. All dNTPs were 
supplied at 100 μM (DNA/DNA) or 200 μM (RNA/DNA), except for dATP, whose concentration was 1 μM (DNA/DNA) or 2 μM 
(RNA/DNA). (B) Processivity assays carried out with M13mp2 single-stranded DNA as template. Elongation reactions were 
monitored in the presence of heparin (5 mg/ml) as an enzyme trap. After formation of the binary complex of RT and T/P 
(M13mp2 single-stranded DNA/ProLac110), reactions were initiated by adding a mixture of all four dNTPs (50 μM final 
concentration), with or without heparin (indicated above the gel with plus and minus signs, respectively). Lanes 1 to 4 
represent samples taken 5, 15, 30 and 45 min after initiating the polymerization reaction. P stands for primer, and C 
represents control reactions where the heparin trap was added before the enzyme. Asterisks indicate bands that are 
significantly more intense in the reactions catalyzed by the M41L/L210W/T215Y/R284K/M357T RT. Time course experiments 
carried out with the D38/25PGA complex did not show significant differences between M41L/L210W/T215Y/R284K and 
M41L/L210W/T215Y/R284K/M357T RTs (see panel below). 
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In addition, the processivity of M41L/L210W/T215Y/R284K/M357T RT was also evaluated on 
M13mp2ssDNA/ProLac110 and D38/25PGA complexes. While on D38/25PGA duplexes RTs with 
and without the M357T substitution showed similar processivities (Fig 38B), we found some 
differences with the M13mp2ssDNA/ProLac110 complex. Thus, when using this T/P, mutant 
M41L/L210W/T215Y/R284K/M357T RT produced longer products than the 
M41L/L210W/T215Y/R284K enzyme (Fig 38B). However, as discussed above, accurate 
quantification of processive polymerization was not possible and therefore the significance of these 
results remains unclear.  
4.2 Mechanistic insights into the association of H208Y and the TAM-1 
pathway mutations M41L, L210W and T215Y 
RT thumb subdomain mutations described so far are away from the DNA polymerase active site 
as well as from the ATP binding site. Results described above show that their impact on ATP-
dependent excision activity is not relevant.  
Another secondary mutation usually found associated with TAMs in treated HIV-1 infected 
patients is H208Y. Residue 208 is located at the palm subdomain, very close to the ATP binding site 
created by TAMs. However, its hypothetical role on excision is unknown, although H208Y has been 
associated with antiretroviral treatment failure and with the presence of TAM-1 mutations M41L, 
L210W and T215Y (Svicher et al., 2006; Nebbia et al., 2007; von Wyl et al., 2010). For these 
studies, in addition to the WT and mutant M41L/L210W/T215Y RTs, we purified two additional 
mutant enzymes containing the amino acid substitution H208Y: M41L/H208Y/L210W/T215Y and 
H208Y RTs. 
4.2.1 ATP-dependent rescue activity of WT and mutant RTs 
The ability of WT and mutant enzymes to rescue primers blocked with different NRTIs in the 
presence of 3.2 mM ATP was first analyzed using DNA/DNA duplexes (i.e., the D38/25PGA 
complex in the case of AZTMP and d4TMP, and D38T/25PGA in the case of tenofovir). Results 
obtained are shown in Fig 39. As expected, the single-mutant enzyme H208Y showed very low or 
negligible rescue activity, with final extension product levels similar to those obtained with the WT 
RT. These levels of rescue activity displayed by both enzymes were similar for all tested NRTIs.  In 
contrast with the single-mutant, when H208Y was present in a background containing 
M41L/L210W/T215Y mutations, a measurable amount of fully-extended primer was obtained (Fig 
39). The mutant M41L/L210W/T215Y RT also showed remarkable rescue activity, as described in 
section 4.1.2.1. However, the amount of fully-extended product was lower than in reactions carried 
out with the M41L/H208Y/L210W/T215Y RT. Differences between M41L/L210W/T215Y and 
M41L/H208Y/L210W/T215Y RTs were significant with tenofovir, as well with both thymidine 
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analogues. Tenofovir- and AZTMP-terminated primers were the best substrates of excision reactions 
carried out with both enzymes. In contrast, rescue of d4TMP-terminated primers was about two times 
less efficient.  
      
Fig 39. DNA rescue activity of WT and mutant RTs from AZTMP-, d4TMP- and tenofovir-terminated T/Ps. Reactions 
were carried out with D38/25PGA and D38T/25PGA complexes (sequences shown to the left of the gel). Primers (lane P) 
were blocked with a nucleot(s)ide analogue to generate a 26-nucleotide blocked primer (lane B). Excision of the inhibitor 
allows the extension of the primer to the final product of 38 nucleotides. Lanes 1 to 9 represent time points at 2, 4, 6, 8, 10, 12, 
15, 20 and 30 min taken after adding a mixture containing all four dNTPs and ATP at a 3.2 mM concentration. Time course 
experiments of primer rescue reactions are shown below. T/P and active RT concentrations in these assays were 30 and 24 
nM, respectively. Mean values ± standard deviations [error bars] were obtained from three independent experiments. 
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Interestingly, when rescue assays were carried out on AZTMP-, d4TMP- and tenofovir-
terminated primers using the RNA/DNA complexes D38rna/25PGA and D38Trna/25PGA, we 
obtained different results than with DNA/DNA duplexes. Although the rescue activity of 
M41L/H208Y/L210W/T215Y RT was slightly higher than the activity of M41L/L210W/T215Y RT, 
differences were very small (Fig 40).  
 
Fig 40. RNA-dependent rescue activity of primers blocked with AZTMP, d4TMP and tenofovir. Time course experiments 
of the excision reaction were carried out in the presence of 3.2 mM ATP. T/Ps used are indicated above their corresponding 
graphs. All dNTPs in the assays were supplied at 200 μM, except dATP or dTTP (depending on the assay) whose 
concentration was 2 μM. T/P and active RT concentrations in these assays were 30 and 24 nM, respectively. Mean values ± 
standard deviations [error bars] were obtained from three independent experiments. 
4.2.2 Effect of H208Y in the RNase H activity of WT and mutant RTs 
Reductions in the rescue efficiency of the M41L/L210W/T215Y/R284K RT compared with the 
M41L/L210W/T215Y RT in assays carried out with RNA/DNA complexes were attributed to its 
higher RNase H activity (see Fig 32). Therefore, we tested whether H208Y had a similar impact on 
RNase H cleavage with the 31Trna/21P complex (Fig 41). Interestingly, as in the case of R284K, 
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addition of H208Y to the M41L/L210W/T215Y complex produced an increase in RNase H cleavage 
rates. Thus, while M41L/L210W/T215Y RT showed a kobs value of 0.41 ± 0.08 min
-1
, addition of 
H208Y produced a two-fold increase in catalytic rate of the RNase H (kobs 0.93 ± 0.013 min
-1
). This 
observation could explain in part the reduced rescue efficiency of this enzyme on RNA/DNA 
complexes, due to the instability of the short RNA fragments rendered by the reaction. The WT RT 
displayed a catalytic rate of 0.62 ± 0.08 min
-1
, a value intermediate between the 
M41L/L210W/T215Y and M41L/H208Y/L210W/T215Y enzymes.  
In addition, secondary cleavages produced by the WT and mutant RTs were monitored by using 
the T35rna/PR26 RNA/DNA complex. Secondary cleavage events at positions -15, -12 and -10 of the 
template strand were observed. However, differences in cleavage efficiency between the two     
TAM-1-containing enzymes were undetectable (Fig 42).  
 
 
 
Fig 41. RNase H activity of WT and mutant RTs. [
32
P]31Trna/21P  (50 nM) cleavage was carried out in the presence of the 
corresponding RT at 50 nM (active enzyme concentration). Time points were taken after 20 s, 40 s, 1, 2, 3 and 4 min.  Arrow 
in the RNA template sequence is used to indicate the cleavage site. Catalytic rate constants were 0.68 ± 0.04 min
-1
, 0.41 ± 
0.08 min
-1
 and 0.93 ± 0.13 min
-1
 for WT, M41L/L210W/T215Y and M41L/H208Y/L210W/T215Y RTs, respectively. 
95
                                                                                                                          Results 
 
 
Fig 42. Secondary RNase H cleavage activity of WT and mutant RTs. The T35rna/PR26 complex (20 nM) was used to 
monitor the secondary cleavages displayed by WT and mutant RTs (200 nM). Aliquots were removed after 10, 20, 30, 60, 90, 
120 and 150 min. Secondary cleavages occurring at -15, -12 and -10 are indicated in the T/P sequence, below the gel. Time 
course of the -10 cleavage event is shown on the right panel. 
4.2.3 DNA binding affinity of WT and mutant RTs 
D38/25PGA DNA/DNA complex binding affinity measurements of WT, H208Y, 
M41L/L210W/T215Y and M41L/H208Y/L210W/T215Y RTs showed no differences in Kd values 
between those RTs, with all of them showing Kd values around 2 nM (Table 16).  
Table 16. Dissociation equilibrium constants for WT and mutant HIV-1 RTs and DNA/DNA T/Ps. 
RT Kd (nM) 
WT 1,65 ± 0,48 
H208Y 2,15 ± 0,59 
M41L/L210W/T215Y 2,37 ± 0,65 
M41L/H208Y/L210W/T215Y 2,65 ± 0,39 
The sequence of the complex was: 
D38    5´ GGGTCCTTTCTTACCTGCAAGAATGTATAGCCCTACCA  3´ 
25PGA  3´              GGACGTTCTTACATATCGGGATGGT  5´ 
Data reported are mean values ± standard deviations obtained from three independent experiments. 
 
4.2.4 Rescue activity of WT and mutant RTs in the presence of different 
ribonucleotides 
Previous studies have shown that GTP is a potent PPi donor, as least as potent as ATP (Meyer et 
al., 1998). Rescue reactions with primers terminated with AZTMP were carried out in the presence of 
9.6 mM GTP. Under these conditions, unlike in ATP-dependent excision reactions, there was a 
significant amount of rescued primer produced by the WT RT (Fig 43). The amounts of rescued 
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primer in reactions catalyzed by the M41L/L210W/T215Y RT were higher in the presence of 9.6 
mM GTP than in the presence of 3.2 mM ATP. However, these differences were not observed with 
RTs having the H208Y substitution that showed similar rescue efficiencies with ATP than with GTP. 
Therefore, the rescue rates of AZTMP-terminated primers obtained in the presence of 9.6 mM GTP 
for the M41L/L210W/T215Y RT and the M41L/H208Y/L210W/T215Y RT showed only minor 
differences. Interestingly, the rescue activity of the WT RT under these conditions was slightly 
higher than the H208Y enzyme (Fig 43).  
 
Fig 43. DNA rescue activity of WT and mutant RTs from AZTMP-terminated complexes in the presence of different 
ribonucleotides. Structures of ATP, GTP and ITP are illustrated in the top-left corner. Rescue assays with D38/25PGA
AZTMP
 
T/Ps were carried out in the presence of 9.6 mM GTP, 9.6 mM GDP or 3.2 mM ADP. All assays were done in the presence of 
30 nM T/P, 24 nM RT and 100 μM dNTPs, except for dATP, whose concentration was 1 μM. 
Assuming that rescue efficiencies are dominated by the catalytic rate of the ribonucleotide-
dependent excision reaction, we determined catalytic parameters (i.e., kcat and Km) for ribonucleotides 
used as PPi donors in the unblocking reaction. Results are shown in Table 17.  In reaction carried out 
97
                                                                                                                          Results 
 
using ATP as a PPi donor, the catalytic rate (kcat) of the excision reaction was significantly lower for 
mutant M41L/L210W/T215Y than for the M41L/H208Y/L210W/T215Y RT (p < 0.05, unpaired 
Student’s t test).  However these differences were not significant for GTP or ITP, suggesting that 
they could be related to the presence of an amino group at position 6´ of the purine ring, instead of an 
oxygen atom (as occurs in GTP or ITP).  
Reactions carried out using ADP or GDP as PPi donors rendered lower amounts of rescued 
products than reactions carried out in the presence of nucleoside triphosphates (i.e., ATP or GTP). 
No differences between the M41L/H208Y/L210W/T215Y RT and the M41L/L210W/T215Y enzyme 
were detected (Fig 43). 
 
 
Table 17. Steady-state kinetics parameters of rescue reaction catalyzed by mutants M41L/L210W/T215Y 
and M41L/H208Y/L210W/T215Y. 
                                                                                                Pyrophosphate donor 
RT 
Km (mM) kcat (min
-1
) 
ATP GTP ITP ATP GTP ITP 
M41L/L210W/T215Y 0.96 ± 0.12 2.26 ± 0.28 0.67 ± 0.08 1.77 ± 0.05 3.12 ± 0.17 0.95 ± 0.04 
M41L/H208Y/L210W/T215Y 1.14 ± 0.12 1.92 ± 0.33 0.67 ± 0.1 2.14 + 0.06 2.79 ± 0.19 0.98 ± 0.03 
Reported data are the mean values ± standard deviations, obtained from at least three independent experiments. 
 
4.2.5 Pre-steady-state kinetics of ATP-dependent excision of primers terminated with 
AZTMP 
We measured the ATP-dependent excision activity of WT and mutant RTs by using the 
D38/25PGA
AZTMP
 complex. Reactions were carried out at fixed 30 nM concentration of T/P in the 
presence of 3.2 mM ATP and with increasing concentration of RT ranging from 3.5 to 210 nM. In all 
cases, addition of H208Y produced an enhancement in the AZTMP excision efficiency of the 
M41L/L210W/T215Y RT (Fig 44). Additional support of these results was obtained from 
experiments carried out in the presence of 60 nM D38/25PGA
AZTMP
 and 21 nM RT, showing also an 
improved excision activity of the M41L/H208Y/L210W/T215Y RT (data not shown). Finally, as 
expected, experiments carried out using 21 nM RT and 3.2 mM GTP did not show significant 
differences between M41L/H208Y/L210W/T215Y and M41L/L210W/T215Y RTs (data not shown). 
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Fig 44. Kinetics of ATP-dependent excision of AZTMP from a blocked D38/25PGA
AZTMP
 T/P.  (A) Representative gel 
showing the results of assays carried out in the presence of 3.2 mM ATP and mutant RTs (90 nM). (B) Dependence of the 
excision rate (kobs) on the RT concentration was determined for mutants M41L/L210W/T215Y and 
M41L/H208Y/L210W/T215Y. 
To further characterize the role of H208Y mutation in the excision reaction, kinetic parameters 
Vmax (maximum velocity of the excision reaction) and Km were determined by maintaining a fixed RT 
concentration of 21 nM and ranging D38/25PGA
AZTMP
 from 2.5 to 100 nM. As shown in Table 18, 
similar Km values were obtained for M41L/H208Y/L210W/T215Y and M41L/L210W/T215Y RTs. 
However, the Vmax of the M41L/H208Y/L210W/T215Y RT was significantly higher than Vmax of the 
M41L/L210W/T215Y enzyme (p < 0.05, unpaired Student’s t test). 
Table 18. Steady-state kinetic parameters of the ATP-dependent excision reaction catalyzed by 
M41L/L210W/T215Y and M41L/H208Y/L210W/T215Y RTs. 
RT Vmax (pM/min) Km (nM) 
M41L/L210W/T215Y 648,1 ± 27,66 29,91 ± 2,81 
M41L/H208Y/L210W/T215Y 713,8 ± 49,62 27,19 ± 4,3 
Data shown are mean values ± standard deviations, obtained from at least three independent experiments. 
4.2.6 Catalytic implications of the presence of the L210W mutation together with 
H208Y 
To study the interaction between residues at positions 208 and 210 we decided to revert the 
L210W mutation to the wild-type amino acid Leu-210 and to check the rescue ability of the resulting 
M41L/H208Y/T215Y RT. As control, mutants M41L/T215Y, M41L/L210W/T215Y and 
M41L/H208Y/L210W/T215Y were incorporated in the assays.  As expected, AZTMP rescue assays 
carried out in the presence of 9 mM GTP showed that all four mutant RTs were equally efficient in 
the rescue of AZTMP-terminated primers (Fig 45A). However, when 3.2 mM ATP was used as PPi 
donor, H208Y conferred increased rescue ability only when accompanied by L210W (Fig 45A). 
When D38rna/25PGA was used as T/P, all mutant RTs (i.e., M41L/T215Y, M41L/H208Y/T215Y, 
M41L/L210W/T215Y and M41L/H208Y/L210W/T215Y) showed a similar efficiency in the rescue 
of AZTMP-blocked primers (Fig 45B).  
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Fig 45. Contribution of L210W mutation on the DNA- and RNA-dependent rescue activity of the 
M41L/H208Y/L210W/T215Y RT. Rescue activity of M41L/T215Y, M41L/H208Y/T215Y, M41L/L210W/T215Y and 
M41L/L210W/H208Y/T215Y mutant RTs on AZTMP-terminated primers. (A) The D38/25PGA
AZTMP
 complex (30 nM) was 
mixed with 30 nM active RT concentration and the rescue activity reaction was then initiated by adding a mixture containing all 
four dNTPs, and 9 mM GTP (left) or 3.2 mM ATP (right). (B) RNA-dependent rescue activity of M41L/H208Y/T215Y, 
M41L/L210W/T215Y and M41L/H208Y/L210W/T215Y mutant enzymes was monitored by using D38rna/25PGA
AZTMP
-blocked 
complexes in the presence of 3.2 mM ATP and the four dNTPs. 
4.3 Role of connection subdomain mutations in resistance to non-
nucleoside RT inhibitors 
The increasing complexity of antiretroviral treatments and suboptimal therapies have lead to the 
accumulation of primary and accessory resistance mutations in the HIV genome. Since the mid-90s 
antiretroviral therapies were based on the combination of one or two NRTIs and one NNRTI and/or 
one protease inhibitor. Therefore, NNRTI resistance mutations have been frequently found in treated 
patients. Classical NNRTI resistance mutations locate around the NNRTI binding pocket. However, 
accumulating data obtained from viral sequences from treated patients have shown that mutations 
located far from this pocket could also play a role in drug resistance. For example, recent studies 
have demonstrated that certain mutations in the RT connection subdomain could increase the IC50 for 
certain NNRTIs (Gupta et al., 2010, 2011). In order to determine the molecular mechanism/s 
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implicated in the selection of resistance mutations in the connection subdomain, HIV-1 RTs bearing 
mutations T369I, T369V, T376S and N348I/T369I were purified and characterized. In addition, 
mutant enzyme N348I was added to the study as control, since this mutation has been previously 
characterized as a substitution contributing to increasing nevirapine resistance (Biondi et al., 2010; 
Schukman et al., 2010; Radzio & Sluis-Cremer, 2011). 
4.3.1 Determination of the half maximal inhibitory concentration (IC50) for NVP, EFV 
and ETR 
DNA polymerase activity of WT and mutant RTs was measured by determining single-
nucleotide incorporation kinetics. None of the connection subdomain mutations produced an effect in 
the catalytic rate of nucleotide incorporation of the RT, since kcat values for WT and mutant RTs 
N348I, T369I, T369V, T376S and N348I/T369I were in the range of 0.8 min
-1
 to 1.16 min
-1
 (data not 
shown).  
Then, we determined the impact of N348I, T369I, T369V, T376S as well as the combination 
N348I/T369I in NNRTI resistance by measuring the IC50 for different NNRTIs in DNA 
polymerization assays. For this purpose, the heteropolymeric DNA/DNA complex D38/25PGA was 
incubated with WT and mutant RTs in the presence of increasing concentrations of NVP, EFV or 
ETV and dTTP, and the amount of extended 26-nucleotide long primer was determined. Data 
obtained are given in Table 19. IC50 values obtained with the WT enzyme were similar for all 
NNRTIs and were in the range of 2.7 to 5 μM. All mutant RTs showed similar susceptibilities to 
EFV and ETR in comparison with the WT enzyme, with IC50 values in the range of 3.2 to 6.2 μM. 
However, in the case of NVP, we observed significant differences in the IC50 values between WT and 
mutant RTs. Thus, mutants T369V and T376S displayed the lowest IC50 values of all mutant RTs, 
which were 2.8 and 3.5 times higher, respectively, compared with the IC50s obtained with the WT 
RT. Mutants N348I and T369I showed an intermediate level (5.5- and 5.2-fold increase in resistance, 
respectively). Finally, the double-mutant N348I/T369I displayed the highest level of NVP resistance, 
showing an IC50 value 7.8 times higher than the IC50 obtained with WT RT (Table 19). 
 
 Table 19. Inhibition of WT and mutant RTs by NNRTIs. 
 
 
 
 
Data shown are mean values ± standard deviations, from at least three independent experiments.   
  
 
                                                IC50 (μM) 
RT  NVP EFV ETR 
WT   2.7 ± 1.1 5.0 ± 1.9 3.2 ± 0.4 
N348I 14.8 ± 3.4 5.5 ± 2.1 4.6 ± 0.8 
T369I   9.4 ± 2.0 5.4 ± 2.2 4.8 ± 1.2 
T369V 14.2 ± 3.9 4.5 ± 1.8 3.4 ± 0.5 
T376S   7.6 ± 2.6 5.9 ± 1. 8 4.3 ± 0.9 
N348I/T369I 21.0 ± 6.8 6.2 ± 2.4 5.2 ± 0.9 
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4.3.2 Role of connection subdomain mutations in NNRTI resistance during different 
steps of reverse transcription 
Recent reports suggested a novel NVP resistance mechanism relevant during PPT extension in 
(+) strand DNA synthesis. This mechanism implies a role for NVP in modulating how RT binds the 
PPT primer; either in a polymerase-dependent binding mode or in the RNase H-dependent binding 
mode (Fig 46). According with the proposed mechanism, while the WT enzyme is pushed by the 
NVP to bind in an RNase H-dependent binding mode, triggering the cleavage of the RNA portion of 
the DNA-RNA primer, and consequently blocking (+) strand DNA synthesis, the N348I mutation 
would favour the DNA polymerase-dependent binding mode (Fig 46) (Biondi et al, 2010).  
 
Fig 46. RT binding orientations on PPT-RNA/DNA complexes. Schematic representation of the two binding modes of the 
RT to an intermediate of the (+) strand DNA synthesis. The T/P (T57d/PPT17r8d) contains a large DNA template annealed to 
a chimeric RNA-DNA primer, with a 5´-RNA region (in uppercase and underlined), involving the PPT sequence, and a 3´-DNA 
region (lowercase) representing 8 nucleotides incorporated during the DNA synthesis. The PPT-U3 junction cleavage point is 
highlighted in red in the sequence. The RT is represented by a big blue oval and the polymerase and RNase H active sites as 
light blue and pink circles, respectively. Polymerase-dependent binding mode promotes primer elongation while RNase H-
dependent binding mode produces the RNase H cleavage of the primer. 
 
4.3.2.1 Determination of the RNase H activity using a physiological relevant intermediate of the 
(+) strand DNA synthesis 
In order to check if the connection subdomain mutations studied could impact NNRTI resistance 
by using a similar mechanism, the endonucleolytic activity of WT and mutant RTs were determined 
with a series of PPT-RNA/DNA complexes mimicking the (+) strand DNA synthesis initiation 
complex (Fig 47). Incubation of the T57d/PPT17r8d complex with the WT and mutant RTs resulted 
in the production of RNase H cleavage products of 17, 16, and sometimes 15 nucleotides (Fig 47A). 
The product of 17 nucleotides is the physiologically relevant cleavage product, resulting from the 
cleavage at the PPT-U3 junction. Subsequent cleavage of this oligonucleotide renders bands 
representing oligonucleotides of 16 and 15 nucleotides. It is important to note that all cleavages 
generated from this T/P result from the RNase H-dependent binding mode of the RT. An alternative 
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binding orientation (i.e., polymerase-dependent binding mode) implies that the RNase H active site 
would interact with the DNA template (Fig 46). 
Interestingly, according with the obtained RNase H catalytic rates, tested enzymes could be 
classified in three groups. WT, T369V, T369I and T376S RTs showed high RNase H activity, with 
kobs values between 0.72 and 1.25 min
-1
 (Fig 47A). The N348I RT, showed an intermediate RNase H 
activity with a kobs of 0.36 min
-1
. Finally, the double-mutant N348I/T369I showed the lowest RNase 
H cleavage rate, with a value of 0.07 min
-1
. These results indicate that the reduced RNase H catalytic 
activity of the N348I mutant RT could be further decreased by the presence of T369I. 
Further characterization of this important step in reverse transcription involved usage of a second 
T/P complex. This complex that contains a 17-nucleotide RNA primer (PPT29DNA/PPT17r) mimics 
the initiation of (+) strand DNA synthesis, where no dNTPs have been incorporated at the 3´-end of 
the primer (Fig 47B). WT, N348I and N348I/T369I RTs were incubated in the presence of this 
complex. Interestingly, unlike in the case of PPT17r8d none of the enzymes were able to cleave the 
RNA primer (Fig 47B).   
 
Fig 47. RNase H activity of WT and mutant enzymes during (+) strand DNA synthesis (A) Representative gel of RNase H 
kinetics obtained using the T57d/PPT17r8d complex. T/P complex T57d/PPT17r8d mimics a (+) strand DNA synthesis 
intermediate where 8 dNTPs have been added to the 17-nucleotide PPT-RNA primer. This complex (25 nM) was incubated 
with WT and mutant enzymes at 125 nM concentration. Aliquots were removed at 20 s, 40 s, and 1, 2, 3, 4 and 5 min. 
Cleavages at positions -16 and -15 in the PPT17r8d strand are indicated with black arrows, while the -17 cleavage at the PPT-
U3 junction is marked with a red arrow. Likewise, bands produced by such cleavages are indicated in the gel. A graphic 
representation of the time course kinetics of the reaction is shown on the right (data were obtained from three independent 
experiments). (B) RNase H activity of WT, N348I/T369I and N348I mutant enzymes on a PPT29DNA/PPT17r complex. This 
complex represents the first step in the (+) strand DNA synthesis, where no dNTPs have been yet added. In the sequence, the 
last PPT ribonucleotide is highlighted in red, as well as the PPT-U3 cleavage point with a red arrow, for direct comparison with 
the PPT/17r8d complex. 
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Analysis of the integrity of the PPT17r8d primer.  
The expected cleavage product resulting from the release of the DNA segment of the PPT17r8d 
primer should have 17 nucleotides. However, band-patterns obtained seemed to correspond with a 
cleavage product 7 nucleotides shorter. To verify than the 25-nucleotide long substrate had the right 
size, it was incubated in the presence of recombinant Exo I from E. coli (Affimetrix), and the 3´ to 5´ 
exonuclease reaction monitored over time. Results shown in Fig 48A indicate that the Exo I enzyme 
eliminated all dNMPs to produce a 17-nucleotide RNA oligonucleotide (PPT17r). Comparison of the 
digestion products with the PPT17r primer showed that bands corresponding to the 17-nucleotide 
product and those corresponding to the 17-nucleotide-RNA elongated after addition of one dNTP 
migrated very close to each other (Fig 48A).  
 
Fig 48. Sequence analysis of the PPT17r8d primer. (A) PPT17r8d primer was subjected to E. coli Exo I digestion and the 
resulting products revealed in a polyacrylamide gel. Bands corresponding to the intact PPT17r8d, PPT17r and PPT17r1d are 
indicated. (B) T57d/PPT17r8d (25 nM) was mixed with the RNase H-deficient HIV-1 group O mutant V75I/E478Q RT (100 nM 
active enzyme). Synthesis reactions were initiated by adding 100 μM dGTP and 50 μM CBVTP. Bands corresponding with the 
unextended primer and those corresponding to primers extended in one or two nucleotides indicated. 
Further confirmation of the composition of the PPT17r8d primer was obtained by incubating the 
preformed T57d/PPT17r8d complex with the RNase H-deficient mutant HIV-1 group O RT 
V75I/E478Q in the presence of dGTP and CBVTP. A correct complex should be a good substrate for 
the incorporation of dGMP in the next two positions (Fig 48). Therefore if PPT17r8d had the right 
size, two incorporation events would be expected. As shown in Fig 48B, at the longest incubation 
times, a product of 27 nucleotides was obtained, thereby confirming the correct length of the primer. 
4.3.2.2 Effects of NVP and EFV in RNase H activity during (+) strand DNA synthesis. 
PPT17r8d cleavage by the RNase H activity of WT and mutant enzymes was monitored in the 
presence of increasing concentrations of NVP and EFV. As shown in Fig 49A, EFV was efficient in 
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promoting the cleavage of the PPT-containing strand. It should be noted that although total amount of 
RNase H-hydrolyzed product was highly variable among tested enzymes, enhancement of the RNase 
H activity by EFV occurred with all RTs.  
A representative example of the experiments carried out in the presence of increasing 
concentrations of NVP is presented in Fig 49B. As observed with EFV, we detected different 
amounts of cleavage products represented by bands of 17, 16 and 15 nucleotides. Interestingly, under 
our assay conditions, NVP showed to be a more potent enhancer of the RNase H activity than EFV, 
since lower concentrations of the inhibitor led to large accumulations of cleavage products (Fig 49B). 
This effect was observed with all tested RTs, independently of their mutational background. 
Therefore, NVP and EFV promoted RNase H cleavage catalyzed by HIV-1 RTs (Fig 49C).  
Kinetics of RNase H cleavage by WT and mutant RTs in the presence of NVP and EFV 
Experiments shown in Fig 49 represented single aliquots taken at 20 s for each NNRTI 
concentration. However, more accurate determinations on the effect of the inhibitors in the RNase H 
function of the RT can be obtained from time course experiments. This was done by measuring 
PPT17r8d cleavage for each RT in the presence of NVP or EFV concentrations that would 
significantly enhance the RNase H activity of the enzymes (e.g., 5 μM and 12.5 μM, respectively). 
Consistent with previous results, all tested RTs showed higher RNase H activity in the presence of 
both inhibitors (Fig 50). Similar results were obtained in RNase H cleavage determinations carried 
out in the presence of 15 μM ETR (data not shown). The amount of cleaved product observed in the 
presence of 12.5 μM EFV was somewhat higher than in the presence of 5 μM NVP, although 
differences were not significant. Interestingly, in the presence of drugs, RNase H activities of WT 
and mutant N348I/T369I RTs were rather similar, although in the absence of RT inhibitor the double-
mutant showed very low activity (Fig 50). These results suggest that the RNase H activity of both 
enzymes was maximal at the tested NNRTI concentrations. Therefore, these results further confirm 
the ability of NVP and EFV to foster the cleavage of the PPT17r8d substrate of all tested RTs.   
When the T/P complex PPT29DNA/PPT17r was used in the same type of experiments, different 
results were obtained. Thus, while in the absence of NNRTIs, the complex PPT29DNA/PPT17r was 
not a substrate for the RNase H activity of WT, N348I/T369I and N348I enzymes, addition of NVP 
and especially EFV produced a strong stimulation of cleavage of the PPT17r oligonucleotide to 
produce bands of 16 and 15 nucleotides. The WT RT showed the highest RNase H activity in the 
presence of the drugs (Fig 50). In contrast, mutant N348I/T369I was not affected by the addition of 5 
μM NVP, while EFV had only a small stimulatory effect of its endonucleolytic activity (Fig 50). 
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Fig 49. Effects of NVP and EFV in the RNase H activity of WT and mutant RTs. T57d/PPT17r8d concentration was 25 nM 
while RTs were supplied at 125 nM. (A) Lanes 0 to 7 below each enzyme reaction correspond to EFV concentrations 0, 0.63, 
1.25, 2.5, 3.75, 5, 7.5 and 12.5 μM. (B) Same as (A) but NVP was supplied at 0, 0.08, 0.16, 0.32, 0.63, 1.25, 2.5 and 5 μM, 
corresponding with lines 0 to 7, respectively. (C) Graphical representation of the percentage of PPT17r8d primer cleavage by 
WT and mutant RTs in the absence of drug, or in the presence of 5 μM NVP or 12.5 μM EFV. 
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Fig 50. Kinetics of T57d/PPT17r8d and PPT29DNA/PPT17r cleavage in the presence of NVP and EFV. WT, N348I and/or 
N348I/T369I RTs (50 nM) were mixed with 25 nM of T57d/PPT17r8d or PPT29DNA/PPT17r complex  and the cleavage of the 
RNA strand monitored in the presence of 5 μM NVP, 12.5 μM EFV, or in the absence of drug. Aliquots were removed at 20 s, 
40 s, and 1, 2, 3, and 4 min. Cleavage products corresponding to bands of 17, 16 and 15 nucleotides are indicated in the gel. 
 
4.3.2.3 Determination of the RNase H activity using different intermediates in which the PPT 
sequence acts as a template 
PPT29RNA/PPT29DNA 
PPT29RNA/PPT29DNA is a PPT-containing RNA template annealed to a DNA primer with a 
recessed 3´-OH end. This complex takes advantage of the preference of the RT to bind a recessed 
DNA 3´-end. Therefore, RT will bind the PPT29RNA/PPT29DNA complex in the DNA-polymerase 
binding mode. In this orientation the PPT-U3 junction between nucleotides G and A is positioned 17 
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nucleotides away from DNA 3´-end, exactly at the same location of the RNA-DNA junction in the 
T57d/PPT17r8d complex (Fig 51).  
 
 
 
Fig 51. RNase H activity of WT and mutant RTs while using the PPT sequence as a template for DNA synthesis. T/P 
complex PPT29RNA/PPT29DNA mimics a (-) strand DNA synthesis intermediate where the PPT has not been yet cut to 
produce the PPT primer. In addition, this complex has a DNA 3´-end available for RT binding, therefore, RT binds this complex 
in a DNA polymerase-dependent binding mode. PPT29RNA/PPT29DNA (25 nM) was incubated with 50 nM of the 
corresponding RT and the RNase H cleavage products quantified. Aliquots were removed at 20 s, 40 s, and 1, 2, 3, and 4 min. 
PPT-U3 cleavage at position -17 renders a product of 21 nucleotides. Additional cleavages in its vicinity are indicated in the 
gel. To facilitate the comparison between PPT29RNA/PPT29DNA and T57d/PPT17r8d, their sequences are depicted below 
the gel, with the PPT-U3 cleavage site indicated with a red arrow and the neighboring cleavage sites by black arrows. Above 
each complex, a red (PPT-U3 cleavage) or black lines (no-specific cleavages) are shown to illustrate nucleotide cleavage 
distances and resulting products. On the right, a graphic representation of a time course kinetics obtained for each enzyme, 
determined from three independent experiments (means ± standard deviations [error bars]) are shown. 
 
RNase H activity measurements using PPT29RNA/PPT29DNA T/P, and based on the 
disappearance of the 29 nucleotide band, showed that T369V and T376S were the RTs with the 
highest activity, followed by the T369I RT. The N348I RT and the WT enzyme showed similar 
kinetics, and the double-mutant N348I/T369I was the RT with the lowest activity (Fig 51). However, 
we also observed remarkable differences affecting the sizes of the reaction products. Thus, the WT 
RT and mutants T369V and T376S only rendered a product of 21 nucleotides, corresponding to the 
canonical cleavage event at position -17, also observed in T57d/PPT17r8d processing. However, all 
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the enzymes mutated in the 348 residue (and in a lesser extend the T369I mutant) produced the band 
of 21 nucleotides, but together with another one that was one nucleotide longer that corresponded to  
a cleavage at position -18 (Fig 51). This was particularly evident in the case of the double-mutant 
N348I/T369I RT, where the -18 band was the major product of the reaction, particularly at the 
earliest time points of the assay. Therefore, although RNase H cleavage kinetics were similar for all 
enzymes, resulting products showed a clearly distinct preference regarding the preferred cleavage 
sites.  
One interesting conclusion drawn from the aforementioned results is that N348I/T369I RT 
preferred to cut the RNA 18 nucleotides away from the polymerase active site, while the preferred 
cleavage site of WT RT was one nucleotide closer, at the PPT-U3-conserved junction. In principle, 
these differences between WT and mutant N348I/T369I RT should not have a large impact in viral 
fitness, since products should be functional in both cases. However, the PPT17r8d primer annealed to 
the T57d template can be cleaved only at positions -17, since the -18 position falls within the DNA 
moiety of PPT17r8d. A reduced ability of the N348I/T369I enzyme to cut at position -17 could 
explain its reduced cleavage efficiency at the PPT-U3 junction in the T57D/PPT17r8d complex. 
However, as shown in Fig 50, the presence of NVP or EFV facilitates cleavage at -17 position by the 
N348I/T369I mutant RT, thereby generating a very similar band pattern in comparison with WT RT 
(Fig 50). 
We tested whether NVP and EFV had similar effects on RNase H cleavage patterns produced by 
N348I/T369I and WT RTs on the T/P PPT29RNA/PPT29DNA. As shown in Fig 52, the 29-
nucelotide band disappeared rapidly in the presence of both inhibitors, slightly faster with EFV than 
with NVP. Interestingly, new cleavage products, not present in the absence of NNRTIs, of 27 (-23 
position), 26 (-22 position) and 24 (-20 position) nucleotides appeared upon NVP and EFV addition 
(Fig 52). While the WT RT yielded processed products corresponding to cleavages at positions -16 
and -15, the N348I/T369I RT only produced a small amount of the -16 cleavage product at the largest 
time points (Fig 52). These results showed that NVP and EFV were able to accelerate the cleavage of 
the PPT29RNA/PPT29DNA complex as much as the T57d/PPT17r8d duplex in reactions catalyzed 
by both enzymes. However, the WT RT was able to produce further cleavages at -16 and -15, while 
the N348I/T369I RT was much less efficient in making these shorter cuts.  
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Fig 52. Time course of RNase H cleavage in the presence of NVP and EFV using T/P PPT29RNA/PPT29DNA. WT and 
N348I/T369I RTs (50 nM) were mixed with 25 nM of the PPT29RNA/PPT29DNA complex (sequence below the gel with the 
PPT-U3 cleavage site indicated with a red arrow) and the cleavage of the PPT29RNA template was then monitored in the 
absence of drug (control) or in the presence of 5 μM NVP or 12.5 μM EFV. Aliquots were removed at 20 s, 40 s, and 1, 2, 3, 
and 4 min. Cleavage products corresponding to the cut at the PPT-U3 junction (-17 position, product of 21 nucleotides) and 
those rendering one and two nucleotides shorter products (at positions -16 and -15) are indicated in the gel. 
 
PPT29RNA/PPT28DNA 
The presence of mutations N348I and T369I seem to impair the ability of the RT to carry out 
cleavages at positions closer to the DNA polymerase active site. This particular phenotype could be 
affecting the adequate processing of the PPT primer. In order to test this hypothesis, we used a T/P 
complex identical to PPT29RNA/PPT29DNA, but with a DNA primer one nucleotide shorter at its 
3´-end. This new T/P (PPT29RNA/PPT28DNA) positions the scissile GA dinucleotide one 
nucleotide closer to the DNA 3´-end and therefore restricts cleavage to the -16 position (Fig 53). This 
restriction reduced the cleavage rate for all tested enzymes by half in comparison with those obtained 
with PPT29RNA/PPT29DNA (Fig 53). Interestingly, while all the RTs yielded the canonical 21-
nucleotide band product (-16 cleavage), N348I/T369I RT and in a lesser extend the N348I mutant 
enzymes also produced bands of 23 and 24 nucleotides, corresponding to cleavages at positions -18 
and -19, respectively (Fig 53). In the case of N348I/T369I RT, these products were more frequent 
than the 21-nucleotide product in all time points, further demonstrating the expanded cleavage 
window of this enzyme compared with the rest of the RTs. 
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Fig 53. Effect of the cleavage window in the RNase H activity of WT and mutant RTs. PPT29RNA/PPT28DNA (25 nM) 
was incubated with the corresponding RT (50 nM) and the RNase H cleavage products quantified. Aliquots were removed at 
20 s, 40 s, and 1, 2, 3, and 4 min. PPT-U3 cleavage at position -16 produces a product of 21 nucleotides. In addition, 
cleavages two and three positions downstream of the RNA template (at positions -18 and -19) are indicated in the gel. The T/P 
sequence of PPT29RNA/PPT28DNA is illustrated below the gel, with the PPT-U3 cleavage site highlighted in red. Above each 
complex, a red (PPT-U3 cleavage) or black lines (no-specific cleavages) are shown to illustrate nucleotide cleavage distances 
and resulting products. Below, a graphic representation of a time course kinetics obtained for each enzyme, determined from 
three independent experiments, (means ± standard deviations [error bars]) are shown. 
 
As with T/P complexes described above, we tested the ability of WT, N348I and N348I/T369I 
RTs to cleave the RNA in the presence of 5 μM NVP and 12.5 μM EFV. As in the case of the 
PPT29RNA/PPT29DNA complex, a large increase on RNase H activity was observed with all 
enzymes (Fig 54), including the production of longer cleavage products undetectable in the absence 
of drugs. Interestingly, while with the PPT29RNA/PPT29DNA complex two cleavages yielding 
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products of 16 and 15 nucleotides (one and two nucleotides shorter than the product resulting from 
the cleavage at the PPT-U3 junction) were detected in reactions carried out by the WT RT, here only 
one band corresponding to a cleavage product one nucleotide shorter than the product resulting from 
the cleavage at the PPT-U3 junction could be observed (Fig 54). This cleavage corresponds to 
position -15 of the template strand, yielding a band of 20 nucleotides. Digested bands of 23 and 24 
nucleotides detected in assays carried out with N348I and N348I/T369I RTs were rapidly processed 
to shorter products when NVP or EFV was added (Fig 54). However, while N348I was able to cleave 
at position -15, producing a band of 20 nucleotides (although in a lesser extend than the WT RT), 
N348I/T369I showed very little efficiency, even in the presence of 12.5 μM EFV (Fig 54).  
 
Fig 54. Time course of RNase H cleavage in the presence of NVP and EFV using T/P PPT29RNA/PPT28DNA. WT, 
N348I/T369I and N348I RTs (50 nM) were mixed with the PPT29RNA/PPT28DNA complex (25 nM) (below the gel with the 
PPT-U3 cleavage site indicated with a red arrow), and the cleavage of the PPT29RNA template was monitored in the absence 
of drug and in presence of 5 μM NVP or 12.5 μM EFV. Aliquots were removed at 20 s, 40 s, and 1, 2, 3, and 4 min. PPT-U3 
cleavage takes place at position -16 and results in a product of 21 nucleotides, while further cleavages at position -15 lead to a 
product of 20 nucleotides. Both cleavage events are indicated in the gel. 
 
PPT29RNA/PPT30DNA 
So far, results obtained indicate that the presence of N348I, but especially N348I/T369I 
mutations impose restrictions in the ability of RT to cleave the RNA template at distances below 18 
nucleotides from the DNA polymerase active site. To further test this possibility, a new T/P complex 
(PPT29RNA/PPT30DNA) was used. This heteroduplex has the same RNA-PPT-containing sequence 
that the two previous ones, but it has one and two nucleotides more in the DNA 3´-end than the 
PPT29DNA and the PPT28DNA oligonucleotides, respectively (Fig 55). Therefore, in the 
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PPT29RNA/PPT30DNA complex the canonical PPT-U3 cleavage would take place 18 nucleotides 
away from the DNA 3´-end. Interestingly, all tested enzymes showed nearly identical RNase H 
activity, since all of them produced only a single cleavage at position  -18 (yielding a band of 21 
nucleotides) and with very similar catalytic rates, except for the T369V mutant that was slightly 
faster (Fig 55). As expected, when the cleavage at the DNA-RNA junction is further away from 
position -17, mutations N348I and N348I/T369I had a minor impact on the RNase H cleavage 
specificity of the RT. 
 
 
Fig 55.  Kinetics of the RNase H cleavage activity of WT and mutant RTs using the PPT29RNA/PPT30DNA complex. 
PPT29RNA/PPT30DNA (25 nM) was incubated with the corresponding RT (50 nM) and the RNase H cleavage products 
quantified. Aliquots were removed at 20 s, 40 s, and 1, 2, 3, and 4 min. PPT-U3 cleavage at position -18 produces a product of 
21 nucleotides. In addition, cleavage one nucleotide upstream of the RNA template (at position -17) is indicated in the gel. The 
T/P sequence of the PPT29RNA/PPT30DNA complex, as well as those of primers PPT29DNA and PPT28 DNA are illustrated 
below the gel, with the PPT-U3 cleavage site highlighted in red. Below each primer strand, a red line indicates the nucleotide 
cleavage length imposed to produce the cleavage at the PPT-U3 junction. On the right, a graphic representation of a time 
course kinetics obtained for each enzyme, determined from three independent experiments, (means ± standard deviations 
[error bars]) are shown. 
 
4.3.3 RNase H activity of WT and mutant RTs in heteropolymeric RNA/DNA 
complexes 
It is important to note that experiments carried out so far have been done using very specific 
substrates. The PPT is resistant to RNase H cleavage and cut at the PPT-U3 junction is highly 
favoured due to the unique structure of PPT-sequence. Therefore, to check if the results obtained 
with PPT-based substrates could be extended to heteropolymeric RNAs, the T/P 31Trna/21P was 
subjected to cleavage by WT, N348I and N348I/T369I RTs. As shown in Fig 56, primary cleavage 
produced by all enzymes yielded a band of 26 nucleotides, corresponding with a cut at position -16. 
However, two other cleavage events occurred at position -15 (in reactions carried out with WT and 
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N348I RTs) and at position -19 (in reactions carried out with N348I and N348I/T369I RTs). A higher 
amount of the 26-nucleotide band was produced by WT and N348I RTs in comparison with the 
double-mutant N348I/T369I, consistent with its expanded cleavage window. In contrast, 
N348I/T369I yielded a higher amount of the 29-nucleotide band product. N348I RT was efficient 
producing both cleavage products, but preferred to cleave at position -16 (Fig 56). Kinetics of the 
disappearance of the 31-nucleotide long substrate showed that N348I was as efficient as the WT 
enzyme (kobs of 0.87 ± 0.08 min
-1
 and 0.85 ± 0.07 min
-1
, respectively). However, the N348I/T369I RT 
cleaved the substrate at a slower rate, showing a kobs of 0.53 ± 0.03 min
-1
.  
 
 
Fig 56. RNase H activity of WT and mutant RTs N348I/T369I and N348I on a heteropolymeric T/P. A mix containing WT, 
N348I/T369I or N348I RTs at 50 nM concentration and 31Trna/21P (25 nM) was incubated at 37ºC, and aliquots removed at 
20 s, 40 s and 1, 2, 3 and 4 min. Cleavage products corresponding to bands of 26 and 29 nucleotides are indicated in the gel 
and in the T/P complex sequence shown below. A graph representing the time course reactions for all three enzymes is 
showed in the right part of the panel. Values representing average ± standard deviations [error bars] were extracted from four 
independent experiments. 
 
As well as in all previous cases, the addition of NNRTIs produced a large increase in the RNase 
H activity of all three RTs, and the appearance of shorter cleavage products (Fig 57). Therefore, 5 
μM NVP or 12.5 μM EFV promoted the RNase H activity of all tested RTs. Interestingly, a cleavage 
at position -13 producing a band of 23 nucleotides was clearly visible in reactions carried out with 
the WT RT. However, this 23-nucleotide band was less intense in reactions carried out with the 
N348I RT and absent in those carried out with the double-mutant N348I/T369I (Fig 57). Therefore, 
the enhancement of the RNase H activity showed by NNRTIs was not only restricted to PPT-
containing complexes. 
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Fig 57. Time course of RNase H cleavage of the heteropolymeric complex 31Trna/21P carried out in the presence of 
NVP and EFV. WT, N348I/T369I and N348I RTs (50 nM) were mixed with 31Trna/21P complex (25 nM) (sequence below) 
and the cleavage of the RNA template monitored in the presence of 5 μM NVP, 12.5 μM EFV, or in the absence of drug. 
Aliquots were removed at 20 s, 40 s, and 1, 2, 3, and 4 min. Cleavage products of 26, 25 and 23 nucleotides occurring at 
positions -16, -15 and -13, respectively, are indicated in the gel. 
 
4.4 HIV-1 IN activity and its effects in RT activity 
The HIV-1 IN is the enzyme responsible of integrating the viral DNA into the host genome. As 
described in the Introduction, IN has two different activities to accomplish this task, a 3´-end 
processing activity that trims the viral ends, and a strand transfer activity, responsible for the covalent 
binding of the viral DNA to the host genome. In addition, IN has been described as a reverse 
transcription factor, promoting efficient production of RT products. Previous works have pointed out 
a role of IN in tRNA extension during (-) strand DNA synthesis, showing an enhancer effect of IN on 
RT-DNA polymerase activity (Dobard et al., 2007).   
Studies using PPT-containing complexes described above have shown that the use of PPT 
primers differs from those of heteropolymeric complexes, regarding their cleavage specificity. As 
PPT processing is a necessary step occurring during reverse transcription, the IN protein could be 
implicated in the removal of the PPT. In order to answer this question and to get insights into the 
possible role of IN as a modulator of RT RNase H activity, we decided to produce and characterize 
the HIV-1 IN enzyme, and then, test its impact on RT RNase H activity using PPT- and 
heteropolymeric-T/Ps. 
4.4.1 Characterization of IN activities 
As described, HIV-1 IN has two major physiological activities: 3´-end processing and strand 
transfer. However, disintegration has been described as a third activity that can be tested in vitro. We 
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check the catalytic integrity of purified IN (HIV-1 group M subtype B NL4-3 strain), by using 
appropriate assays for all three activities. 
4.4.1.1 IN 3´-end processing  
Through this reaction IN recognizes a conserved dinucleotide CA from both viral ends and 
removes the 2 nucleotides (GT pair) situated at 3´-end of this sequence. Therefore, at this stage the 
IN acts as an endonuclease, catalyzing a metal-dependent nucleophilic attack. Its 3´-end processing 
activity can be measured by using the C220/C120 complex, which resembles a viral end (Fig 58A). 
Assays carried out in the presence of a large excess of IN over T/P (200 nM and 5 nM, respectively), 
allowed the identification of cleavage products, of 19 nucleotides, lacking the GT dinucleotide of 
their 3´-end (Fig 58A). Conditions in these assays involve the use of Mn
2+
, instead of Mg
2+
. No 
activity was detected in the presence of Mg
2+
 at 3 mM or 10 mM concentration (Fig 58B).  
 
    
 
Fig 58. HIV-1 IN 3´-end processing activity. The T/P C220/C120 mimics a viral DNA end. (A) 200 nM IN was incubated with 
5 nM C220/C120 and production of a band of 19 nucleotides resulting from IN cleavage was monitored. The sequence of the 
T/P complex is given below the gel, indicating the IN cleavage site with a black arrow. (B) Representative gel showing the lack 
of IN 3´-end processing activity in the presence of different MgCl2 concentrations under our assay conditions. 
 
 4.4.1.2 Strand transfer activity 
The strand transfer reaction uses the pre-processed 3´-ends of viral DNA for the nucleophilic 
attack of chromosomal DNA, creating the integrated product. Therefore, the pre-processed complex 
C120/B2-1, which contains a 2-nucleotides recessed 3´-end was used to measure the strand transfer 
activity of IN (Fig 59).  
As shown in Fig 59, purified IN was efficient in strand transfer. The random nature of the 
integration process in vitro produced different integrated products of variable length, depending on 
the integration site.  
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Fig 59. HIV-1 IN strand transfer activity.  The left part of the figure shows the C120/B2-1 complex used in this assay, 
indicating the result of one possible integration event. 200 nM IN was incubated with 5 nM C120/B2-1 and production of 
integration products monitored. A representative gel showing a time course reaction is also illustrated, where the original B2-1 
primer of 19 nucleotides and the strand transfer products obtained are indicated. 
 
 
4.4.1.3 Disintegration 
The disintegration activity has no apparent physiological role during HIV-1 life cycle in vivo. 
However, it can be tested by using the “dumbbell” strand as substrate. The dumbbell consists of a 
single oligonuleotide with self-complementation, resembling an integration intermediate (Fig 60). IN 
cleaves after the conserved CA dinucleotide, liberating a “disintegrated” product, in a reaction that is 
the strand transfer reaction run in reverse. As depicted in Fig 60, purified IN showed measurable 
activity in “dumbbell” cleavage, confirming the ability of the HIV-1 IN in processing integrated 
products in vitro. 
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Fig 60. HIV-1 IN disintegration activity. The single-stranded “dumbbell” substrate sequence used in the disintegration 
activity measurements is shown in the left part of the figure, in its folded configuration. IN (200 nM) was incubated with 5 nM 
“dumbbell” substrate and production of the 14-nucleotide band resulting from IN cleavage was monitored. A gel containing the 
result of a disintegration assay is shown, together with the size of the obtained products. 
 
4.4.2 Modulation of RT activity by IN 
Available studies on the interactions between RT and IN have mainly focused on the impact of 
IN in the DNA polymerase activity of the RT (Oz et al., 2002; Hehl et al., 2004; Dobard et al., 
2007). Therefore, we decided to study the influence of IN in the RNase H activity of the RT, 
examining the cleavage of heteropolymeric complexes, as well as processing of PPT during (-) and 
(+) strand DNA synthesis, since both steps are physiologically relevant during reverse transcription. 
4.4.2.1 Impact of IN on the RNase H activity of the RT over heteropolymeric complexes 
We measured the endonucleolytic digestion of the heteropolymeric T/P 31Trna/21P by RT in the 
presence of 10-fold excess of IN. Although an increase in the RNase H catalytic rate of the WT RT 
was obtained in reactions carried out in the presence of small concentrations of CHAPS or NP-40 
(around 60 μM and 0.0006%, respectively) (Fig 61), cleavage of the 31Trna template strand to 
produce the 26 nucleotides product occurred at similar rates in the presence of active IN or the heat-
inactivated enzyme (Fig 62A). Similar results were obtained with the IN mutant V250E (provided by 
Shewit Tekeste; University of California, Los Angeles) that is unable to interact with the RT (Tom 
Wilkinson and Shewit Tekeste; University of California, Los Angeles, personal communication), 
produced a cleavage activity indistinguishable from that seen in the presence of the WT IN (Fig 
62B). These results lead us to conclude that under our assay conditions, cleavage of the 
heteropolymeric 31Trna/21P was not enhanced by the presence of IN.  
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Fig 61. Effect of detergents NP-40 and CHAPS in the RNase H activity of the RT.  Gels corresponding to RNase H 
digestion of the 31Trna/21P complex in the presence of increasing concentrations of NP-40 (up) or CHAPS (down). Below 
each RNase H reaction the detergent concentration used is indicated. Highlighted in red, significant increases in RNase H 
activity are shown. The T/P sequence is given in the lower part of the figure, indicating with an arrow the cleavage site 
producing the band of 26 nucleotides. RT and T/P were used at 50 nM concentration. 
 
 
Fig 62. Effect of IN on the RT-mediated cleavage of heteropolymeric RNA/DNA complexes.  The 31Trna/21P complex 
(50 nM) was mixed with equimolar WT RT concentration and a 10-fold excess of WT IN, heat-inactivated IN or the RT-
interacting deficient mutant V250E. The T/P sequence is shown below the gels, indicating with an arrow the cleavage site 
producing the band of 26 nucleotides. Aliquots were removed 20 s, 40 s and 1, 2, and 4 min and the formation of the 26-
nucleotide product was quantified.   
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4.4.2.2 PPT cleavage in the presence of IN during (-) and (+) strand DNA synthesis 
The complex PPT29RNA/PPT29DNA (Fig 63) mimics a possible intermediate during (-) strand 
DNA synthesis. Thus, the RT has to cleave the RNA at the 3´-end of the PPT (i.e., at the PPT-U3 
junction) to leave the free 3´-OH of the PPT primer that will be used to initiate (+) strand DNA 
synthesis afterwards. 
According with results shown in Fig 63, the presence of a large excess of IN over RT (100 nM 
and 10 nM, respectively), produced a substantial increase in the ability of the WT RT to cleavage at 
the PPT-U3 junction. However, heat-inactivated IN (heated at 90ºC for 10 min), did not produce such 
an effect (Fig 63). Therefore, a 10-fold excess of IN over the RT increased the apparent kobs of RNase 
H cleavage from 0.62 min
-1
 to 1.29 min
-1
.  On the other hand, unlike in the presence of NNRTIs (see 
Fig 52), IN addition did not produce cleavages at new positions, but only the canonical PPT-U3 cut, 
rendering a product of 21 nucleotides (Fig 63).  
 
 
Fig 63. Effect of IN on the RT-mediated cleavage of PPT-containing RNA (DNA-dependent binding mode). Complex 
PPT29RNA/PPT29DNA (100 nM) was incubated with 10 nM WT RT and 100 nM IN. The T/P sequence is shown below the 
gel. The PPT-U3 cleavage site is highlighted in red. Aliquots were removed 20 s, 40 s and 1, 2, 4 and 6 min and the formation 
of the 21-nucleotide product was quantified.  Time course experiments carried out in the presence of IN and heat-inactivated 
IN were performed in triplicate. Averages ± standard deviations [error bars] were extracted from three independent 
experiments and are represented in the graph shown on the right. 
 
In addition, the ability of IN to modulate the RNase H activity of the RT using a complex 
mimicking the (+) strand DNA synthesis was tested. For this purpose, the aforementioned 
T57d/PPT17r8d (Fig 64) was incubated in the presence of the RT and a large excess of IN or heat-
inactivated IN. The amount of cleaved product of 17 nucleotides was clearly increased when 10-fold 
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IN relative to RT was included in the reaction mixture, in comparison with the heat-inactivated IN 
(Fig 64). In fact, in the presence of IN,  in addition to the expected cleavage at position -17, a one-
nucleotide shorter product was also obtained, probably derived from the -17 product (Fig 64).  
 
 
Fig 64. Effect of IN on the RT-mediated cleavage of PPT-containing RNA (RNase H-dependent binding mode). The 
T57d/PPT17r8d sequence is indicated, as well as the PPT-U3 cleavage site (red characters and red arrow). This complex 
represents a possible intermediate during (+) strand DNA synthesis. RT cleavage at the RNA-DNA junction of PPT17r8d 
produces a 17 nucleotide product, in a reaction that is enhanced by the presence of IN.  
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5. Discussion 
Suboptimal use of anti-HIV drugs facilitates the development of RT mutations and the selection 
of drug-resistant strains. Mutations conferring resistance to NRTIs can act by two different 
mechanisms: (i) by discriminating against the triphosphorylated form of the NRTI or (ii), by 
promoting the excision of the incorporated NRTI from the 3´-end of the primer. One of the most 
common sets of mutations selected during antiretroviral treatment that confer resistance to NRTIs 
through the excision mechanism are thymidine analogue resistance mutations (TAMs).  
TAMs are classified in two different clusters: TAM-1 and TAM-2. TAM-2 cluster includes 
mutations D67N, K70R and K219Q or N, and sometimes T215F. The TAM-1 set of mutations 
includes M41L, L210W and T215Y. The TAM-1 pathway is more prevalent in clinical isolates, and in 
general it confers higher levels of resistance to NRTIs (reviewed in Menéndez-Arias, 2010). TAMs are 
frequently selected in therapies including thymidine analogues (i.e., containing AZT or d4T). 
Combinations of TAMs can confer resistance to virtually all NRTIs except cytidine analogues (Meyer 
et al., 1999; Mas et al., 2000). However, in virus isolated from patients receiving therapy for a long 
time, it is common to identify additional mutations that appear associated with the TAM-1 and TAM-2 
clusters (Cane et al., 2007; Santoro et al., 2013). In most cases, these associated mutations do not play 
a direct role in NRTI resistance, but they can facilitate the selection of TAM-containing strains during 
exposure to antiretroviral drugs. By virtue of their secondary role, TAM-associated mutations are also 
known as accessory mutations, and in this work we have shown different mechanisms of action that 
favor the selection of accessory mutations specifically associated with the TAM-1 cluster.  
Many amino acid substitutions in the RT have been associated with TAMs in epidemiological 
studies. Examples are E40F, K43E or Q or N, E44A or D, K64H, V118I, K122E, I135T, E203D or K, 
H208Y, L214F, D218E, K223E or Q, L228H or R, the cluster A272P/K277R/A286T and R284K 
(Stürmer et al., 2003; Lu et al., 2005a; Svicher et al., 2006; Cane et al., 2007; Nebbia et al., 2007; 
Garriga et al., 2009; Puertas et al., 2009; Melikian et al., 2012). Phe-40, Glu-43, Asp-44, Ile-118, Tyr-
208, the cluster Pro-272/Arg-277/Thr-286 and Lys-284 have been shown to associate with the TAM-1 
pathway (Romano et al., 2002; Gonzales et al., 2003; Saracino et al., 2006; Svicher et al., 2006; 
Nebbia et al., 2007; Huigen et al., 2008; Garriga et al., 2009; von Wyl et al., 2010). However, there 
are very few studies estimating the impact of accessory mutations on resistance mediated by TAMs. 
 Mutations E40F (Huigen et al., 2008) and Q207D (Lu et al., 2005a) have been found to increase 
AZT resistance of viral strains bearing different subsets of TAMs, while substitution L214F was found 
to increase the replication capacity of viral strains bearing TAM-1 mutation T215Y in the presence of 
AZT (Puertas et al., 2009). Interestingly, molecular models predict that the presence of Leu-214 
together with Tyr-215 could interfere in the interaction between the RT and AZTMP-terminated T/P 
complexes, hampering the excision of the inhibitor (Puertas et al., 2009). More detailed biochemical 
studies have been carried out only for mutations E44D and V118I (Hertogs et al., 2000; Girouard et 
al., 2003). Mutation E44D has been found associated with TAMs in HIV isolates obtained from 
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patients treated with various NRTIs (Ceccherini-Silberstein, et al., 2005), and more specifically with 
d4T or ddI (Romano et al., 2002), AZT (Stoeckli et al., 2002), AZT and 3TC (Hertogs et al., 2000) or 
with thymidine analogues (von Wyl et al., 2010). In biochemical assays, E44D has been found to 
improve the ATP-dependent rescue activity of DNA/DNA complexes containing a 3TCMP-terminated 
primer (Girouard et al., 2003). However, V118I confers AZT and 3TC resistance in the absence of 
TAMs, and therefore cannot be considered as an accessory mutation associated with TAMs (Hertogs 
et al., 2000; Girouard et al., 2003). 
More recently, mutations in the connection subdomain and the RNase H domain of the RT have 
been also identified in RT sequences of HIV-1 isolates from treated patients. Thus, N348I, A360V and 
Q509L have been found associated with the exposure to treatments containing different NRTI 
combinations, as well as with the presence of TAMs (Nikolenko et al., 2007; Yap et al., 2007; Brehm 
et al., 2008, 2012; Ehteshami et al., 2008; Hachiya et al., 2008; Radzio & Sluis-Cremer, 2008; von 
Wyl et al., 2010; Lengruber et al., 2011). These mutations act by altering the balance between NRTI 
excision from blocked-primers and RNA template degradation. Thus, a slower rate of cleavage of the 
RNA template strand, allows more time for the RT to be in the right location to excise the chain-
terminator inhibitor, and then resume DNA synthesis (Nikolenko et al., 2005; Acosta-Hoyos et al., 
2012; reviewed in Delviks-Frankenberry et al., 2010; Menéndez-Arias, 2013) (Fig 65). Among all of 
the mutations that have been associated with the TAM-1 pathway, we have selected for our study the 
palm subdomain mutation H208Y, the thumb subdomain mutation R284K and the set of thumb 
subdomain polymorphisms Pro-272/Arg-277/Thr-286.  
H208Y is relatively uncommon in virus isolated from naïve patients. In the Stanford HIV Drug 
Resistance Database (http://hivdb.stanford.edu/; accessed in October 2013), only 0.2% of HIV-1 
group M subtype B isolates from untreated patients contained H208Y. However, the frequency of the 
H208Y substitution increases up to 9.1% in treated individuals. In agreement with these observations, 
several epidemiological studies have shown a relationship between the increased prevalence of H208Y 
and the exposure to antiretroviral drugs (Rhee et al., 2005; Nebbia et al., 2007; von Wyl et al., 2010). 
H208Y has been associated with therapies consisting of combinations of several nucleoside analogues 
including excisable NRTIs  (Gonzales et al., 2003; Stürmer et al., 2003; Rhee et al., 2005; Saracino et 
al., 2006; Svicher et al., 2006; Nebbia et al., 2007; Garriga et al., 2009; Shahriar et al., 2009). 
Interestingly, the cluster H208Y/R211K/L214F in virus containing several TAMs (i.e., D67N, K70R, 
M41L, L210W, T215Y and K219E) was found to be more prevalent in isolates from patients who 
failed therapies containing AZT and 3TC (Stoeckli et al., 2002; Stürmer at al., 2003). Several studies 
have found a strong association between H208Y and the mutations of the TAM-1 pathway (Gonzales 
et al., 2003; Saracino et al., 2006; Svicher et al., 2006; Nebbia et al., 2007; von Wyl et al., 2010). In a 
study including 223 samples, authors found that the presence of M41L and T215Y is required for the 
development of H208Y (Stürmer et al., 2003). 
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Fig 65. Model showing the potential effect of mutations in the connection subdomain and the RNase H domain of the 
RT in NRTI resistance. An RNA/DNA complex containing an inhibitor blocking the 3´-end of the primer (black box) is 
represented. The RT is represented by a gray oval, with an RNase H active site (green circle) and a DNA polymerase active site 
containing a priming (P) site and nucleotide binding (N) site, indicated with blue and brown circles, respectively. Reduced 
RNase H activity reduces degradation of the RNA template strand and increases the time available for the RT to excise the 3´-
end inhibitor before RT-RNA/DNA dissociation. 
Further support of the role of H208Y in drug resistance has been obtained from viral drug 
susceptibility measurements. The addition of the combination V118I/H208Y to a viral background 
bearing mutation T215Y increased phenotypic resistance to d4T (Clark et al., 2006). In addition, 
studies carried out in the lab of Dr. M. A. Martínez (Fundació IrsiCaixa, Hospital Universitari 
Germans Trias i Pujol, Badalona, Spain) with recombinant HIV-1 carrying mutated RTs showed that 
viral strains bearing the combination M41L/H208Y/L210W/T215Y showed a higher level of 
resistance to AZT than viruses with the TAM-1 cluster of mutations alone (Table 20). However, both 
mutants were equally susceptible to d4T and tenofovir. It is well known that primers terminated with 
d4TMP or tenofovir are more susceptible than primers terminated with AZTMP to the inhibition by 
the next complementary nucleotide, and therefore have a stronger tendency to form “dead-end-
complexes” (DEC) (Tong et al., 1997; Meyer et al., 2000). Since MT-4 cells used in viral IC50 
determinations contain high dNTP concentrations, it is not surprising that the largest differences in 
drug susceptibility between WT and mutants were observed only with AZT. 
Unlike the H208Y mutation, the amino acid substitution R284K and the cluster of polymorphisms 
Pro-272/Arg-277/Thr-286 are located in the thumb subdomain of the RT, far from the putative ATP 
binding site created by TAMs (see Fig 11). The thumb subdomain is essential in RT activity and 
alanine scanning mutagenesis studies affecting key residues in α-helices H and I have shown that 
mutations in this region produce large alterations in RT processivity, fidelity, T/P affinity and in the 
catalytic rate of DNA polymerization (Beard et al., 1994, 1996; Bebenek et al., 1995; Wang et al., 
2008). 
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Table 20. Susceptibility of HIV-1 constructs with and without H208Y to RT inhibitors  
                           IC50 (nM)
 
RT   AZT   d4T Tenofovir
a 
WT   2.3 ± 1.5    276 ± 90.5   6.7 ± 2.2 
H208Y   2.3 ±  1.2 (1) 160.3 ± 53.5 (0.58)   7.4 ± 2.8 (1.1) 
M41L/T215Y 17.7 ± 6.1 (7.6) 302.7 ± 69 (1.1) 15.9 ± 3.3 (2.4) 
M41L/L210W/T215Y 11.7 ± 1.2 (5)    217 ± 75.5 (0.8)    11 ± 4.6 (1.6) 
M41L/H208Y/L210W/T215Y 24.5 ± 1.5 (10.5)
b    314 ± 56.3 (1.1) 20.6 ± 6.9 (3.1) 
The IC50 values shown are the averages ± standard deviations of at least three independent determinations, each one 
performed six times. The fold-increase in IC50 relative to the wild-type HXB2 virus control carrying the RT sequence of BH10 is 
shown between parentheses. Unpublished data obtained by Drs. M. Nevot and M. A. Martínez (Fundació IrsiCaixa, Hospital 
Universitari Germans Trias i Pujol, Badalona, Spain). 
a 
Experiments were carried out with the water soluble diester prodrug tenofovir disoproxil fumarate. 
b
 Significant differences between M41L/L210W/T215Y and M41L/H208Y/L210W/T215Y RTs (Student t test p < 0.05). 
 
 
Positions 272, 277 and 286 are highly polymorphic in group M subtype B HIV-1 isolated from 
untreated patients. According to the Stanford HIV Drug Resistance Database 
(http://hivdb.stanford.edu/; accessed in October 2013), in untreated patients residue 272 is a proline in 
47.6% of the isolates, alanine in 44.6% of the cases, and serine in 5.6% of the isolates. Positions 277 
and 286 are less polymorphic. At position 277, lysine is predominant (57.5%) while arginine is 
observed in 42.1% of the HIV-1 isolates. At position 286, most isolates contain threonine (68.0%), 
followed by alanine (29.5%). A cross-sectional study carried out with HIV-1 group M subtype B pol 
sequences from patients treated in Spanish hospitals revealed that Pro-272, Arg-277 and Thr-286 
increased their prevalence in individuals failing therapy with abacavir/d4T and other NRTI 
combinations (Garriga et al., 2009). In that study, Pro-272, Arg-277 and Thr-286 were found in 
45.0%, 25.7% and 54.5% of the isolates obtained from untreated patients, respectively. However, their 
frequency increased up to 82.6%, 63.0% and 91.3%, respectively, in virus identified in patients who 
had failed abacavir/d4T therapy. In the same study, an association between TAMs, mainly Leu-41 and 
Tyr-215 and polymorphisms Pro-272, Arg-277 and Thr-286 was also detected. In addition, another 
study has also reported on the association of T286A with exposure to NRTIs during the antiretroviral 
treatment (Ceccherini-Silberstein et al., 2005).  
Addition of thumb subdomain polymorphisms Pro-272/Arg-277/Thr-286 to viral strains bearing 
RT mutations M41L/T215Y had no effect on viral susceptibility to NRTIs in MT4-cells (Table 21). As 
described for the H208Y mutants, recombinant HIV-1 susceptibility to NRTIs was measured using 
MT-4 cells, whose high dNTP concentrations could facilitate the production of “dead-end-complexes” 
(Smith & Scott, 2006).  
Phenotypic drug susceptibility assays failed to detect differences between viruses that carry the 
three thumb subdomain polymorphisms in the presence of M41L/T215Y, and those that only contain 
the two TAM-1 mutations. Viral replication capacity assays carried out in the presence of AZT with 
peripheral blood mononuclear cells (PBMCs), characterized by their low dNTP concentration (Back et 
al., 1996), showed an increased growth rate of the recombinant HIV-1 strains bearing Pro-272, Arg-
277 and Thr-286 in the RT, compared with those that had Ala-272, Lys-277 and Ala-286 (Fig 66). 
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Table 21. Susceptibility of HIV-1 constructs with and without P272A/R277K/T286A to RT inhibitors 
 
The IC50 values shown are averages ± standard deviations of at least three independent determinations, each one performed 
six times. The fold-increase in IC50 relative to the wild-type HXB2 virus control carrying the RT sequence of BH10 is shown 
between parentheses. Values obtained by Drs. M. Nevot and M. A. Martínez (Fundació IrsiCaixa, Hospital Universitari Germans 
Trias i Pujol, Badalona, Spain). 
a 
RTs LY, LYAKA and AKA correspond to mutant enzymes M41L/T215Y, M41L/T215Y/P272A/R277K/T286A and 
P272A/R277K/T286A, respectively. 
 
 
 
Fig 66. Replication kinetics assays carried out in the absence and in the presence of AZT. Histograms show the slope of 
p24 antigen production of each virus after infection of PBMCs (mixed from two donors). Comparisons of WT versus mutant 
P272A/R277K/T286A virus and mutant M41L/T215Y virus versus M41L/T215Y/P272A/R277K/T286A virus are shown in panels 
A and B, respectively. The significance of the differences between slopes was calculated using the GraphPrism v. 4 software    
(* p < 0.05; **, p < 0.01). Solid black circles represent the percentage loss of replication capacity of the recombinant HIV-1 
variants containing the P272A, R277K, and T286A mutations in the absence (A) or presence (B) of M41L/T215Y, under different 
assay conditions. Figure provided by Drs. M. C. Puertas and J. Martínez-Picado (Fundació IrsiCaixa, Hospital Universitari 
Germans Trias i Pujol, Badalona, Spain).  
Mutation R284K is rare in HIV-1 variants of therapy-naïve individuals. According to the Stanford 
HIV Drug Resistance Database (http://hivdb.stanford.edu/; accessed in October 2013), 1.9% of the 
group M subtype B HIV-1 isolates from untreated patients contained such a substitution. However, 
this number increases up to 4.2% for viruses isolated from patients who had been exposed to NRTIs in 
their treatment, consistent with published data showing the higher frequency of this mutation among 
isolates from treated individuals. Thus, in a study carried out with 100 naïve-patients and 248 treated 
individuals in the United States, authors found that the prevalence of this mutation was 7.3% in treated 
individuals, although it was not found in any of the untreated patients (Waters et al., 2009). An 
increase in the frequency of R284K was also observed in patients who had been treated with a 
combination of thymidine analogues plus ddI (i.e., from 1.1% in naïve individuals to 6.0% in patients 
treated with thymidine analogues plus ddI) (von Wyl et al., 2010).  
 IC50 (μM)
 
RT
a 
AZT d4T Abacavir ddI Tenofovir 3TC 
WT 5.1 ± 2.6 x 10
-3
  0.32 ± 0.04 1.28 ± 0.24 2.21 ± 0.36 0.18 ± 0.04 1.01 ± 0.04 
AKA 6.1 ± 2.3  x 10
-3 
(1.2) 0.29 ± 0.05 (0.9) 1.17 ± 0.11 (0.9) 2.50 ± 0.89 (1.1) 0.22 ± 0.03 (1.2) 1.52 ± 0.49 (1.5) 
LY 1.45 ± 0.8 x 10
-2 
 (2.8) 0.40 ± 0.05 (1.3) 1.53 ± 0.24 (1.2) 1.89 ± 0.60 (0.9) 0.26 ± 0.04 (1.5) 1.99 ± 0.63 (1.9) 
LYAKA 1.07 ± 6.5 x 10
-2 
 (2.1) 0.38 ± 0.09 (1.2) 1.77 ± 0.19 (1.4) 2.56 ± 0.71 (1.2) 0.26 ± 008 (1.4) 1.56 ± 0.85 (1.5) 
129
                                                                                                                      Discussion 
 
When pol sequences of virus isolated from patients treated in Spanish hospitals who had failed 
combination therapies including tenofovir and emtricitabine were examined, a 3.8-fold increase in the 
frequency of R284K was detected (from 2.5% in naïve patients to 9.6% in treated individuals) (C. 
Garriga and L. Menéndez-Arias, personal communication). Interestingly, in a principal factoring 
analysis, R284K associated with the cluster formed by TAM-1 mutations M41L, L210W and T215Y 
(Fig 67). The strongest correlation was found with T215Y. This result was consistent with data 
obtained in a study carried out in the U.K., where more than 3,000 HIV-1 pol sequences from treated 
patients were analyzed. In this study, authors reported a strong association between the presence of 
R284K and the number of TAMs found in the viral isolates (Cane et al., 2007).  
 
Fig 67. Principal axis factoring analysis of correlations between mutations associated with tenofovir/emtricitabine 
therapy failure. Amino acid changes with high coefficients of covariation are close together, while large distances separate 
those substitutions that show low or negative coefficients of association. Major mutations of the TAM-1 and TAM-2 complexes 
are indicated in red and blue, respectively. A cluster including the TAM-1 and R284K mutations is highlighted with a green 
circle. Figure and data provided by C. Garriga (Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain).  
As in the case of thumb subdomain polymorphisms Pro-272/Arg-277/Thr-286, addition of R284K 
to viral strains bearing TAM-1 mutations (i.e., M41L, L210W and T215Y) had no apparent effect on 
their susceptibility to AZT, d4T or tenofovir in assays carried out in MT-4 cells (Table 22). However, 
when viral replication assays were carried out in PBMCs, recombinant HIV-1 bearing RT mutations 
M41L/L210W/T215Y/R284K showed higher replication capacity in the presence of AZT and 
tenofovir than the virus carrying mutations M41L/L210W/T15Y (Fig 68). 
Taken together, available virological data reveal an impact of H208Y on phenotypic drug 
susceptibility, while the thumb subdomain polymorphisms Pro-272/Arg-277/Thr-286 and R284K 
influence viral replication capacity in PBMCs, in the presence of excisable NRTIs such as AZT or 
tenofovir. 
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Table 22. Susceptibility of HIV-1 constructs with and without R284K to RT inhibitors 
 IC50 (nM) 
RT AZT d4T Tenofovir
a 
FTC 
WT 2.3 ± 1.5 276.0 ± 90.5 6.7 ± 2.2 144.3 ± 69.9 
R284K 1.7 ± 1.1 (0.7) 130.0 ± 24.8 (0.5) 12.1 ± 5.3 (1.8) 104.2 ± 81.5 (0.7) 
M41L/L210W/T215Y 11.7 ± 1.1 (5.1) 217.0 ± 75.5 (0.8) 11.0 ± 4.6 (1.6) 226.9 ± 113.2 (1.6) 
M41L/L210W/T215Y/R284K 13.3 ± 1.5 (5.8) 287.3 ± 84.5 (1.0) 18.1 ± 4.4 (2.7) 294.7 ± 93.7 (2.0) 
The IC50 values represent averages ± standard deviations of at least three independent determinations, each one performed six 
times. The fold increase in IC50 relative to the wild-type HXB2 virus control carrying the RT sequence of BH10 is shown between 
parentheses. Values obtained by Drs. M. Nevot and M. A. Martínez (Fundació IrsiCaixa, Hospital Universitari Germans Trias i 
Pujol, Badalona, Spain). 
a 
Experiments were carried out with the water soluble diester prodrug tenofovir disoproxil fumarate. 
 
 
 
Figure 68. Replication kinetics of WT and mutant RTs in the absence and in the presence of AZT and tenofovir 
disoproxil fumarate (tenofovir-DF). In each case, histograms show the relative replication capacity (%), compared to the WT 
virus cultured in the absence of drug, based on the slopes of p24 antigen production of each recombinant virus after infection of 
stimulated PBMCs. The significance of the difference between slopes was calculated using the GraphPrism v. 4 software and 
significant p values are represented above the bars. Statistical analyses were performed by using a Student t test. Figure and 
data provided by Drs. M. C. Puertas and J. Martínez-Picado (Fundació IrsiCaixa, Hospital Universitari Germans Trias i Pujol, 
Badalona, Spain).  
 
5.1 Role of mutations H208Y, R284K and the combination                       
Pro-272/Arg-277/Thr-286 in resistance to NRTIs mediated by amino acid 
substitutions of the TAM-1 pathway 
It is well known that TAM-1 mutations confer resistance to thymidine analogues and other NRTIs 
by improving the excision of inhibitors from the 3´-end of blocked primers (Meyer et al., 1998, 1999). 
During this project, rescue assays have been used to simulate the events taking place during reverse 
transcription. Accordingly, primer termination due to the incorporation of an NRTI at the 3´-end of the 
growing DNA chain can be repaired by the RT through excision mediated by a PPi donor. DNA 
synthesis will then continue from the free 3´-end of the primer. Therefore, this assay can be divided in 
three different phases: (i) incorporation of the inhibitor in the 3´-end of the primer, (ii) excision of the 
inhibitor mediated by a PPi donor molecule (ATP, under physiological conditions), and (iii) extension 
of the free primer to the final product.  
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Different factors can be affecting the rate of the overall rescue reaction: the ability of the RT to 
bind nucleic acid complexes (i.e., RNA/DNA and DNA/DNA T/Ps), the efficiency in the NRTI 
incorporation to the 3´-end of the primer (i.e., the ability to discriminate against the NRTI), the 
capacity to excise the monophosphate form of the inhibitor from a terminated primer using a PPi 
donor molecule, and the catalytic rate of nucleotide incorporation and primer extension ability needed 
to elongate the primer to the final fully-extended product. 
5.1.1 H208Y, a mutation contributing to NRTI excision 
None of the studied RT thumb subdomain substitutions (i.e., R284K and the set of polymorphisms 
Pro-272/Arg-277/Thr-286) showed a direct effect in the ability of TAM-containing RTs to excise 
chain-terminators from the 3´-end of blocked primers. On the other hand, excision of AZTMP from 
terminated DNA primers in T/P complexes was enhanced by the addition of the H208Y substitution to 
an RT containing the TAM-1 mutations M41L, L210W and T215Y. This effect was observed over a 
wide range of RT concentrations, suggesting that this mechanism of resistance could operate at many 
different multiplicities of infection. In addition, this result is in agreement with the lower susceptibility 
to AZT of viral strains bearing RT mutations M41L/H208Y/L210W/T215Y compared with those 
bearing the TAM-1 set of amino acid substitutions (i.e., M41L/L210W/T215Y) (Table 20). The higher 
excision of AZTMP from blocked primers translates in a higher rescue rate of AZTMP-blocked 
DNA/DNA complexes. A similar mechanism is probably implicated in the higher rescue activity of 
d4TMP- and tenofovir-blocked DNA/DNA complexes shown by the M41L/H208Y/L210W/T215Y 
RT, compared with the enzyme containing only the TAM-1 mutations. 
H208Y has been previously described as a foscarnet resistance-associated mutation (Mellors et 
al., 1995). Previous studies have shown that foscarnet resistance mutations increase the AZT 
susceptibility of TAM-containing enzymes (Tachedjian et al., 1996). Thus, introduction of H208Y and 
Q161L (another foscarnet resistance mutation) in an RT containing mutations 
D67N/K70R/T215F/K219Q produced a large reduction of the ATP-dependent excision of AZTMP 
from blocked complexes, although the individual effects of H208Y and Q161L were not elucidated 
(Meyer et al., 2003). Studies carried out with WT and mutant RTs bearing H208Y, Q161L or the 
double-mutant Q161L/H208Y showed that Q161L was a major contributor to foscarnet resistance with 
IC50 values of 0.37, 0.52, 1.45 and 4.0 μM for WT RT and mutants H208Y, Q161L/H208Y and 
Q161L, respectively, in assays carried out with poly(rA)/oligo(dT)10 (Tramontano et al., 1998).  
His-208 is situated in the vicinity of the ATP binding site created by TAMs, but not close enough 
to interact directly with the ribonucleotide needed for the excision reaction (Tu et al., 2010). 
Molecular dynamics simulations of the structures of M41L/L210W/T215Y and 
M41L/H208Y/L210W/T215Y RTs carried out by Dr. J. Mendieta (Centro de Biología Molecular 
“Severo Ochoa”, Madrid, Spain), and based on molecular models constructed by using as template the 
crystal structure of the ternary complex of M41L/D67N/K70R/T215Y/K219Q RT, dsDNA and 
AZTp4A revealed a potential role of the H208Y mutation in ATP-mediated excision. In the crystal 
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structure, the ATP moiety of the AZTp4A molecule is expected to locate at a position equivalent to 
that of the ATP molecule prior to the nucleophilic attack, resulting in the excision of the 3´-end 
inhibitor (Tu et al., 2010). 
 Models generated by molecular dynamics predict that the relative position of the side-chain of 
Tyr-215 in the M41L/H208Y/L210W/T215Y RT is similar to that observed in the crystal structure of 
the M41L/D67N/K70R/T215Y/K219Q excision-proficient RT, with Tyr-215 making a stacking 
interaction with the adenine ring of the AZTp4A molecule (Fig 69A). However, in the RT containing 
Leu-41, Trp-210 and Tyr-215, the side-chain of Tyr-215 adopts a rather different conformation, away 
from the adenine ring of the AZTp4A molecule (Fig 69B). The phosphates of the AZTp4A molecule 
adopt a similar conformation in both RTs, compatible with the structural requirements of the excision 
reaction. It should be noted that in the crystal structure of the WT RT complexed with dsDNA and 
AZTp4A (Tu et al., 2010), important hydrogen bonds are lost while the conformation of the ATP 
moiety would be incompatible with excision. 
In the M41L/H208Y/L210W/T215Y RT model, the side-chains of Tyr-208 and Trp-212 make 
stacking interactions at the C-terminal end of α-helix F. These interactions affect the conformation of 
Arg-211 and indirectly the positioning of the side-chain of Trp-210, that shows a downwards location 
relative to the Tyr-215 ring (Fig 69A). This modified position eliminates the steric clash present in the 
M41L/L210W/T215Y model, created by the conformation of Trp-210 that pushes the side-chain of 
Tyr-215 towards the adenine ring of AZTp4A. The presence of histidine at position 208 reduces its 
potential interaction with Trp-212, relaxing the packing of the C-terminal end of α-helix F, and 
ultimately affecting the interaction of Tyr-215 with the adenine moiety of AZTp4A (Fig 69B). 
Hence, modeling studies reveal that a key factor that could explain the differences between the 
excision rates of M41L/H208Y/L210W/T215Y and M41L/L210W/T215Y RTs is the proper 
packaging of residues at the C-terminal end of α-helix F and their long-distance effect on the 
conformation of Tyr-215. This notion is consistent with results obtained in GTP- and ITP-dependent 
rescue assays. Thus, while ATP was more efficiently used by the M41L/H208Y/L210W/T215Y RT, 
no differences were detected between this RT and the M41L/L210W/T215Y mutant enzyme, when 
rescue assays were carried out in the presence of GTP or ITP. ATP differs from these two NTPs in the 
6´-substituent of its nitrogen base, a position important for the proper interaction of the adenosine 
moiety with the side-chain of Tyr-215 (Fig 69). 
In addition, results obtained in rescue assays carried out with the M41L/H208Y/T215Y RT 
provided further support for the modeling studies. Hence, when the interaction between the side-
chains of Tyr-208 and Trp-210 was eliminated by reverting Trp-210 to Leu, the ability of the resulting 
M41L/H208Y/T215Y RT to rescue DNA synthesis from blocked-DNA/DNA complexes was 
indistinguishable from that of M41L/T215Y and M41L/L210W/T215Y RTs. According to the 
Stanford HIV Drug Resistance Database (http://hivdb.stanford.edu/; accessed in October 2013), only 
6.4% of the 1,881 of all HIV-1 group M subtype B isolates bearing mutations M41L, H208Y and 
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T215Y contained Leu-210. In agreement with this observation, studies of phenotypic susceptibility to 
AZT have shown that viral strains bearing the H208Y/T215Y mutations are equally susceptible to 
those with only T215Y (Clark et al., 2006), thereby indicating that the mutation H208Y alone is not 
enough to improve the resistance profile conferred by the T215Y substitution.  
 
Fig 69. Comparison of the structural models of mutant M41L/L210W/T215Y and M41L/H208Y/L210W/T215Y RTs in 
complex with dsDNA and AZTp4A. (A) Superposition of the refined crystal structure of M41L/D67N/K70R/T215Y/K219Q 
RT/dsDNA/AZTp4A and the equivalent molecular model of the complex containing M41L/H208Y/L210W/T215Y RT.  Cartoon 
representations of the polypeptide backbone of the M41L/D67N/K70R/T215Y/K219Q and M41L/H208Y/L210W/T215Y RTs are 
shown in yellow and cyan, respectively.  Stick representations are used to indicate the location of relevant residues at positions 
41, 208-212 and 215. The AZTp4A molecule in the refined crystal structure is shown in orange, and in the molecular model 
containing the M41L/H208Y/L210W/T215Y RT is shown in purple.  Adenine rings are shown in red. (B) Superposition of the 
refined molecular models of the ternary complexes containing M41L/H208Y/L210W/T215Y and M41L/L210W/T215Y RTs (cyan 
and wheat, respectively). Orange and green stick representations are used to show the AZTp4A molecules in complexes 
containing M41L/H208Y/L210W/T215Y and M41L/L210W/T215Y RTs, respectively.  In both cases, adenine moieties are shown 
in red. Molecular dynamics simulations were carried out by Dr. J. Mendieta (Centro de Biología Molecular “Severo Ochoa”, 
Madrid, Spain). Structures were obtained with the PyMol molecular Graphics Systems (DeLano Scientific) software. Atom 
coordinates were taken from PDB file 3KLE. 
 
 
 
5.1.2 R284K facilitates rescue of blocked DNA primers in DNA/DNA 
complexes by improving DNA polymerization efficiency of RTs containing 
TAM-1 mutations 
The presence of the combination of TAMs M41L, L210W and T215Y confers relatively high 
rescue efficiency of primers terminated with AZTMP or tenofovir. This is a consequence of their high 
excision activity in the presence of ATP. R284K does not affect the ATP-mediated excision activity of 
mutant RTs bearing the combination M41L/L210W/T215Y. However, it improves the rescue 
efficiencies of these enzymes. This effect could not be attributed to an influence of the mutation on 
DNA binding affinity (Kd values for all tested RTs were around 2 nM for DNA/DNA complexes) or 
nucleotide discrimination, since AZTTP and tenofovir-DP inhibition constants (Ki) were essentially 
the same for M41L/L210W/T215Y and M41L/L210W/T215Y/R284K RTs.  
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However, the rescue advantage conferred by the presence of R284K in a TAM-1 background 
seems to be driven by its higher rates of nucleotide incorporation during DNA synthesis. The kcat and 
kpol values for nucleotide incorporation are 60-77% and 80% higher, respectively, for the mutant 
M41L/L210W/T215Y/R284K than for the M41L/L210W/T215Y RT. These significant increases 
translate in a higher efficiency of primer extension by the M41L/L210W/T215Y/R284K RT at 
different T/P concentrations. This effect was also observed when R284K was added to an otherwise 
WT background. Consistent with those results, a significant enhancement in the processivity of the 
M41L/L210W/T215Y/R284K RT was also observed.  
The R284K mutation seems to affect the polymerase activity of the RT in a different way than 
other RT thumb subdomain substitutions as N255D, I257T, G262A, N265D or W266T, which have 
been reported to impair RT primer extension and processivity (Gao et al., 1998; Fisher et al., 2003). In 
addition, the higher catalytic rate of nucleotide incorporation provides a rational explanation for the 
higher fitness of the viral strain bearing mutations M41L/L210W/T215Y/R284K in its RT coding 
sequence when grown in the presence of AZT or tenofovir disoproxil fumarate (Fig 68). 
Analysis of the structure of the ternary complex of RT, DNA/DNA and dTTP (Huang et al., 1998) 
shows that in the p66 thumb subdomain the side-chain of Arg-284 is close to the template strand (Fig 
70A). Amino groups of the side-chain of Arg-284 are situated 3.6 and 4.4 Å away from oxygen 
substituents of the phosphate group joining DNA template nucleotides -12 and -13 (Fig 70B).  
 
Fig 70. Structural role of Arg-284. (A) Structure of HIV-1 RT in complex with DNA/DNA and dTTP. The RT subunits are 
represented as ribbon diagrams (blue for p66, with the thumb subdomain in green, and grey for p51). The DNA primer is shown 
in orange, the template DNA in cyan and the dTTP molecule as brown spheres. The side-chains of Arg-284 in the p66 and p51 
subunits are shown with a sphere representation in yellow and red, respectively. (B) Relevant distances (expressed in Å) 
between the side-chain of Arg-284 and the DNA template strand. The DNA backbone is shown in cyan with oxygen, nitrogen 
and sulfur atoms in red, blue and orange, respectively. (C) Relevant distances (expressed in Å) between main-chain of Arg-284 
in the p51 subunit and Gly-541 in the p66 subunit. Structures were obtained with the PyMol molecular Graphics Systems 
(DeLano Scientific) software. Atom coordinates were taken from PDB file 1RTD. 
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Therefore, extensive contacts between the amino acid at position 284 and the template strand 
could be influencing T/P binding and probably its proper alignment at the DNA polymerase active 
site, thereby affecting nucleotide incorporation rates. In addition, residue 284 in the p51 thumb 
subdomain is also close to the p66 RNase H domain. The main-chain amino group of Arg-284 is 
located at 4.1 Å from p66 Gly-541 (Fig 70C). Hence, as proposed by others previously, the interaction 
of residue 284 in the p51 subunit with p66 could also contribute to the altered behavior of the RT 
(Hermann et al., 1994; Waters et al., 2009). The contribution of Lys-284 to the enhanced RNase H 
activity of the M41L/L210W/T215Y/R284K RT compared with the enzyme containing only the 
TAM-1 mutations could be due to the proximity of the p51 Lys-284 residue and the p66 RNase H 
domain.  
5.1.3 The triad Pro-272/Arg-277/Thr-286 facilitates rescue of primers 
terminated with NRTIs annealed to an RNA template 
As discussed above, in comparison with RTs having the TAM-1 cluster alone, mutant RTs 
M41L/H208Y/L210W/T215Y and M41L/L210W/T215Y/R284K showed enhanced rescue ability of 
primers terminated with NRTIs (d4TMP, AZTMP or tenofovir) annealed to DNA templates. However, 
these effects were not observed in rescue assays carried out with RNA/DNA-blocked complexes. A 
rational explanation for this behavior can be proposed from the results of RNase H measurements 
carried out with H208Y- and R284K-containing enzymes. Both RTs showed higher RNase H catalytic 
rates than their homologs having either only the TAM-1 mutations M41L, L210W and T215Y, or the 
WT sequence. Hence, enhanced template cleavage would be decreasing the excision of the inhibitor 
and the subsequent DNA primer elongation during the rescue reaction.   
Many previous studies have shown that the higher the RNase H activity, the lower is the 
RNA/DNA-dependent rescue activity of the RT (Brehm et al., 2008, 2012; Ehteshami et al., 2008a; 
Radzio et al., 2010; reviewed in Delviks-Frankenberry et al., 2010), supporting our conclusion that the 
increased RNase H activity of the H208Y- and R284K-containing RTs is negatively affecting the 
rescue activity on RNA/DNA-blocked complexes.  
RNase H activity assays carried out with three different complexes showed that thumb subdomain 
polymorphisms Pro-272, Arg-277 and Thr-286 had a minor impact on the generation of RNase H 
primary or secondary cleavage products by the RT. Thus, rescue assays with AZTMP-terminated 
DNA primers bound to RNA templates showed that the mutant M41L/T215Y RT (bearing Pro-
272/Arg-277/Thr-286) produced a significantly higher amount of fully-extended product, compared 
with the M41L/T215Y/P272A/R277K/T286A mutant enzyme. Similar differences were also found in 
the case of d4TMP- and CBVMP-blocked complexes. In addition, we also observed that with all three 
inhibitors the rescue efficiency of the WT enzyme was higher than that of the P272A/R277K/T286A 
RT, when blocked primers were annealed to RNA templates.  
The increased rescue activity of the M41L/T215Y RT cannot be attributed to a higher ATP-
dependent excision rate, since mutant RTs bearing mutations M41L/T215Y with and without thumb 
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subdomain polymorphisms showed the same excision activity on d4TMP- and CBVMP-terminated 
primers annealed to RNA templates (Fig 26). However, our nucleic-acid binding affinity 
measurements showed that the presence of Pro-272, Arg-277 and Thr-286 increased the affinity of 
WT and M41L/T215Y RTs for RNA/DNA complexes, without affecting their interaction with 
DNA/DNA heteroduplexes. This result was consistent with data from primer extension assays carried 
out with RNA/DNA complexes under limiting T/P concentrations (1 nM). These experiments showed 
that the addition of Pro-272, Arg-277 and Thr-286 increased the amount of extended product in 
reactions catalyzed by the mutant M41L/T215Y RT. The enhanced ability to use RNA/DNA 
complexes at low concentrations conferred by polymorphisms Pro-272, Arg-277 and Thr-286 provides 
a rational explanation for the increased ability of the WT and M41L/T215Y RTs to rescue 
RNA/DNA
AZTMP
-blocked complexes, as well as for the higher replication capacity of the viral clones 
bearing these RTs when grown in the presence of low concentrations of AZT (Fig. 66). Interestingly, 
the connection subdomain mutation G333D has also been found to improve rescue of DNA/DNA
AZTMP
 
T/Ps by increasing the affinity of the M41L/M184V/L210W/T215Y RT for these blocked-complexes 
(Zelina et al., 2008). 
The increased affinity of RTs bearing Pro-272, Arg-277 and Thr-286 for binding RNA/DNA 
complexes can be analyzed from a structural point of view. Comparison of RT-DNA/DNA and       
RT-RNA/DNA crystal structures shows that Arg-277 and Thr-286 make more extensive contacts with 
the RNA template than with the DNA template (Ding et al., 1998; Huang et al., 1998; Sarafianos et 
al., 2001) (Fig 71A). Thus, amino groups of Arg-277 are situated between 3.3 and 3.5 Å away from 
the oxygen substituent of the phosphate group linking RNA nucleotides -7 and -8, while in the 
DNA/DNA complex, Arg-277 is rotated away from the nucleic acid (Fig 71B, C). The hydroxyl group 
of the side-chain of Thr-286 is situated at 4.4 Å from the 2´-OH group of the ribose at position -8 of 
the template RNA, while the interaction with the template strand in the DNA/DNA complexes 
involves contacts with the sugar-phosphate backbone at positions -8 and -9 of the template, situated at 
around 3.7 to 5.5 Å (Fig 71B, C). Pro-272 lies in a region far from the template strand, independently 
of the nature of the nucleic acid, and could contribute to the proper folding of the thumb subdomain. 
However, Pro-272 has been found to reduce DNA/DNA binding affinity and RT processivity (Wang 
et al., 2008). In the p51 subunit, studied thumb subdomain polymorphisms are located away from the 
T/P, except for Thr-286, which is situated near the p66 connection residue Asn-460 (Fig 71A). 
However, it is unlikely that Thr-286 could affect the interaction of the RT with the T/P complex.  
In summary, our data show that there are at least three different mechanisms by which accessory 
mutations could facilitate the selection of HIV-1 variants carrying TAM-1 mutations under the 
selection pressure of drugs such as AZT or tenofovir. The palm subdomain mutation H208Y directly 
plays its role by increasing the excision ability of TAMs. The thumb subdomain substitution R284K 
and the polymorphisms Pro-272/Arg-277/Thr-286 enhance NRTI resistance by improving a natural 
property of the RT, not necessary related with the resistance mechanism per se (i.e., not related to 
excision), that translates in an improved DNA synthesis in the presence of excisable NRTIs. RT thumb 
subdomain polymorphisms Pro-272/Arg-277/Thr-286 enhance the RT affinity for RNA/DNA 
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complexes, even in a WT background, while R284K improves the primer extension ability in WT and 
TAM-1-containing RTs. Although these mutations do not require the presence of TAMs to act, their 
impact in viral fitness in the absence of drug pressure seems to be negligible or very small, explaining 
why they are selected mainly during treatments containing NRTIs. Taken together, our results provide 
further evidence indicating that mutations far from the DNA polymerase active site or residues 
involved in TAMs could facilitate the selection of recombinant HIV-1 variants in the presence of 
drugs. In addition, our data highlight the plasticity of the RT, showing three different mechanisms by 
which amino acid substitutions in the DNA polymerase domain could modulate resistance to NRTIs. 
 
 
Fig 71. Interaction of RT thumb subdomain residues Pro-272, Arg-277 and Thr-286 with the template strand. (A) 
Structure of HIV-1 RT in complex with RNA/DNA. The RT subunits are represented as ribbon diagrams (blue for p66, with the 
thumb subdomain in green, and grey for p51). The DNA primer is shown in red and the template RNA in orange. The side-
chains of residues Pro-272, Arg-277 and Thr-286 are shown using a sphere representation in yellow and cyan for p66 and p51 
subunits, respectively. (B) Relevant interaction atomic distances (expressed in Å) between the side-chains of Arg-277 and Thr-
286 and the RNA strand. The backbone of the RNA template is shown in blue, with oxygen, nitrogen and sulfur atoms in red, 
blue and orange, respectively. (C) Relevant interactions and distances (expressed in Å) between the side-chains of Arg-277 and 
Thr-286 and the template DNA strand in a binary complex of HIV-1 RT and a DNA/DNA T/P. The backbone of the DNA template 
is shown in purple, with oxygen, nitrogen and sulfur atoms in red, blue and orange, respectively. Atom coordinates of the RT 
bound to RNA/DNA and those of the RT bound to DNA/DNA were taken from PDB files 1HYS and 2HMI, respectively. 
Structures were obtained with the PyMol molecular Graphics Systems (DeLano Scientific) software.  
5.2 Influence of RT connection subdomain mutations in NNRTI 
resistance and RNase H cleavage specificity 
Very often, currently prescribed HAART regimens contain one NNRTI. Detailed sequence 
analysis of the whole RT-coding sequence in HIV-1 isolates has allowed the identification of residues 
far from the NNRTI binding-pocket implicated in drug resistance. Mutations N348I, T369I/V, and 
T376S have been related to exposure to NNRTIs, particularly NVP (Cane et al., 2007; Hachiya et al., 
2009; Shariar et al., 2009; Gupta et al., 2010; Lengruber et al., 2011; Paredes et al., 2011). NVP 
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susceptibility data obtained in our study for mutant RTs N348I, T369I, T369V, T376S and 
N348I/T369I are consistent with those previous studies, since all RTs showed some degree of drug 
resistance. However, we did not detect a significant impact of those amino acid substitutions on the 
susceptibility to more potent inhibitors such as EFV and ETR. Previously, it has been shown that 
while mutant RTs N348I (Biondi et al., 2010) and T376S (Paredes et al., 2011) are resistant to NVP, 
both remain susceptible to EFV. Although some authors have reported low-level EFV resistance of 
viral strains carrying the T369I/V mutation or the combination N348I/T369I in phenotypic assays with 
mutant HIV-1 (Zhang et al., 2007; Gupta et al., 2010, 2011; Lengruber et al., 2011), drug 
susceptibility assays carried out with recombinant viruses bearing our RT constructs failed to detect 
significant differences in resistance to EFV, ETR or RPV with any of the tested mutants and the WT 
RT (Table 23). Consistent with the NVP IC50 value obtained in our biochemical measurements, the 
viral strain carrying N348I/T369I showed the highest levels of NVP resistance in phenotypic assays.  
 
Table 23. Susceptibility of HIV-1 constructs bearing mutations at the RT connection subdomain and the 
reference strain K103N
a
 
 IC50 (nM) 
RT NVP DLV EFV ETR RPV 
WT 15.0 ± 1.70 1.8 ± 0.5 1.1 ± 0.2 1.0 ± 0.1 0.1 ± 0.01 
T369I 28.0 ± 1.50 (1.9) 3.2 ± 0.6 (1.8) 1.1 ± 0.4 (1.0) 1.0 ± 0.1 (1.0) 0.1 ± 0.03 (1.1) 
T369V 27.0 ± 12.0 (1.8) 2.9 ± 1.0 (1.6) 1.0 ± 0.1 (0.9) 1.1 ± 0.3 (1.1) 0.3 ± 0.03 (2.5) 
T376S 26.0 ± 7.20 (1.7) 4.4 ± 0.8 (2.4) 1.5 ± 0.2 (1.4) 1.4 ± 0.2 (1.5) 0.2 ± 0.05 (1.7) 
N348I 33.0 ± 4.60 (2.2) 4.1 ± 0.7 (2.3) 1.2 ± 0.3 (1.1) 1.2 ± 0.1 (1.2) 0.2 ± 0.10 (2.3) 
N348I/T369I  102 ± 2.50 (6.8) 3.1 ± 0.6 (1.7) 1.4 ± 0.3 (1.3) 1.1 ± 0.1 (1.1) 0.1 ± 0.03 (0.7) 
K103N 1830 ± 226 (122) 332 ± 39 (184)  44 ± 15 (38) 1.2 ± 0.4 (1.2) 0.1 ± 0.02 (1.2) 
The IC50 values represent averages ± standard deviations of at least three independent determinations, each one performed six 
times. The fold-increase in IC50 relative to the wild-type HXB2 virus control carrying the RT sequence of BH10 is shown between 
parentheses. Values obtained by Drs. M. Nevot and M. A. Martínez (Fundació IrsiCaixa, Hospital Universitari Germans Trias i 
Pujol, Badalona, Spain). 
a
 K103N is a well-characterized DLV, NVP and EFV resistance mutation.  
 
It has been shown that viral strains bearing mutations N348I, T369I or N348I/T369I have a 
reduced replication capacity in the absence of drugs, especially the double-mutant, whose fitness was 
estimated around 11% relative to the WT virus (Gupta et al., 2010). Our DNA polymerase activity 
determinations showed only minor differences in the nucleotide incorporation rates between N348I, 
T369I and N348I/T369I mutants and the WT RT. However, RNase H activity measurements have 
shown that the N348I/T369I RT had reduced RNase H activity on heteropolymeric RNA/DNA 
complexes. Its lower endonucleolytic activity could explain the reduced viral fitness observed in 
replication capacity assays. 
Interestingly, RTs containing mutations N348I or T369I, but especially the double-mutant 
N348I/T369I also showed significant differences in cleavage specificity with PPT-containing 
oligonucleotides used either as templates (as in (-) strand DNA synthesis) or as primers (as in (+) 
strand DNA synthesis) (Fig 72). Our results indicate that the N348I/T369I RT has a different cleavage 
window specificity compared to the WT enzyme. Thus, when the highly conserved PPT-U3 cleavage 
site (Huber & Richardson, 1990; Powell et al., 1999; Jones & Hughes, 2007) was situated less than 18 
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nucleotides away from the DNA 3´-end in systems mimicking (-) strand DNA synthesis (i.e., in 
complexes with an RNA template containing the PPT sequence annealed to a DNA primer containing 
a recessed 3´-OH end), the N348I/T369I RT showed a stronger tendency than the WT enzyme to 
generate RNase H hydrolysis products longer than the PPT (Fig 72).  
However, this change in cleavage specificity has more dramatic effects in PPT-processing when 
our system is mimicking the initiation of (+) strand DNA synthesis (i.e., using the T57d/PPT17r8d 
complex). In this case, the change in cleavage specificity of the N348I/T369I mutant produced a large 
drop in its RNase H catalytic rate (Fig 72, lower left panel). This was due to the fact that the preferred 
cleavage site of this RT would locate in the DNA/DNA double-stranded region (Fig 72). These results 
provide additional support for impaired RNase H activity as the hypothetical main cause of the 
reduced fitness of the N348I/T369I viral strain. 
 
Fig 72. Schematic representation of the cleavage specificity of the WT RT and the double-mutant N348I/T369I. Upper 
part of the panel shows a scheme of a system mimicking the (-) strand DNA synthesis. The DNA primer (black line) is annealed 
to the viral RNA, with the PPT segment indicated by using 17 red boxes (equivalent to 17 ribonucleotides), with non-PPT RNA 
segments at both extremes (blue boxes). Cleavage specificity and substrate preference of WT and N348I/T369I RTs is 
indicated by using green arrows. The thickness of the arrow is equivalent to the preference of the enzyme to cut at that position. 
Longer-distance cleavages produced by the presence of NNRTIs are indicated with black bolts. The lower panel shows a 
system mimicking (+) strand DNA synthesis. The large template DNA (black line) is annealed to a primer containing the PPT 
segment, drawn as 17 red boxes (equivalent to 17 ribonucleotides) and with added dNTPs as blue triangles. Preferred cleavage 
sites of WT and N348I/T369I RTs in the absence of NNRTI are indicated with a purple and blue arrow, respectively, accounting 
for the overall higher RNase H rates of the WT RT. In the presence of NNRTIs RNase H cleavage sites are marked as in the 
upper panel.  
 
Addition of NNRTIs produces a strong enhancement of the RNase H activity of all tested RTs. 
Although higher concentrations of EFV and ETR than of NVP were needed to promote the observed 
increase of RNase H activity, saturating concentrations of all NNRTIs had essentially the same effect. 
Interestingly, NNRTIs also changed the specificity of the RNase H-mediated cleavage, since 
unspecific long-distance cuts were detected in assays carried out using systems mimicking (-) strand 
DNA synthesis with WT, N348I and N348I/T369I RTs (Fig 72). Binding of NNRTIs has been 
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previously described to promote slippage of the RT along the T/P, and this could be the likely cause of 
the observed unspecific cleavage patterns (Palaniappan et al., 1995). These results are also consistent 
with previous work showing that NVP, EFV and other NNRTIs enhance the RT RNase H activity 
(Gopalakrishnan & Benkovic, 1994; Palanippan et al., 1995; Shaw-Reid et al., 2005; Hang et al., 
2007; Radzio & Sluis-Cremer, 2008). Although there is no clear explanation for such a phenomenon, 
several studies have shown that some NNRTIs, especially EFV, promote the dimerization of the RT 
subunits (Tachedjian et al., 2001; Figuereido et al., 2006; Braz et al., 2010a,b). However, enhanced 
RT dimerization does not completely explain the observed effect, since NVP does not promote RT 
subunit association, despite being a potent enhancer of RNase H activity.  
Under our assay conditions, cleavage of the PPT17r8d by the WT RT and the N348I mutant 
enzyme was enhanced in the presence of NVP. However, Biondi and colleagues have previously 
reported that the N348I RT was not affected by NVP. According to these authors, in the presence of 
NVP this enzyme prefers to bind the T/P in the polymerase-dependent binding mode, thereby reducing 
the cleavage of the PPT17r8d strand (Biondi et al., 2010). Although we do not have a clear 
explanation for this discrepancy, it is possible that differences in the RT background of the enzyme 
carrying the N348I mutation (i.e., BH10 in our experiments and HXB2 in the assays of Biondi et al.) 
could be influencing the results. In agreement with this proposal, it has been shown that the presence 
of polymorphism R172K in the RT background (as is the case of our BH10 strain) could have a clear 
influence in the susceptibility to NVP of mutant N348I RT (Hachiya et al., 2012). 
PPT processing is a pivotal step in reverse transcription. Correct cleavage of this RNA sequence 
during (-) strand DNA synthesis yields primers of 15, 17 and 19 nucleotides (Huber & Richardson 
1990; Julias et al., 2002; Rausch & LeGrice, 2007). While the PPT 5´-end (A tract) accepts some 
variation, the tract of 6 Gs forming the 3´-end is highly conserved. Nucleotide substitutions or 
deletions at the polyguanosine segment produce a large reduction in the efficiency with which the RT 
uses the PPT during (+) strand DNA synthesis (Huber & Richardson 1990; Julias et al., 2004; Jones & 
Hughes, 2007; Rausch & LeGrice, 2007). In addition, the correct cleavage at the PPT-U3 junction also 
determines the 5´-end of viral DNA, which should be conserved in order to be recognized by the IN to 
carry out the integration of the provirus. Results presented in this Thesis show that NNRTIs enhanced 
the RNase H activity of the RT to a level in which Gs situated at positions -1 and sometimes -2 of the 
PPT 3´-end were removed (Fig 73). Therefore, it seems likely that apart from inhibiting the DNA 
polymerase activity of the enzyme, NNRTIs could facilitate the formation of abortive PPT products. In 
agreement with these observations, it has been also shown that PPT-dependent synthesis is more 
susceptible to NVP and EFV inhibition than DNA-primed polymerization (Grobler et al., 2007). 
Recent structural and biochemical reports have found that residue 348 in the p51 subunit of the 
RT could be playing an important role in maintaining the stability of this subunit, affecting the 
interaction between both subunits and the correct positioning of the RNA strand in RNA/DNA T/Ps 
susceptible to cleavage by the viral RT (Chung et al., 2013; Lapkouski et al., 2013). Therefore, 
mutations affecting Asn-348 could distort the interaction between p66 and p51 and their spatial 
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organization. Residue 369 in p51 and p66 subunits is away from the T/P, the NNRTI binding pocket 
or the p66-p51 interface (Lapkouski et al., 2013). Thr-369 has not been study thoroughly, but the 
similar phenotype of RTs N348I and T369I in RNase H cleavage measurements could be indicative of 
a similar role in affecting RT subunits interaction. 
 
Fig 73. Schematic representation of RNase H cleavages displayed by the WT RT and the double-mutant N348I/T369I in 
a system mimicking the (+) strand DNA synthesis. The DNA template (black line) is annealed to a PPT primer of 17 
ribonucleotides (represented by 17 red boxes). In the absence of NNRTIs none of the RTs is able to cut the PPT 3´-end. 
Addition of NNRTIs triggers the cleavage of the 3´-end of the PPT primer in the case of the WT RT, but it is much less effective 
in the case of the N348I/T369I RT. Cleavage sites are represented by blue arrows. Thickness of the arrow represents the cut 
preference at that position. 
 
As discussed above, common PPTs produced during (-) strand DNA synthesis contain 17 
nucleotides (Huber & Richardson, 1990). The length of the PPT-RNA primer is the factor that 
determines the distance between the DNA polymerase active site and the RNase H cleavage site, that 
is required to release the PPT sequence during (+) strand DNA synthesis (Götte et al., 1999, 2001), 
Thus, PPTs of 17 nucleotides impose an RNase H cleavage window of 17 nucleotides. Our 
PPT29DNA/PPT17r system mimics the very first step during the (+) strand DNA synthesis when no 
dNTPs have been added. While in the absence of NNRTIs the 17-nucleotide RNA strand remains 
resistant to hydrolysis by all RTs (i.e., the WT RT and mutants N348I and N348I/T369I), in the 
presence of NVP or EFV, WT and N348I RTs degrade the polyguanosine tract at the 3´-end of the 
PPT primer (Fig 73). These degraded PPTs are not expected to be used in (+) strand DNA synthesis. 
However, the double-mutant N348I/T369I RT was completely resistant to NVP and only partially 
susceptible to EFV. Under our assay conditions, this RT is able to maintain the intact PPT structure in 
the presence of NNRTIs, and therefore it would increase the amount of PPT primer available for 
initiation of (+) strand DNA synthesis (Fig 73). Although the combination of mutations N348I and 
T369I has a dramatic impact on viral fitness in the absence of drugs, probably due to an impaired 
RNase H activity, in the presence of NVP or EFV the different cleavage specificity of this mutant 
could prevent the degradation of the PPT primer prior to initiation of (+) strand DNA synthesis 
providing a selective advantage for the selection of these mutations in NNRTI-treated patients. 
Reductions in viral fitness have also been observed in different studies carried out with viral 
strains lacking the IN, or carrying certain IN mutations (Wu et al., 1999; Zhu et al., 2004; Lu et al., 
2005b). In these studies, a severe impairment in the synthesis of reverse transcription products was 
detected. For example, Zhu and colleges showed that viral strains bearing an IN variant with the 
C130S mutation (that eliminates the interaction with the RT), were highly impaired for the production 
of early products of reverse transcription (Zhu et al., 2004). Since a correct cleavage of the PPT is an 
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essential step in reverse transcription, it is possible that an impairment in this step would be the cause 
of the reduced fitness of IN mutant viruses.  
Our studies show that although addition of IN to an RT preparation containing a heteropolymeric 
RNA/DNA complex did not increase the endonucleolytic activity of the RT, during PPT processing in 
(-) and (+) strand DNA synthesis the presence of IN increased the RNase H activity of the RT. 
Interestingly, this enhancement of PPT processing proceeded only with the production of PPTs of the 
correct length (i.e., without degradation of the polyguanosine tract at the 3´-end of the PPT).  
IN has been implicated in the promotion of RT polymerase activity during first steps of (-) strand 
DNA synthesis (Dobard et al., 2007; Nishitsuji et al., 2009). Our results are consistent with these 
studies, since the presence of IN seems to facilitate the correct cleavage of the PPT during both (-) and 
(+) strand DNA synthesis. The more efficient hydrolysis of the PPT could result in a higher viral 
fitness, thereby providing a plausible explanation for the reduced replication capacity of viral strains 
bearing IN mutations (Wu et al., 1999; Zhu et al., 2004).   
However, the exact role of IN in reverse transcription seems to be more complicated. For 
example, an interaction between IN and the cellular protein Gemin2 has been described as a factor 
promoting reverse transcription (Hamamoto et al., 2006; Nishitsuji et al., 2009). In addition, other 
viral proteins have been described as components of the reverse transcription complex. Examples are 
Tat, Nef and NC (Fournier et al., 2002; Apolloni et al., 2007; Levin et al., 2010). 
In this Thesis we have shown that the interaction between RT and IN could be important in (-) 
and (+) strand DNA synthesis during reverse transcription. We have also shown the high adaptability 
of the RT to drug pressure. Thus, the potent NRTI-excision activity provided by TAM-1 mutations 
could be further potentiated by improving the usage of ATP molecules as PPi donors, by increasing 
the binding affinity of the enzyme to RNA/DNA complexes or by enhancing the RT DNA 
polymerization ability. In addition, structural features of the RT, such as the distance between the 
DNA polymerase and the RNase H active sites could be playing a role in drug resistance by impairing 
PPT degradation during reverse transcription in the presence of NNRTIs.  
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6. Conclusions 
1. In the presence of M41L, L210W and T215Y (TAM-1 cluster of mutations), the amino acid 
substitution H208Y increases rescue efficiency of primers terminated with AZTMP, d4TMP or 
tenofovir by improving the ATP-dependent excision activity of the RT. These results are 
consistent with the decreased phenotypic susceptibility to AZT of recombinant HIV-1 strains 
bearing RT mutations M41L/H208Y/L210W/T215Y relative to those having only M41L, L210W 
and T215Y. 
2. The amino acid substitution R284K improves the ATP-dependent rescue activity of the 
M41L/L210W/T215Y mutant RT on primers terminated with AZTMP, tenofovir and d4TMP 
annealed to DNA templates. However, R284K does not affect the rate of excision of NRTIs in 
the presence of ATP, but stimulates the nucleotide incorporation activity of the RT. In rescue 
assays, R284K promotes primer extension after excision of the corresponding NRTI. This result 
is in agreement with the observed fitness advantage of viral strains bearing the combination of 
R284K with TAM-1 mutations in the presence of AZT or tenofovir. 
3. Substitutions R284K and H208Y increase the RNase H activity of the RT. As a consequence, 
when any of these mutations is added to an RT containing the substitutions 
M41L/L210W/T215Y, the resulting enzyme shows reduced rescue efficiency of RNA/DNA 
complexes containing blocked DNA primers. 
4. RT thumb subdomain polymorphisms Pro-272, Arg-277 and Thr-286 have no effect in the ATP-
dependent rescue activity of blocked-DNA/DNA complexes of RTs containing the amino acid 
substitutions M41L and T215Y. However, those thumb subdomain polymorphisms improve the 
ability of the M41L/T215Y RT to rescue RNA/DNA complexes blocked with thymidine 
analogues. 
5. The Pro-272/Arg-277/Thr-286 triad increased the affinity of the RT for RNA/DNA complexes 
either in the absence of mutations or in the presence of TAMs M41L and T215Y. However, 
thumb polymorphisms do not affect the interaction of the RT with DNA/DNA template/primers. 
The increased affinity for RNA/DNA complexes facilitates rescue of blocked-DNA primers 
annealed to RNA templates, particularly at low concentrations of template/primer. These results 
are consistent with the observed fitness advantage of viral strains bearing RT polymorphisms 
Pro272/Arg-277/Thr-286 and TAM-1 mutations, in the presence of low concentrations of AZT.  
6. RT connection subdomain mutations N348I, T369I, T369V, T376S, as well as the combination 
N348I/T369I confer nevirapine resistance without affecting the susceptibility to efavirenz or 
etravirine. All three NNRTIs enhance the RNase H activity of wild-type and mutant RTs as 
determined with heteropolymeric and PPT-containing RNA/DNA complexes.   
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7. N348I/T369I RT and in a lesser extent the mutant N348I show reduced RNase H activity, 
particularly when the distance between the DNA polymerase and the RNase H active sites is 
shorter than 18 nucleotides. This property has been demonstrated by measuring the susceptibility 
of the PPT primer to RNase H hydrolysis during (-) and (+) strand DNA synthesis, and is 
expected to modulate the inhibitory effect of NNRTIs during these steps of reverse transcription. 
8. HIV-1 integrase also enhances RNase H activity while processing the PPT sequence, in (-) and 
(+) strand DNA synthesis, but it does not affect the RNase H catalytic rate during the hydrolysis 
of heteropolymeric RNA/DNA complexes. However, unlike the case of NNRTIs, the HIV-1 IN 
promotes specific cleavage at the PPT-U3 junction without generating PPT products degraded at 
their 3´-end. 
148
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                                                                         Conclusiones 
 
 
6. Conclusiones 
1. En presencia de M41L, L210W y T215Y (grupo de mutaciones TAM-1), el cambio de 
aminoácido H208Y aumenta la eficacia de rescate de iniciadores bloqueados con AZTMP, 
d4TMP o tenofovir, debido a que mejora la actividad de escisión dependiente de ATP de la RT. 
Estos resultados justifican la menor susceptibilidad fenotípica al AZT de cepas recombinantes 
del VIH-1 portadoras de la RT M41L/H208Y/L210W/T215Y en comparación con aquellas que 
sólo tienen las mutaciones M41L, L210W y T215Y. 
2. El cambio de aminoácido R284K mejora la actividad de rescate dependiente de ATP de la RT 
mutante M41L/L210W/T215Y sobre iniciadores terminados con AZTMP, tenofovir y d4TMP, 
hibridados con moldes ADN. Sin embargo, R284K no afecta a la capacidad de escisión de 
NRTIs de la enzima en presencia de ATP, si bien aumenta su tasa de incorporación de 
nucleótidos en reacciones de síntesis de ADN. En ensayos de rescate de iniciadores bloqueados 
en su extremo 3´, R284K promueve su extensión tras la escisión del correspondiente NRTI. Este 
resultado es coherente con la mayor capacidad replicativa de las cepas virales portadoras de la 
combinación de R284K junto con las mutaciones TAM-1, observada en presencia de AZT o 
tenofovir. 
3. Las sustituciones H208Y y R284K incrementan la actividad RNasa H de la RT. Como 
consecuencia de ello, cuando cualquiera de estas mutaciones se añade a una RT portadora de los 
cambios M41L/L210W/T215Y, la enzima resultante muestra menor eficacia en el rescate de 
complejos ARN/ADN que contienen un iniciador de ADN bloqueado con AZTMP, d4TMP o 
tenofovir. 
4. Los polimorfismos del subdominio “thumb” Pro-272, Arg-277 y Thr-286 no tienen ningún 
efecto en la actividad de rescate dependiente de ATP sobre complejos ADN/ADN bloqueados 
de RTs portadoras de las sustituciones de aminoácidos M41L y T215Y. Sin embargo, los 
polimorfismos del subdominio “thumb” mejoran la capacidad de la RT M41L/T215Y para 
rescatar complejos de ARN/ADN bloqueados con análogos a timidina.  
5. La triada Pro-272/Arg-277/Thr-286 aumenta la afinidad de la RT por complejos ARN/ADN 
tanto en ausencia como en presencia de las TAMs M41L y T215Y. Sin embargo, los 
polimorfismos del “thumb” no afectan a la interacción de la RT con complejos molde/iniciador 
de tipo ADN/ADN. La mayor afinidad por complejos ARN/ADN facilita el rescate de 
iniciadores de ADN bloqueados e hibridados con moldes de ARN. Estos resultados podrían 
explicar la mayor capacidad replicativa de las cepas virales portadoras de los polimorfismos 
Pro-272/Arg-277/Thr-286 y las mutaciones TAM-1 respecto a las que sólo llevan TAMs, 
observada en presencia de bajas concentraciones de AZT. 
6. Las mutaciones del subdominio “connection” de la RT N348I, T369I, T369V, T376S, así 
como la combinación N348I/T369I confieren resistencia a nevirapina sin afectar a su 
susceptibilidad a efavirenz o etravirina. Los tres inhibidores de la RT no análogos a nucleósido 
(NNRTIs) aumentan la actividad RNasa H de las RTs de genotipo silvestre y mutantes, tal y 
como se ha determinado con complejos ARN/ADN heteropoliméricos y con complejos 
portadores de oligonucleótidos con la secuencia de polipurinas, PPT. 
7. La RT N348I/T369I y en menor medida el mutante N348I muestran menor actividad RNasa 
H, especialmente cuando la distancia entre los centros activos de la actividad ADN polimerasa y 
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de la  RNasa H es menor a 18 nucleótidos. Esta propiedad ha sido demostrada mediante 
medidas de la susceptibilidad del iniciador PPT a la hidrólisis por la actividad RNasa H de la 
RT durante la síntesis de las cadenas de ADN de polaridad negativa y positiva, propiedad que 
podría modular el efecto inhibidor de los NNRTIs durante dichas etapas de la retrotranscripción.  
8. La integrasa (IN) del VIH-1 también aumenta la actividad RNasa H de la RT durante el 
procesamiento de la secuencia PPT en la síntesis de las cadenas de ADN de polaridad negativa y 
positiva. Sin embargo, la presencia de IN en la reacción no afecta a la tasa catalítica de la 
actividad RNasa H durante la hidrólisis de complejos ARN/ADN heteropoliméricos. Al 
contrario de lo que sucede en reacciones llevadas a cabo en presencia de NNRTIs, la IN del 
VIH-1 promueve los cortes específicos del molde ARN en el sitio PPT-U3, sin generar 
productos derivados de la secuencia del PPT con extremos 3´degradados. 
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